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Summary
The key original contribution of this work is the use of a Bayes optimisation
framework for the decision made at the interim analysis of Adaptive Enrichment
trials.
Adaptive Enrichment designs make efficient use of pre-identified patient sub-
populations. They begin by recruiting from all eligible patients, then at a pre-
planned interim analysis select which sub-populations will be recruited from for
the remainder of the sample. We ensure strong control of the Familywise Error
Rate whichever sub-populations are selected by constructing an overall hypothesis
testing structure using both closed testing procedures and combination tests.
This allows us to make interim decision by any method we choose. We find the
Bayes optimal decision, recruiting the remainder of the trial to optimise the Bayes
expected gain of the trial. We compare the Bayes optimal Adaptive Enrichment
trials with fixed sampling designs to understand the overall advantage of using
adaptive trials.
This optimisation framework is very flexible, we evaluate the performance of
Bayes optimal Adaptive Enrichment designs for different forms of data: delayed
responses, longitudinal analysis and discuss the extension of these methods to
survival data. Through this we see that although the information at the interim
analysis is reduced the adaptive trials still offer some benefit. Additionally we
investigate what may happen when we alter the pattern of recruitment of the
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1.1 Adaptive Enrichment trials
The aim of this work is to use a Bayesian decision framework to optimise
design choices at the interim analysis in adaptive clinical trials. We focus on
the optimisation of the decision at the interim analysis of Adaptive Enrichment
trials.
When the patient population for a clinical trial may be split into patient sub-
populations we would like to recruit only the patients that receive a benefit from
the new treatment. This decision may be difficult to make before beginning the
trial; Adaptive Enrichment trials delay the selection of sub-populations until an
interim analysis where the decision can be made based on trial observations.
For example if we have two sub-populations we may recruit the first half of the
sample from both, then at an interim analysis we may choose whether to recruit
the remaining sample from either sub-population only or continue recruiting from
both. In addition to optimising the decision at the interim analysis we may also
use the Bayesian decision framework to find where using an Adaptive Enrichment
trial is beneficial compared to a fixed sampling design.
The trials that we consider in this work are intended for use in Phase III of the
clinical development process. We will work in the setting of randomised controlled
trials, where patients are randomised to the new treatment and a control in order
to establish whether the new treatment offers some improvement. This is the
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same setting as Turnbull and Jennison (2000) consider for their group sequential
methods; group sequential designs use multiple interim analyses throughout the
trial to allow early stopping reducing the expected sample size and are well
established methods for conducting clinical trials.
The idea of Adaptive Enrichment designs stem from the Adaptive Signature
design proposed by Freidlin and Simon (2005), these Adaptive Signature trials
differ from Adaptive Enrichment in that they attempt to identify the patient sub-
populations during the trial whereas Adaptive Enrichment trials make use of pre
specified sub-populations. Temple (2005) discusses the potential improvement in
detecting efficacy of a new treatment by making use of sub-populations, where this
improvement would come from selecting the appropriate sub-population. Bhatt
and Mehta (2016) present some recent examples of adaptive trials and discuss
the use of Adaptive Enrichment in this context, discussing the potential benefits
of more widespread use of adaptive trials such as accelerating the development
process. Bhatt and Mehta (2016) also discuss some regulatory concerns for
adaptive trials but state that “to date, regulatory agencies have opined favourably
about adaptive designs”.
Regulatory bodies have published their thoughts on the use of adaptive clinical
trials in a confirmatory setting. Elsa¨ßer et al. (2014) give a summary of
scientific advice letters from the European Medicines Agency for adaptive clinical
trials. The FDA published guidelines for adaptive clinical trials Food and Drug
Administration and others (2010), from the discussion in these guidelines the
Adaptive Enrichment designs that fall under the “less well-understood” methods.
The guidance in this setting would be useful to anyone considering the use of
an adaptive design for a clinical trial. The key consideration we make from
the guidelines in our work is the need to control the study wide type I error
rate. Controlling the error rate where multiplicity is present in the design is a
well established area, points to consider are given by Committee for Proprietary
Medicinal Products and others (2002) and guidance is included in the ICH E9
document International Conference on Harmonisation E9 Expert Working Group
and others (1999). Dmitrienko et al. (2013) cover key issues of multiplicity in the
context of clinical trials.
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The papers by Bretz et al. (2006) and Schmidli et al. (2006) discuss the selection
of hypotheses at an interim analyses in a similar context to which we are now
working. The analyses of these designs require some additional techniques since
there are multiple hypotheses and due to the interim observations of the data,
Bauer and Kohne (1994) discuss appropriate methods for experiments where an
adaptive interim analysis is to be used. For the analysis of multiple hypotheses,
a closed testing procedures Marcus et al. (1976) are used. For analysis over
multiple stages we use combination tests as suggested by Bauer and Kohne
(1994), to combine the stages of the trial. Jennison and Turnbull (2007) provide
further discussion of the appropriate methods of hypothesis testing for Adaptive
Enrichment trials. Simulation studies by Wang et al. (2009) have shown how the
error rate is well controlled by these techniques, although we will use methods
where this may be proven directly.
Rosenblum (2014) examine the overall performance of Adaptive Enrichment
trials in terms of the power to reject null hypotheses, they show that any single
fixed sampling design cannot dominate a comparable Adaptive Enrichment trial
in terms of rejecting null hypotheses. This result may seem to be an unsurprising
property but highlights two things: firstly it shows that the adaptive design
is doing something unique when compared with fixed sampling alternatives,
suggesting that the adaptation may be useful in some way; secondly we note
that there are multiple fixed sampling alternatives that we should consider
comparing our optimal Adaptive Enrichment trials with in order to make a
complete assessment of their overall benefit.
We use a Bayesian optimisation framework for the interim decision of the
Adaptive Enrichment trials, the book by Berger (2013) offers a broad introduction
to statistical decision making with Bayesian methods. We construct a gain
function as an overall measure of trial performance and seek to make the decision
at the interim analysis that maximises this. The use of Bayesian methods has also
been addressed by regulatory bodies for example the FDA guidance US Food and
Drug Administration and others (2010) in the context of medical device trials.
The main concern here is demonstrating that these methods do not inflate the
error rate, we ensure this is the case with the methods we use for hypothesis
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testing.
The Bayes optimisation allows us to construct Bayes optimal Adaptive
Enrichment trials across a range of scenarios. We find that these optimal
adaptive designs offer an improvement of the overall performance of the trial
when compared to fixed sampling alternatives. Our optimisation is sufficiently
flexible that it is not limited to the particular scenarios that we present, for
example we are able to easily incorporate other possible interim decisions such
as early stopping. Posch and Bauer (2013) consider Adaptive budgets in clinical
trials, their work introduces a cost of sampling into the utility function. We use
this cost of sampling to motivate early stopping of the entire trial for futility
in our utility function; this could be further extended to allow for an adaptive
sample size but we have not done so within this work.
Our optimisation is also not restricted to the type of data being used, one of
the examples of alternative data types we have included is the use of survival
endpoints. Schmidli et al. (2007) looked at the use of Bayesian methods in
the interim analysis of seamless phase II/III trials with survival endpoints, both
Jenkins et al. (2011) and Irle and Scha¨fer (2012) use the log rank score statistic to
define the appropriate distributions for a trial using survival endpoints. We take
the same approach as Jenkins et al. (2011) simulating trials using only the log
rank score statistics. Another alternative is to consider longitudinal observations,
in this case we follow the method of Hampson and Jennison (2013) to decrease
the variance of the estimate of the final treatment effect at the time of the interim
analysis.
In the literature there have not been any such extensive approaches to the
optimisation of the inteirm decision in Adaptive Enrichment trials. Brannath
et al. (2009) use Bayesian decision tools to optimise the decision at the interim
analysis, however their focus is the Bayesian predictive probability of rejecting
any null hypothesis. Brannath et al. (2009) do not explicitly define a utility
function in their optimisation, if we construct the equivalent utlity function we
see that this is a special case of our form of optimisation; this is computationally
simpler as finding the interim decision depends only on the posterior predictive
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distribution. Go¨tte et al. (2015) go about the optimisation of the interim decision
quite differently, where they seek to maximise the probability of a correct decision,
as with the optimisation of Brannath et al. (2009) this could also be written as
a special case of our version of optimisation under the correct choice of utility
function.
The Bayesian decision framework we use to optimise the decision at the
interim analysis of Adaptive Enrichment trials may also be used to compare the
overall trial performance with fixed sampling alternatives. The paper by Ondra
et al. (2016) recently took this approach to comparing competing design choices
(including Adaptive Enrichment) for a particular trial, they did not optimise the
interim decision of the trial. Thus our use of the Bayesian decision framework to
optimise Adaptive Enrichment trials extends upon the current literature in this
aspect. We are also able to compare the overall performance of the Bayes optimal
Adaptive Enrichment trials to show the maximum benefit that may be achieved
by using an Adaptive Enrichment trial in any particular scenario.
1.2 Roadmap of this work
In Chapter 2 we introduce randomised controlled trials in a simple form,
defining our notation and discussing the basic principles of conducting a trial.
Chapter 3 extends immediately from this, introducing the two formulations of
the problem that we consider when conducting Adaptive Enrichment trials. In
this Chapter we introduce all of the necessary hypothesis testing methods and
describe the recruitment of Adaptive Enrichment trials and the fixed sampling
alternatives used throughout the work.
In Chapter 4 we evaluate the overall performance of Adaptive Enrichment trials
in comparison to the fixed sampling alternatives using a gain function as a single
measure. We introduce Oracle decision rules as the first form of optimisation,
this is the best possible optimisation as it assumes the true treatment effects are
known. We then introduce the Bayes decision framework allowing us to optimise
rules of a simple form and ultimately find the Bayes optimal decisions. Using
the same framework we compare the performance advantage of these optimised
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decision rules, learning about the improvement the optimal adaptive designs may
offer over fixed sampling trials.
In Chapter 5 we remove the simplifying assumption that observations are im-
mediately available, applying our decision making framework to more complicated
data. First we look at a delayed response, in this setting we have less informa-
tion to make our decision but still have the same remaining sample size to alter.
Despite these extra complications we are still able to use the same optimisation
framework to optimise the interim decision and to evaluate the overall perfor-
mance. Using survival endpoints we find that using the log-rank score statistic to
summarise the trial gives the equivalent performance to that seen when assuming
a delay to responses. We then see that if we have longitudinal observations the
interim decisions may be enhanced by assuming a joint model for the observations
over time, this recovers some of the performance lost in the designs assuming a
delayed response.
In Chapter 6 we examine the sensitivity of the Adaptive Enrichment trial to
the values of the design parameters we chose in earlier Chapters, we vary the prior
distributions and the recruitment patterns and evaluate the effect on the overall
performance of the designs. In addtion to these parameters we also made choices
about how any hypothesis tests would be conducted and what decisions would be
available at the interim analysis, we examine how the overall performance may
be improved by changing the hypothesis testing methods or allowing for early
stopping for futility in Chapter 7.
In Chapter 8 we summarise our conclusions from our work and dicscuss some





2.1 A simple clinical trial
Randomised controlled clinical trials are used to establish the efficacy and
safety of new treatments in comparison to the current standard of care, statistical
principles for clinical trials are given by ICH Steering Committee and others
(1998). We begin by discussing a randomised controlled trial in their simplest
form. This allows the introduction of necessary notation and explanation of
assumptions that have been made. The purpose of a randomised controlled trial
is to find out whether a new treatment is more effective than a control treatment
for treating some illness. The control is commonly an existing treatment that
is the current standard of care for the illness, or where this is not available a
suitable placebo is used. The trial will provide evidence about the effect of the
new treatment in comparison to the control. Typically the trial will be conducted
in some sub-set of the population with the illness, based on specific eligibility
criteria. The trial designs presented in this work are intended to be suitable for
use as Phase III or confirmatory trials, and so hypothesis testing will be required
to ensure control of the type I error rate.
Suppose we have a single primary endpoint, we shall assume that an increase in
the mean value of the response indicates a positive effect on the illness. Thus the
new treatment giving a higher value than the control implies the new treatment
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is better for patients. Conversely we could choose to look for a reduction in the
observed endpoint meaning an improvement for the patient.
Initially we shall assume that the endpoint is observed immediately, or at least
that any delay in observation is negligible. For example we might observe some
measure of the illness before giving the treatment and then again 24 hours later,
this allows us to assess the difference the treatment has made in a very short
amount of time. The assumption of immediate response is made in Chapters 3, 4,
6 and 7. In Chapter 5 we remove this assumption working with delayed responses
and discuss the application to survival endpoints.
Defining the average improvement provided by the new treatment as µx and
the average improvement provided by the control as µy. It is µx and µy that
must be compared by the trial, if the new treatment is better than the control
treatment then we expect to see µx > µy. Proving µx > µy shows that the new
treatment is superior to that given in the control.
An alternative representation of the new treatment being superior to the control
is to consider only the difference between the µx and µy, we will refer to this as
the treatment effect denoted by θ, where θ = µx − µy. Conducting the trial
to assess whether θ > 0 is equivalent to assessing whether µx > µy. We will
formulate the questions of interest in terms of θ as this will allow for a clearer
notation, particularly in the more complicated examples of the later chapters.
From the treatment effect we define the null hypothesis H0 : θ ≤ 0, with the
alternative hypothesis being H1 : θ > 0. The trial is then conducted to provide
evidence to perform a hypothesis test with type I error rate = α. Where we
control the type I error at level α when,
Pθ(Reject H0) ≤ α for all θ ≤ 0. (2.1)
The type I error rate may be thought of as the probability that a false claim of
efficacy is made and is used to protect patients from treatments that provide no
benefit.
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2.2 Conducting a simple trial
In conducting a trial, patients are recruited from the population of interest.
This population is the group of people with the disease being investigated who
should benefit from the new treatment, there may be additional eligibility criteria
based on other factors such as the stage of the disease. The patients are
randomised into two treatment groups, one group of patients will be given the
new treatment the other group of patients will be given the control. Within each
group we observe the response to treatment allowing us to estimate the treatment
effect. In practice recruitment and randomisation are non-trivial aspects of a trial
design, however they are not the focus of the work to follow; we shall assume that
recruitment and randomisation are conducted in such a way as to ensure that the
patients on each treatment arm are representative of the overall population and
randomised evenly.
We assume a total of n patients are recruited, where n is chosen before the trial
begins. Of these patients nx are randomised to the new treatment and ny to the
control treatment; the ratio nx/ny is chosen before randomisation to achieve
the required sample size in each treatment arm. The observations collected
from the patients receiving the new treatment are given by X1, ..., Xnx , and the
observations from the patients receiving the control are given by Y1, ..., Yny . We
shall assume that these observations are independent and identically distributed
with Xi ∼ N(µx, σ2x) for all i = 1, ..., nx and Yi ∼ N(µy, σ2y) for all i = 1, ..., ny.
From the observations of the patients response to the treatment we find
estimates X¯ = 1
nx
∑nx




i=1 Yi for µx and µy respectively. The
estimate of the treatment effect, θˆ say, is given by θˆ = X¯ − Y¯ and under the
assumptions that nx = ny and the treatment and control have a common variance,








It is not always the case that such simple assumptions may be made about the
observations, however these assumptions will be sufficient for our investigations.
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The methods that follow for Adaptive Enrichment do not require these assump-
tions, all that is required is the ability to provide a p-value for hypothesis testing.
From our estimate of the treatment effect we construct a hypothesis test for
the null hypothesis. We find the Z-value from the estimate of the treatment effect






which has the corresponding one sided P-value
P = 1− Φ (Z) .
Under the null hypothesis Z ∼ N(0, 1) and P ∼ Unif(0, 1) and we reject the
null hypothesis at level α when Z ≥ φ−1(1 − α) and P ≤ α. This ensures
Pθ(Reject true H0)≤ α for all θ ≤ 0.
If H0 is rejected (and therefore H1 is accepted) then there is evidence to suggest
that the new treatment is effective for treating the disease when compared to that
used in the control. Recall here that the control of the type I error was important
in the context of a confirmatory trial, as this is one of the requirements for
approval of the treatment by the regulatory bodies. With this in mind we will
also require control of type I error when conducting Adaptive Enrichment trials.
Example
Let us consider a small example to illustrate how a trial of this simplified form
might run. Our aim is to demonstrate that µx > µy or θ > 0, giving the null
hypothesis H0 : θ ≤ 0 which we test at α = 0.025.
In this example we will use σ2 = 222, from which we will select a suitable
sample size. To choose the sample size we consider the power, 1 − β say, of our
trial at a given important value δ where this is given by
P(Reject H0|θ = δ) = 1− β.
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Defining Φ to be the CDF of the standard normal distribution then to achieve
power 1 − β at a given value of the true treatment effect θ = δ we require the
sample size given by
n = 4σ2
(




Setting the type I error to be α = 0.025 for a one sided test of the null hypothesis
and aiming for 1− β = 0.9 at τ = 10, gives a required sample size of n ≈ 200.
Choosing the true values to be µx = 15 and µy = 0 we simulate a single trial. By
simulation we get values x1, ..., x100 for the new treatment with xi ∼ N(15, 222) for
i = 1, ..., 100 and y1, ..., y100 for the control with yi ∼ N(0, 222) for i = 1, ..., 100.
Looking at the results from one particular simulation, we observe x¯ = 17.18 and
y¯ = −1.62, this gives θˆ = 18.80. From this value of θˆ we obtain the p-value for
the one sided test of the null hypothesis p = 0.001 and so under this particular
realisation of the trial the null hypothesis H0 : θ ≤ 0 is rejected.
Simulating a single realisation of a trial is interesting, however we will be
placing higher emphasis on the overall properties of each trial designs. In this
example the key characteristic is the power, we may wish to consider what
happens to the power over a range of possible values of θ. A power curve such as
the one shown in Figure 2-1 will help us to understand how the trial will behave
as we change characteristics governing the design of a trial. Here we observe the
power over a range of possible values of θ, where for a given true value θ = δ we
achieve power = 1− β.
Although we can perform the computation of power directly it is worth
discussing now how these results can be simulated as we will do this regularly
in subsequent examples. For any particular value of θ we may repeat the above
simulation in order to find the proportion of times that the null hypothesis is
rejected. Table 2.1 shows some results from such a simulation, this simulation
used the same parameters as the rest of the example. For the given values of
µx and µy we simulate m trials, from this we obtain an estimate ˆ1− β as the
proportion of the time the null hypothesis was rejected, we also find the standard
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Figure 2-1: Example of a power curve




( ˆ1− β)βˆ. The table shows that each set of simulations have
produced good estimates of power, as the number of simulations increase we see
that the standard error of the estimate decreases. In the examples that follow
we ensure we have run enough simulations to give our estimates the degree of
accuracy we desire.
Assurance
In addition to understanding what happens over a range of possible values
for θ we may also wish to consider the uncertainty about the true value of θ.
Assurance allows us to do this; see O’Hagan et al. (2005). The uncertainty of
the true parameter value is captured by defining a prior distribution for the true
values, denote this by pi(θ), the assurance is defined as the expected power over

















µx µy θ m ˆ1− β Standard error True power
10 10 0 1,000 0.021 0.005 0.025
10 10 0 10,000 0.025 0.002 0.025
10 10 0 100,000 0.025 0.001 0.025
10 5 5 1,000 0.355 0.015 0.362
10 5 5 10,000 0.371 0.005 0.362
10 5 5 100,000 0.364 0.002 0.362
10 0 10 1,000 0.901 0.010 0.895
10 0 10 10,000 0.892 0.003 0.895
10 0 10 100,000 0.896 0.001 0.895
Table 2.1: Demonstration of estimating power by simulating trials
Example
Returning to our previous example to add some uncertainty we choose the
prior distribution for θ as θ ∼ N(10, 4). From this prior distribution we evaluate
Equation 2.4 to find Epi(θ)(ν(θ)) = 0.86.
If we had competing designs we could compare the value of assurance for each
design and use this to inform our choice. We shall return to the idea of using






3.1.1 Identification of sub-populations
The patient population to be used in the trial will have been carefully selected
based on a set of inclusion criteria, despite this it is not always homogeneous.
It is often possible to identify sub-populations that will react differently to the
treatments, for our purposes we consider how this may impact on the treatment
effect. It may be that part of the population has a particular characteristic that
is expected to interact more favourably with the new treatment and hence this
part of the population may receive a higher treatment effect. Thus we focus on
trials that make use of this predictive information, such as those explained by the
FDA draft guidance on Enrichment strategies of clinical trials, Food and Drug
Administration and others (2012).
Our key assumption is that any sub-populations we use are identified before
the trial begins and thus may be incorporated into the design of the trial. They
may have been identified based on how the treatment is expected to work and
characteristics that will assist this, or they may have been observed in previous
stages of the development process or other trials for the disease.
19
Adaptive Enrichment trials aim to make efficient use of these pre-identified
sub-populations by allowing for hypothesis testing of multiple sub-populations,
selecting which should be used based on trial observations. When planning to test
multiple hypotheses we must ensure we do not inflate the error rate, this requires
the introduction of further methods in our hypothesis testing structure. We
discuss these tools in simpler settings first before combining them. In Section 3.1.2
we formalise the questions of interest as the null hypotheses to be investigated,
in Section 3.2 we discuss how the error rate can be controlled when multiple
hypotheses are tested, in Section 3.4 we introduce combination tests as these are
required when observing the data multiple times, in Section 3.5.1 we bring all of
these tools together to see how a typical adaptive enrichment may be conducted.
3.1.2 Formulating the problem
We formulate our problem in a setting of exactly two sub-populations and only
two hypotheses, however all of the methods described are easily extended to more
hypotheses. We consider two scenarios for the sub-populations for conducting
Adaptive Enrichment trials. The first is that there is a single sub-population of
interest within a full population, where we expect the sub-population to react
more favourably to the new treatment than the rest of the population. The
second is that there are two distinct sub-populations that are thought to react
favourably to the new treatment but it is not known which will receive the greater
benefit.
It is possible to consider other scenarios for the sub-populations. For example
if sub-populations are defined by the presence of some gene then a patient may
belong to multiple sub-populations, giving a correlation between sub-populations.
The two scenarios we consider allow us to investigate the performance of Adaptive
Enrichment trials in a simple setting, while demonstrating how the methods may
be applied across a range of formulations for the sub-populations.
Single sub-population
Under the first scenario it is believed that a single sub-population within the
full population may receive a greater benefit from the new treatment. This is
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the first formulation of our problem, we will refer to the sub-population as the
first sub-population or the sub-population of interest. Our trials will attempt to
answer two questions. Is the new treatment effective in the sub-population of
interest? Is the new treatment effective in the population as a whole? To answer
these questions a trial must be conducted that investigates both the treatment
effect in the sub-population, θ1 say, and the treatment effect in the full population,
θ3 say.
The treatment effect in each population may be found as it was in Section 2.2.
In the sub-population of interest let µx1 denote the average response in the
patients who receive the new treatment and µy1 denote the average response
in the patients who receive the control treatment, then θ1 = µx1 − µy1. Consider
also the complement of the sub-population in this second sub-population let µx2
denote the average response in the patients who receive the new treatment and
µy2 denote the average response in the patients who receive the control treatment.
The treatment effect in the complement of the sub-population of interest, θ2 say,
is defined as θ2 = µx2 − µy2.
To answer the question of whether the treatment is beneficial for all patients
we define the treatment effect in the full population, θ3 say. We combine the
treatment effects from each sub-population to find the treatment effect in the
full population. Let λ be the proportion of the full population that this sub-
population of interest makes up, it follows that θ3 = λθ1 + (1− λ)θ2.
From the treatment effects we define two null hypotheses that we wish to test,
H01 : θ1 ≤ 0 in the sub-population of interest and H03 : θ3 ≤ 0 in the full
population; note that the full population may represent the same patients as the
trial population we used in Section 2.2, in which case H03 is equivalent to the H0
we used previously. It is possible to conduct a trial similarly to Section 2.2 that
allows testing of both H01 and H03 or we could choose to conduct the trial only in
the sub-population. Adaptive Enrichment provides a compromise between these
two options in order to make efficient use of the sub-populations.
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Double sub-population
Under the second scenario where there are two separate sub-populations, there
are two key questions for any trial under this formulation of the problem. Is the
new treatment effective in the first population? Is the new treatment effective in
the second population? In this setting we do not test a null hypothesis for the full
population. We refer to this as the second formulation of the problem. As before,
a trial may be conducted to investigate the treatment effects in each population,
θ1 in the first population and θ2 in the second population. Where sub-population
1 accounts for λ of the total sample and sub-population 2 accounts for 1 − λ of
the total sample where λ ∈ (0, 1).
As with the first formulation of the problem we may find estimates of the
treatment effects in the two sub-populations, θˆ1 and θˆ2 in the first and second
sub-populations respectively. From these treatment effects we define the null
hypotheses H01 : θ1 ≤ 0 in the first sub-population and H02 : θ2 ≤ 0 in the
second sub-population. As previously we may choose to conduct trials using
either one of the sub-populations or using both, recruiting the trial from the
appropriate sub-populations and testing the corresponding null hypotheses. The
Adaptive Enrichment trial provides a compromise between these fixed sampling
methods in order to make efficient use of the sub-populations.
3.2 Testing multiple hypotheses
3.2.1 Familywise error rate
Under both formulations of the problem we wish to test multiple null
hypotheses. The testing of multiple hypotheses in the setting of a confirmatory
clinical trial requires more careful definition of the error rate. The FamilyWise
Error Rate (FWER) is defined as the probability of rejecting one or more true
null hypotheses, in our case we require strong control of the FWER. Define θ as
a vector of the true treatment effects then we have strong control of the FWER
at level α if
Pθ(Reject at least one true null hypothesis) ≤ α for all θ. (3.1)
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Dmitrienko et al. (2013) discuss techniques appropriate for strong control of
the FWER, noting that the need to address multiplicity has been recognised
byICH Steering Committee and others (1998) and regulatory bodies Food and
Drug Administration and others (1998) and Committee for Proprietary Medicinal
Products and others (2002).
Example
To demonstrate FWER consider the hypotheses presented in section 3.1.2.
Under the second formulation of the problem we test both H01 : θ1 ≤ 0 and
H02 : θ2 ≤ 0. Given all possible values for θ = (θ1, θ2) there are four possible
combinations of true and false null hypotheses: both H01 and H02 are true, H01
is true and H02 is false, H01 is false and H02 is true, and finally both H01 and H02
are false. Note that changing 2 to 3 in the index of the second hypothesis yields
identical results for the first formulation of the problem.
Under each combination of true and false null hypotheses we may state the
conditions for strong control of the FWER. If both H01 and H02 are true then we
require,
Pθ(Reject H01, H02 or both) ≤ α.
If H01 is true and H02 is false then we require,
Pθ(Reject H01) ≤ α.
Simillarly if H01 is false and H02 is true then we require,
Pθ(Reject H02) ≤ α
If both H01 and H02 are false then no false claim can be made and so no
condition is necessary. If all of these conditions are met by a particular method
for hypothesis testing then we have strong control of the FWER as defined in
equation 3.1.
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3.2.2 Closed testing procedures
Gabriel (1969) discusses simultaneous test procedures for making multiple
comparisons building on the work of Tukey (1951). Marcus et al. (1976) build on
this in the form of a closed testing procedure. A closed testing procedure can be
used to test a general number of null hypotheses while ensuring strong control of
the FWER. Suppose we have n ∈ N treatment effects, θ1, ..., θn say, which define
the null hypotheses H0i : θi ≤ 0 for i = 1, ..., n. In addition to the individual
hypotheses we define all the possible intersections of these null hypotheses from
H01 ∩ H02 to
⋂n
i=1H0i. The intersection between hypotheses, say H0i ∩ H0j for
i 6= j, is given by
H0i ∩H0j = θi ≤ 0 ∩ θj ≤ 0.
Suppose we are able to define level α tests for all possible intersection hypotheses
then to reject any null hypothesis, say H0i : θi ≤ 0 for i = 1, ..., n, globally at
level α we must reject all of the level α tests for hypotheses in which θi appears.
Example
Suppose we wish to conduct hypothesis test for the null hypotheses
H01 : θ1 ≤ 0 and H02 : θ2 ≤ 0 whilst strongly controlling the FWER.
A closed testing procedure for this pair of hypotheses will require level α
tests of H01, H02 and H01 ∩H02. In order to reject H01 globally at level α
the individual tests of H01 and H01 ∩H02 must both be rejected. Similarly
in order to reject H02 globally at level α the individual tests of H02 and
H01 ∩H02 must both be rejected.
Recall from equation 3.1 that in order to achieve strong control of the FWER
we require,
Pθ(Reject at least one true null hypothesis) ≤ α for all θ.
Let θ = (θ1, ..., θn), for any choice of θ there is a corresponding set of true null
hypotheses. We define H as the vector of indexes corresponding to the true null
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hypotheses, thus the intersection of all true null hypotheses is⋂
i∈H
H0i.
Under a closed testing procedure to reject any individual null hypothesis we must
reject
⋂
i∈H H0i in order to reject any of the true null hypotheses globally. From




H0i) ≤ α for all θ,
and hence we have strong control of the FWER.
Example
Returning to our two hypothesis example we can check that the
conditions required for strong control of the FWER are met. If both H01
and H02 are true then the level α test of H01 ∩ H02 must be rejected
to reject either or both of the true null hypotheses globally and since
H01 ∩ H02 is true we have Pθ(Reject H01) ≤ α, Pθ(Reject H02) ≤ α and
Pθ(Reject H01 and H02) ≤ α. If H01 is true and H02 is false then the level
α test of H01 must be rejected to reject the true null hypothesis and we
have Pθ(Reject H01) ≤ α. Similarly if H01 is false and H02 is true then the
level α test of H02 must be rejected to reject the true null hypothesis and
so Pθ(Reject H02) ≤ α. With all of these conditions met strong control of
the FWER is achieved.
3.2.3 Procedures that give strong control of the FWER
are closed testing procedures
Testing of multiple hypotheses is a problem that can be approached in many
different ways, however I will only consider the use of closed testing procedures.
This does not restrict the use of the trial designs presented as we claim that any
testing procedure that gives strong control of the FWER for multiple hypotheses
can be written as a closed testing procedure.
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Proposition 3.2.1. A hypothesis testing procedure gives strong control of the
FWER if and only if it is a closed testing procedure.
To see that this is true consider any testing procedure that gives strong control
of FWER for n ∈ N null hypotheses, recalling equation 3.1 this means that
Pθ(Reject at least one true null hypothesis) ≤ α for all θ.
Let ξ1, ..., ξn be the rejection regions say corresponding to globally rejecting the
null hypotheses H01, ..., H0n. Let X be the observed data from the trial then we
reject the null hypothesis H0i : θi ≤ 0 globally at level α if X ∈ ξi. So from
strong control of the FWER we have
Pθ(θˆ ∈ ξi) ≤ α
for all θ such that H0i is true. These rejection regions may be used to form the
closed testing procedure for testing all the null hypotheses.
Strong control of the FWER ensures Pθi(Reject H0i) ≤ α for all θ where θi ≤ 0,
for i = 1, ..., n so the tests of individual hypotheses are at level α as required for
a closed testing procedure.
For any subset I of 1, ...n and associated interesection null hypothesis HI =
∩i∈IH0i we require a level α test for the closed testing procedure. We define the
rejection region for the test of HI as RI = ∪i∈Iξi. For example for I = (1, 2)
then the intersection null hypothesis is HI = H01 ∩H02 and the rejection region
is defined as RI = ξ1 ∪ ξ2. We have that Pθ(Reject HI) = Pθ(X ∈ RI) and by
strong control of the FWER
Pθ(X ∈ RI) ≤ α for all θ for which HI is true
since X ∈ RI implies a Familywise error is comitted. So this rejection region
provides a level α test for the intersection of the null hypothesis HI .
By construction X ∈ ξi implies that X ∈ RI for every HI with i ∈ I. So
using the tests of the individual hypotheses defined by the ξi and the intersection
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hypotheses as we have defined above as a closed testing procedure is equivalent
to the original multiple testing procedure that gave strong control of the FWER.
3.2.4 Consonance
Even in the simple case of two hypotheses a closed testing procedure requires
rejection of multiple hypothesis tests to reject a single hypothesis globally. If a
test of an intersection hypothesis can be rejected when the hypotheses involved
may not be rejected globally the testing procedure is inefficient, this is the concept
of consonance, see Romano et al. (2011). In the two hypothesis case we have
rejection regions ξ1, ξ2 and ξ12 for testing the null hypotheses H01, H02 and
H01 ∩H02 the closed testing procedure is said to be consonant if
ξ12 ⊆ ξ1 ∪ ξ2.
That is any test of intersection hypothesis should not be rejected where no
hypotheses may be rejected globally, this property ensures that the testing
procedure spends the full α efficiently. In our two hypothesis example if there
are outcomes where X ∈ ξ12 and X 6∈ ξ1∪ ξ2 then the type I error rate for testing
H01 ∩H02 is not used efficiently.
3.3 Fixed sampling designs
3.3.1 Formulation 1: single sub-population
Before we describe the Adaptive Enrichment designs we consider some fixed
sampling designs that will allow testing of the same null hypotheses. Recall from
section 3.1.2 that under the first formulation of the problem the null hypotheses
are H01 : θ1 ≤ 0 and H03 : θ3 ≤ 0. Where θ1 is the treatment effect in the
sub-population of interest and θ3 is the treatment effect in the full population.
The conduct of the trial is similar to that seen in section 2.2, however now we
must keep track of which patients belong to each of the sub-populations.
Fixing the total sample size to be a total of n patients the recruitment is
split between the sub-population of interest and its complement. We denote the
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proportion of patients recruited from the sub-population of interest by λ and so
the number of patients in the first sub-population is
n1 = λn.
Similarly the number of patients in the complement is
n2 = (1− λ)n
and n = n1 + n2. Within each sub-population patients are randomised between
the new treatment and the control. In the first sub-population nx1 is the number
of patients allocated to the new treatment and ny1 is the number of patients
allocated to the control treatment. Likewise in the second sub-population nx2 is
the number of patients allocated to the new treatment and ny2 is the number of
patients allocated to the control treatment.
When collecting our observations we introduce an additional subscript to indi-
cate the sub-population the patient is from. X1,1, ..., Xnx1,1 are the observations
from patients in the sub-population of interest receiving the new treatment and
X1,2, ..., Xnx2,2 are the observations from the patients in the complement pop-
ulation receiving the new treatment. Similarly Y1,1, ..., Yny1,1 are the observa-
tions from patients in the sub-population of interest receiving the control and
Y1,2, ..., Yny2,2 are the observations from the patients in the complement popula-
tion receiving the control.

















i=1 Yi,2 respectively. These estimates can then be used to obtain estimates
for θ1 and θ3, we start by finding the treatment effect in each sub-population
θˆ1 = X¯1 − Y¯1, θˆ2 = X¯2 − Y¯2 and the treatment effect in the full population is
given by θˆ3 = λθˆ1 + (1 − λ)θˆ2. As we did in Section 2.2 we assume a common
variance, σ2 say, and split the sample evenly between the new treatment and the































respectively. The corresponding P-values are
P1 = 1− Φ (Z1) , P3 = 1− Φ (Z3) .
If θ1 = 0, Z1 ∼ N(0, 1) and P1 ∼ Unif(0, 1) and we reject H01 : θ1 ≤ 0 when
Z1 ≥ Φ−1(1−α) which is equivalent to P1 ≤ α. This ensures Pθ1(Reject H01) ≤ α
for all θ1 ≤ 0. Similarly if θ3 = 0, Z3 ∼ N(0, 1) and P3 ∼ Unif(0, 1) and we reject
H03 : θ3 ≤ 0 when Z3 ≥ Φ−1(1− α) which is equivalent to P3 ≤ α. This ensures
Pθ3(Reject H03) ≤ α for all θ3 ≤ 0. To apply the closed testing procedure we still
require a test of the intersection of these null hypotheses.
3.3.2 Formulation 2: double sub-population
Under the second formulation of the problem presented in Section 3.1.2 we
define the null hypotheses to be H01 : θ1 ≤ 0 and H02 : θ2 ≤ 0. Recruitment and
randomisation within each sub-population proceeds in exactly the same way as
seen in Section 3.3.1.
As before, with λ as the proportion of the sample in the first sub-population
the sample in sub-population 1 is n1 = λn and the sample in sub-population
2 is n2 = (1 − λ)n. Assuming as before that exactly half of the patients are
randomised to each treatment observations are collected in the same way, and
with the same common variance the treatment effects follow the distributions















In this formulation of the problem we do not require an estimate of the treatment
effect in the full population.
In the same way as before the Z-values for testing the null hypotheses H01 :









respectively. The corresponding P-values are
P1 = 1− Φ (Z1) , P2 = 1− Φ (Z2) .
If θ1 = 0, Z1 ∼ N(0, 1) and P1 ∼ Unif(0, 1) and we reject H01 : θ1 ≤ 0 when
Z1 ≥ Φ−1(1−α) which is equivalent to P1 ≤ α. This ensures Pθ1(Reject H01) ≤ α
for all θ1 ≤ 0. Similarly if θ3 = 0, Z3 ∼ N(0, 1) and P3 ∼ Unif(0, 1) and we reject
H02 : θ2 ≤ 0 when Z2 ≥ Φ−1(1− α) which is equivalent to P2 ≤ α. This ensures
Pθ2(Reject H02) ≤ α for all θ2 ≤ 0. Again to apply the closed testing procedure
we still require a test of the intersection of these null hypotheses.
3.3.3 Simes method for testing the intersection hypothe-
sis
In the closed testing procedure we require a test of the intersection hypothesis.
The method introduced by Simes (1986) allows the construction of a level α
test for an intersection hypothesis with less conservatism than the Bonferroni
correction. Suppose we wish to test H01 ∩H02, let P1 and P2 be the p-values for
testing H01 and H02 respectively, Simes method defines the p-value for testing
H01 ∩H02 to be
P12 = min(2min(P1, P2),max(P1, P2)). (3.4)
When θ1 = 0 and θ2 = 0 P1 and P2 are independent with P1 and P2 ∼
Unif(0, 1). To reject H1 ∩ H2 we must either have 2min(P1, P2) ≤ α which
requires P1 or P2 ≤ α/2 or max(P1, P2) ≤ α which requires P1 and P2 ≤ α.
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Taking the minimum of these means that P(P12 ≤ α) may be written as,
P(P12 ≤ α) = P ((P1 ∩ P2 ≤ α) ∪ (P1 ≤ α/2 ∩ P2 > α) ∪ (P1 > α ∩ P2 ≤ α/2)) .
Using the independent uniform distributions under the null hypotheses we can
see that,
P((P1 ∩ P2 ≤ α) ∪ (P1 ≤ α/2 ∩ P2 > α) ∪ (P1 > α ∩ P2 ≤ α/2))
= P(P1 ∩ P2 ≤ α) + P(P1 ≤ α/2 ∩ P2 > α) + P(P1 > α ∩ P2 ≤ α/2)
= P(P1 ≤ α)P(P2 ≤ α) + P(P1 ≤ α/2)P(P2 > α) + P(P1 > α)P(P2 ≤ α/2)
= α2 + 2(α/2)(1− α)
= α2 + α− α2 = α
and thus the probability we reject the null hypothesis H1 ∩H2 when θ1 = 0 and
θ2 = 0 is α. In this case the argument is easily demonstrated graphically. The
solid line in Figure 3-1 shows the boundary where the intersection p-value is at
level α, P12 = α, below this line P12 < α, the dashed lines show the corresponding
boundaries where P1 = α and P2 = α. The areas for rejecting the null hypotheses
H01 ≤ 0 and H02 ≤ 0 are α, assuming uniform probability in this square it is clear
to see the total area for rejecting the intersection H01∩H02 is also α. Consonance
is also easily observed as whenever the intersection is rejected at least one of the
individual hypotheses is also rejected.
When θ1 < 0 and θ2 < 0 the proof requires more detail; the pclud condition
introduced by Brannath et al. (2002) in the context of combination tests is that
the P-values are stochastically larger than or equal to the Unif(0, 1) and could
be used for this proof, we omit the full detail here. Likewise the proof that
Simes method is appropriate under the first formulation of our problem is more
detailed as we do not have independence between the estimates θˆ1 and θˆ3. A
general proof of the suitability of Simes method is given by Sarkar and Chang
(1997) and Sarkar (1998), this proof applies in this case as it requires a positive
association between the variables which is given by the positive correlation.
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Figure 3-1: Demonstrating Simes method
Simes method is consonant. If the intersection hypothesis H01∩H02 is rejected
at level α then we show that either H01 or H02 must have been rejected. If we
reject H01 ∩H02 we have
P12 ≤ α
this gives
min(2min(P1, P2),max(P1, P2)) ≤ α,
so either
2min(P1, P2) ≤ α
or
max(P1, P2) ≤ α.
If the intersection is rejected due to 2min(P1, P2) ≤ α then Pi ≤ α/2 for i = 1, 2
and so either H01 or H02 must have been rejected. If the intersection is rejected
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due to max(P1, P2) ≤ α then both P1 ≤ α and P2 ≤ α and so both H01 and H02
must have been rejected. This argument also applies under the first formulation
of our problem if we change the subscript 2 to 3.
3.3.4 Example: Formulation 2
A single trial
We now extend the example from Chapter 2 into two sub-populations. Under
the second formulation of the problem we test the null hypotheses H01 : θ1 ≤ 0
and H02 : θ2 ≤ 0 while strongly controlling the FWER at α = 0.025. Choosing
λ = 1/2 we use the same variance and total sample size from Section 2.2, σ2 = 222
and n = 200. Splitting this sample between each sub-population and treatment
group gives nx1 = nx2 = ny1 = ny2 = 50. We could change the proportion of
the sample in each sub-population and hence the sample sizes based on desired
power for each hypothesis as we did before, however in order to make comparisons
between different trial designs we will keep this constant.
For this example we will also assume both populations receive the same benefit
from the new treatment. Setting the true treatment effects µx1 = µx2 = 10 for
the new treatment and µy1 = µy2 = 0 we may simulate an example trial. By
simulation we get observations: xi,1 ∼ N(10, 222) for i = 1, ..., 50 in the first
sub-population for the new treatment, xi,2 ∼ N(10, 222) for i = 1, ..., 50 in the
second sub-population for the new treatment, yi,1 ∼ N(0, 222) for i = 1, ..., 50 in
the first sub-population for the control and yi,2 ∼ N(0, 222) for i = 1, ..., 50 in
the second sub-population for the control.
Suppose for one particular realisation in population 1 we observe x¯1 = 13.5 and
y¯1 = −3.7 giving θˆ1 = 17.2, and in population 2 we observe x¯2 = 5.3 and y¯2 = 0.1
giving θˆ2 = 5.2. This gives p-values p1 < 0.001 and p2 = 0.119 for testing the
null hypotheses in sub-population 1 and 2 respectively, furthermore using Simes
method we find the intersection p-value p12 < 0.001. In this realisation of the
trial we are able to reject H01 since both p1 < α and p12 < α however we accept
H02 since p2 > α.
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Overall characteristics
When comparing trial designs we want to understand the operating charac-
teristics of each trial. Given the two null hypotheses we measure the perfor-
mance of the trial by the probabilities of rejecting each hypothesis individually
or both hypotheses at the same time, these are P(reject H01 and accept H02),
P(accept H01 and reject H02) and P(reject both H01 and H02). To reject H01 we
must observe p1 ≤ α and p12 ≤ α, similarly to reject H02 we must observe p2 ≤ α
and p12 ≤ α and to reject both H01 and H02 we must observe p1 ≤ α, p2 ≤ α and
p12 ≤ α.
Noting that under Simes rule if p2 > α then for p12 ≤ α we must have p1 ≤ α/2
and vice versa. Thus if p1 = α when θˆ1 = k1,α and p2 = α when θˆ2 = k2,α we may
compute the probabilities of rejecting the null hypotheses as follows:
P(reject H01 and accept H02) = P(p1 ≤ α ∩ p2 > α ∩ p12 ≤ α)
= P(p1 ≤ α/2 ∩ p2 > α)
= P(θˆ1 ≥ k1,α/2 ∩ θˆ2 < k2,α),
P(accept H01 and reject H02) = P(p1 > α ∩ p2 ≤ α ∩ p12 ≤ α)
= P(p1 > α ∩ p2 ≤ α/2)
= P(θˆ1 < k1,α ∩ θˆ2 ≥ k2,α/2),
P(reject both H01 and H02) = P(p1 ≤ α ∩ p2 ≤ α ∩ p12 ≤ α)
= P(p1 ≤ α ∩ p2 ≤ α)
= P(θˆ1 ≥ k1,α ∩ θˆ2 ≥ k2,α).
Furthermore in this example we have independence of θˆ1 and θˆ2 so
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P(reject H01 and accept H02) = P(p1 ≤ α ∩ p2 > α ∩ p12 ≤ α)
= P(θˆ1 ≥ k1,α/2)P(θˆ2 < k2,α)
P(accept H01 and reject H02) = P(p1 > α ∩ p2 ≤ α ∩ p12 ≤ α)
= P(θˆ1 < k1,α)P(θˆ2 ≥ k2,α/2)
and
P(reject H01 and reject H02) = P(θˆ1 ≥ k1,α)P(θˆ2 ≥ k2,α)
which may all be evaluated directly when the distributions are known. From













Table 3.1 shows how these probabilities vary as we vary the values of θ1 and θ2.
We see that the probability of falsely rejecting one or more true null hypotheses
is never more than the nominal α = 0.025, as expected. We also observe that the
probability of rejecting each null hypothesis depends not only on the effect in that
null hypothesis but also the effect in the other, this is due to the additional rigour
required under multiple testing. Notice that even when both treatment effects
are 10 (which is what the original sample size was based on) the probability of
rejecting at least one null hypothesis is reduced to 0.774 from the 0.895 seen in
example from section 2.2 where a single hypothesis is tested.
3.3.5 Example: Formulation 1
A single trial
Under the first formulation of our problem we consider a sub-population within
a full population. The key difference with the previous example is that our
hypothesis testing is now concerned with the null hypotheses H01 : θ1 ≤ 0 and
H03 : θ3 ≤ 0. Using λ = 1/2, σ2 = 222 and n = 200 as we did previously we
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θ1 θ2 P(reject both) P(reject H01 only) P(reject H02 only) Σ
0 0 0.001 0.012 0.012 0.025
10 0 0.016 0.500 0.005 0.521
0 10 0.005 0.016 0.500 0.521
10 10 0.388 0.193 0.193 0.774
10 5 0.128 0.407 0.051 0.586
10 7.5 0.249 0.308 0.111 0.668
Table 3.1: Probabilities of rejecting null hypotheses in independent sub-
populations using Simes’ method for the intersection hypothesis
simulate the observations from a single trial in the same way as we did for the
second formulation of the problem.
Using the same realisations for the observations as we did for formulation 2
we may test H01 and H03. Recall that we observed x¯1 = 13.5 and y¯1 = −3.7
giving θˆ1 = 17.2 in population 1, and we observed x¯2 = 5.3 and y¯2 = 0.1 giving
θˆ2 = 5.2 in population 2, combining the information from both sub-populations
gives θˆ3 = 11.2. This gives p-values p1 < 0.001 as before and p3 < 0.001 and
using Simes method we find the intersection p-value p13 < 0.001. So we may
reject both H01 and H03 since p1 < α, p3 < α and p13 < α.
Overall characteristics
To compute the operating characteristics of this trial we make use of the same
computations as the previous example
P(reject H01 and accept H03) = P(θˆ1 ≥ k1,α/2 ∩ θˆ2 < k3,α),
P(accept H01 and reject H03) = P(θˆ1 < k1,α ∩ θˆ2 ≥ k3,α/2),
P(reject both H01 and H03) = P(θˆ1 ≥ k1,α ∩ θˆ2 ≥ k3,α).
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θ1 θ2 θ3 P(reject both) P(reject H01 only) P(reject H03 only)
0 0 0 0.008 0.007 0.007
10 -10 0 0.025 0.488 0.000
10 10 10 0.611 0.006 0.239
10 0 5 0.328 0.212 0.016
10 5 7.5 0.531 0.057 0.095
Table 3.2: Probabilities of rejecting null hypotheses in sub and full populations
using Simes’ method for the intersection hypothesis
Under this formulation of the problem we do not have independence of the














from which we may compute these probabilities (the covariance is given by
cov(θ1, λθ1 + (1− λ)θ2) = λvar(θ1)), we use the R package mvtnorm Genz et al.
(2008).
Table 3.2 shows the operating characteristics of the trial under this formulation
of the problem. As expected we see that the FWER is strongly controlled
although there is some conservatism due to the correlation between the sub-
populations. As before the probabilities of rejecting null hypotheses depend on
both treatment effects. Under this formulation of the problem we see that the
trials most often reject both null hypotheses, even when this effect is mostly
driven by the sub-population of interest.
3.3.6 Fixed enrichment
Under either formulation of the problem we may conduct the trial entirely
within a single sub-population; if we do this we are conducting a fixed Enrichment
design as discussed under the predictive Enrichment designs discussed in Food
and Drug Administration and others (2012). The fixed Enrichment design is
conducted in exactly the same way as the trial described in section 2.2 with the
trials patient population restricted to the selected sub-population.
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Recall that the null hypothesis to be tested is of the form H0 : θ ≤ 0, this
could be H01 : θ1 ≤ 0 under both formulations of the problem or H02 : θ2 ≤ 0
under the second formulation of the problem. The same total of n patients will
be recruited and randomised equally between the new treatment and the control.
As in Section 2.2 we collect observations from the treatment and control to
estimate the treatment effect. Suppose we are conducting the trial in sub-















which has the corresponding P-value
P1 = 1− Φ (Zi) .
If θ1 = 0, Z1 ∼ N(0, 1) and P1 ∼ Unif(0, 1) and we reject H01 : θ1 ≤ 0 when
Z1 ≥ Φ−1(1−α) which is equivalent to P1 ≤ α. This ensures Pθ1(Reject H01) ≤ α
for all θ1 ≤ 0.
Example
Suppose we restrict recruitment to sub-population i and test the corresponding
null hypothesis H0i : θi ≤ 0 for i = 1, 2. The probability of rejecting H0i depends
on θi in exactly the same way as the example of Section 2.2. Table 3.3 is a
recap of the operating characteristics of this trial given true treatment effects, as
expected we see an increase in power as the treatment effect rises.
3.4 Combination tests
Adaptive Enrichment designs involve an interim analysis where we may adapt
the recruitment strategy for the remainder of the trial. Which data are collected
after the interim analysis depends on the interim decision, and therefore the
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µx µy θi Pθi(Reject H0i)
10 10 0 0.025
10 5 5 0.362
10 2.5 7.5 0.674
10 0 10 0.895
Table 3.3: Power in a single hypothesis trial
data observed by this interim point. These multiple looks at the data must be
accounted for when hypothesis testing in order to maintain strong control of the
FWER.
Consider a single null hypothesis H0 : θ ≤ 0 which is to be tested in a two
stage experimental design. Suppose we split our sample such that we have n(1)
observations from the first stage of the trial and n(2) observations from the second
stage and we have a common variance σ2. We obtain estimates θˆ(1) and θˆ(2), for










respectively, for which the corresponding P-values are
P (1) = 1− Φ (Z(1)) , P (2) = 1− Φ (Z(2)) .
From this a combination test will find the corresponding combined Z-value, Z(c)
say, and P-value, P (c) say. We require control of the type I error rate, recall from
Equation 2.1 that this is the case when
Pθ(Reject H0) ≤ α for all θ ≤ 0.
To achieve this combination tests require that Z(1) and Z(2) are independent
random variables, and thus P (1) and P (2) are also independent. When θ = 0
this means Z(i) ∼ N(0, 1) and P (i) ∼ Unif(0, 1) for i = 1, 2 which ensures
Pθ(Reject H0) ≤ α for θ = 0. For our designs the data from the first stage D(1)
may change how the second stage is conducted and so Z(2)|D(1) = d(1) ∼ N(0, 1),
however this is true for all realisations of the first stage d(1) giving us conditional
independence between Z(1) and Z(2) and we have Z(2) ∼ N(0, 1). For the case
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when θ < 0 Brannath et al. (2002) use the the pclud condition, requiring only that
the P-values to be stochastically larger than or equal to the Unif(0, 1).
3.4.1 Weighted inverse normal
For the time being we shall use the weighted inverse normal combination test,
see Lehmacher and Wassmer (1999), this uses Z(1) and Z(2) to find P (c). The
statistics Z(1) and Z(2) are weighted together to find the combined Z-value Z(c).








The combined Z-value corresponds to the combined p-value in the usual way
P (c) = 1− Φ(Z(c)).
When θ = 0, Z(c) is a sum of two independent normal random variables
and is therefore normally distributed. The choice of the weights give us that
Z(c) ∼ N(0, 1) and so P (c) ∼ Unif(0, 1) which gives a level α test for H0. When
θ < 0 the Pclud argument applies, as in Brannath et al. (2002). Using either Z
(c)
or P (c) we construct a level α test for H0 in the usual way.
The pre-specified weights w1 and w2 influence the probability of rejecting the
null hypothesis of this procedure, if we achieve a sample such that the weights are
in the same proportion as the sample size in each stage then the weighted inverse
normal is as powerful a test for H0 : θ ≤ 0 as testing without multiple stages
since we achieve the same variance. Having pre-specified the weights achieving







will be optimal, the consequence of this is that we choose our weights based on
the expected sample size within each stage.
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Example
We return again to the example from section 2.2, but now we split the trial
into two stages. The pre-interim recruitment cohort will recruit n(1) patients and
the post-interim recruitment cohort will recruit the remaining n(2) patients such
that n(1) + n(2) = n. Splitting the trial such that we recruit half of the patients
in the first stage of the trial we will first observe 50 patients from each treatment
arm in stage 1 and then 50 patients from each treatment arm in stage 2.
We assume the observations are still from the same distributions but now
we also index them by stage. So in the first stage we collect observations
x
(1)
i ∼ N(10, 222), i = 1, ..., 50, for the new treatment and y(1)i ∼ N(0, 222),
i = 1, ..., 50, for the control. Similarly in the second stage we collect observations
x
(2)
i ∼ N(10, 222), i = 1, ..., 50, for the new treatment and y(2)i ∼ N(0, 222),
i = 1, ..., 50, for the control. We obtain estimates of the treatment effect within
each stage: θˆ(1) in the first stage and θˆ(1) in the second stage. These estimates are
combined using the weighted inverse normal combination test to give an overall
p-value for the null hypothesis.
For one particular simulation we observe µˆ
(1)
x = 10.9 , µˆ
(1)





y = −3.8. These give θˆ(1) = 6.6 and θˆ(2) = 17.8, to combine these we
find the corresponding Z-values Z(1) = 1.5 and Z(2) = 4.0. Choosing weights
w1 = w2 = 1/
√
2, applying these gives the combined Z-value Z(c) = 3.9 which
may be used to find the p-value p(c) < 0.001 which allows us to accept/reject the
null hypothesis for the two stage trial.
In Adaptive Enrichment trials we still have to pre-specify the weights for the
overall testing procedure, however the proportions of the sample in the first and
second stages will vary based on the choice of recruitment made at the interim
analysis. Fixing an overall sample size Table 3.4 compares the power of the
trial as this proportion varies when the weights for the weighted inverse normal
are 1/
√
2 and the treatment effect is 10. We see when the sample matches the
weights at 0.50 the probability of rejecting the null hypothesis is 0.90 as planned
for the single stage trial, this power drops off as the observed trial proportions
move further from optimal. For our investigations of Adaptive Enrichment trials
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Table 3.4: Power when varying the first stage proportion
we will usually use these weights, with the proportion of the sample in the first
stage being either 1/2 or 1/3. The results from Table 3.4 show that this choice
of weights will perform reasonably well in both cases.
3.5 Conducting adaptive enrichment trials
3.5.1 Adaptive enrichment methodology
We now have all of the basic components required to conduct Adaptive
Enrichment trials, all that remains is to put them together. Under either
formulation of the problem the Adaptive Enrichment trial will begin in the same
way as the fixed sampling method testing multiple hypotheses. Patients are
initially recruited from all available populations, with the ability to be able to
test both hypotheses as appropriate to the formulation being used. After a pre-
determined amount of the total sample has been recruited, an interim analysis
is conducted to decide which sub-populations will be sampled for the rest of
the trial. The options at the interim analysis are given by the sub-populations
as defined by the formulation: the trial may continue as it started (recruiting
from all populations) or the trial may be enriched, that is the remainder of
the observations are all recruited from one sub population. Wang and Hung
(2013) give an overview of Adaptive Enrichment designs, with a case study of a
confirmatory trial. Note that the hypothesis testing methods for the Adaptive
Enrichment trial must be pre-defined, thus the null hypotheses are defined and
the formulation of the problem is chosen before the trial begins.
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Data collection
Taking the same total sample size as the fixed sample designs, n patients will
be recruited overall, choosing n(1) as the number of patients to be recruited in
the pre-interim cohort and n(2) as the number of patients to be recruited in
the post-interim cohort. Whichever formulation is being used there are two sub-
populations from which to recruit. The patients in the pre-interim cohort are split
between the two sub-populations. If λ is the proportion of the total population
represented by sub-population 1 then n
(1)
1 = λn
(1) is the number of patients in
the first sub-population in the pre-interim cohort and n
(1)
2 = (1 − λ)n(1) is the
number of patients in the second sub-population in the pre-interim cohort.
In the post interim cohort, we denote the number of patients from the first sub-
population by n
(2)
1 and the number of patients from the second sub-population by
n
(2)
2 . If the decision at the interim analysis was to continue with all populations
then the patients are split between the two sub-populations as they were in the





2 = (1 − λ)n(2). Under both






2 = 0. For formulation 2 it is also possible to enrich into
the second sub-population, in which case n
(2)




Within each of these recruitment groups the patients are randomised equally
between the new treatment and the control treatment as we did before. In the
pre-interim recruitment cohort we collect observations as before: in the first
subpopulation we observe X
(1)
i,1 , i = 1, ..., n
(1)
1 /2, from those receiving the new
treatment and Y
(1)
i,1 , i = 1, ..., n
(1)
1 /2, from those receiving the control; in the
second subpopulation we observe X
(1)
i,2 , i = 1, ..., n
(1)
2 /2, from those receiving the
new treatment and Y
(1)
i,2 , i = 1, ..., n
(1)
2 /2, from those receiving the control.
From these observations estimates of the treatment effects are found as
previously, giving us estimates of the treatment effect from the pre-interim
cohort: θˆ
(1)
1 from sub-population 1, θˆ
(1)
2 from sub-population 2 and under the




1 + (1 − λ)θˆ(1)2 . As before we use a
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The recruitment of the post-interim cohort depends on the decision made at
the interim analysis. If the trial continues in both sub-populations observations





and under the first formulation of the problem θˆ
(2)





















































































Alternatively the trial may continue only in one sub-population in which case
all patients are recruited from this sub-population. Patients are still randomised
equally between the new treatment and the control allowing us to estimate the






























































We require strong control of the FWER when conducting our hypothesis
tests for Adaptive Enrichment designs. Appropriate testing procedures have
been discussed many times for example Bauer and Kohne (1994), Jennison and
Turnbull (2007) and Wang et al. (2009), we follow the same methods.
Under the first formulation of the problem we test the null hypotheses H01 :





3 we find a P-value for the intersection hypothesis using Simes












From the post-interim cohort the p-values available depend on the interim





3 and find a P-value for the intersection hypothesis using












if trial continues only recruiting from the sub-population we only get P
(2)
1 from
the data, we set P
(2)
3 = 1 as this ensures H03 cannot be rejected overall and




1 as we now focus our test on the
data we have collected. For the individual P-values we have already defined
the corresponding Z-values and we may find the equivalent Z-values for the
intersection P-values. We use the weighted inverse normal combination test,
























and the corresponding P-values
P
(c)
































13 are used for the closed testing procedure:
rejecting H01 globally when P
(c)
1 ≤ α and P (c)13 ≤ α and rejecting H03 globally
when P
(c)
3 ≤ α and P (c)13 ≤ α.
We use the same testing methods for the second formulation of the problem.
The only difference here is that the trial may be enriched into either population,
we take the same approach for the intersection hypothesis whichever sub-











In this example we focus on the second formulation of our problem. Using a
total sample size n = 200 we start by splitting this sample size equally between
both sub-populations and both recruitment cohorts. We aim to test the null




Under one particular realisation of this trial we observe: x¯
(1)
1 = 15.0 and
y¯
(1)
1 = −2.0 from which we find θˆ(1)1 = 17.0 for the first sub-population; and
x¯
(1)
2 = 10.7 and y¯
(1)
2 = 2.7 from which we find θˆ
(1)
2 = 8.0 for the second sub-
population. From this we must decide whether to continue the trial in both
populations or in a single population only. To make this decision we will define
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a simple decision rule,
decision =






continue only in sub-population 1 if θˆ
(1)
1 ≥ θˆ(1)2 and θˆ(1)1 , θˆ(1)2 < 7.5










Applying this decision rule to our observations we continue the trial in both
populations. For the second stage of the trial we observe : x¯
(2)
1 = 13.2 and
y¯
(2)
1 = 0.7 from which we find θˆ
(2)
1 = 12.5 for the first sub-population; and
x¯
(2)
2 = 9.1 and y¯
(2)
2 = 8.4 from which we find θˆ
(2)
2 = 0.7 for the second sub-
population.
We now find the combined p-values for the trial to find which hypotheses we





2 = 0.182, using Simes method we get the intersection p-value for the first
stage p
(1)
12 = 0.054. During the second stage, again using Simes method, we get
p
(2)
1 = 0.078, p
(2)
2 = 0.468 and p
(2)
12 = 0.156. As discussed above we find the
combined p-values using the weighted inverse normal giving combined p-values
p
(c)
1 = 0.009, p
(c)
2 = 0.20 and p
(c)
12 = 0.029. In this particular trial we must accept
both null hypotheses, even though we have p
(c)
1 < α the intersection p-value
p
(c)
12 > α and so we are unable to reject the null hypothesis globally.
3.6 An alternative presentation of the summary
statistics
Understanding fully how the trial is constructed at a patient level is important
when designing an actual trial, however our primary concern will be to optimise
the interim decision for the Adaptive Enrichment trial and then compare the
overall behaviour of these optimised Adaptive Enrichment trials with the fixed
sampling alternatives we defined in Section 3.3. The decision rule we used
in Equation 3.6 does not depend on the individual patient results but rather
the summary statistics. Similarly when conducting the hypothesis test we only
require the summary statistics and knowledge of their distributions. We now take
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a simplified approach to these summary statistics rather than considering exact
patient numbers for the rest of our work.
We may define the distributions of the summary statistics without directly
defining the sample size and variance. The Fisher information about the




For normally distributed data (and approximately for large samples in other
cases) the estimate of this parameter is distributed as
θˆ ∼ N(θ, I(θ)−1).
For a clinical trial with total sample size n, split equally between the two
treatments the estimate of the treatment effect we have seen that the estimate
of the treatment effect has variance 4σ2/n. Defining
I˜ = n
4σ2
we can describe the distributions of the summary statistics for the trial designs
we are interested in terms of I˜−1 in place of 4σ2/n that we used previously. The
fixed Enrichment trial recruiting only from sub-population 1 testing H01 : θ1 ≤ 0
finds the corresponding summary statistic θˆ1 which follows the distribution
θˆ1 ∼ N(θ1, I˜−1).
Similarly the fixed Enrichment trial recruiting only from sub-population 2 testing
H02 : θ2 ≤ 0 finds the corresponding summary statistic θˆ2 which follows the
distribution
θˆ2 ∼ N(θ2, I˜−1).
The fixed sampling testing multiple hypotheses varies depending on which
formulation of the problem we are working under. Under both formulations
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of the problem we find
θˆ1 ∼ N(θ1, (λI˜)−1))
and
θˆ2 ∼ N(θ2, ((1− λ)I˜)−1).
Under the second formulation of the problem we have null hypotheses H01 : θ1 ≤ 0
andH02 : θ2 ≤ 0. Under the first formulation we have null hypothesesH01 : θ1 ≤ 0
















Finally the distributions for Adaptive Enrichment designs become easier to
handle. Keeping λ as the proportion of the population in the first sub-population
and defining τ as the proportion of the sample from the pre-interim recruitment
cohort we may define the distributions for each stage and population.
Under the second formulation of the problem the pre-interim recruitment




2 which have distributions,
θˆ
(1)




2 ∼ N(θ2, ((1− λ)τ I˜)−1).
The post interim recruitment cohort may then follow one of three options: If
the trial continues in both sub-populations then the summary statistics for the




2 are distributed as,
θˆ
(2)




2 ∼ N(θ2, ((1− λ)(1− τ)I˜)−1);
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if the trial continues in only a single sub-population then only the summary
statistic in the sub-population will be observed and all of the remaining sample




i ∼ N(θi, ((1− τ)I˜)−1)
Whichever option is chosen we have summary statistics with known distributions
and may conduct the analysis of the trial as outlined in Section 3.5.2.
Similarly under the first formulation of the problem we now see our summary




















(λτ I˜)−1 (τ I˜)−1
(τ I˜)−1 (τ I˜)−1
))
.
This is equivalent to considering the sub-population of interest and comple-
ment separately and then combining these afterwards. This gives
θˆ
(1)
1 ∼ N(θ1, (λτ I˜)−1))
in the sub-population of interest and
θˆ
(1)
2 ∼ N(θ2, ((1− λ)τ I˜)−1)




1 + (1−λ)θˆ(1)2 . The advantage of splitting the
distributions in this way is it allows for simulation from 2 independent normals
which is simpler and provides more detail if desired at the interim analysis.
In this formulation of the problem the post-interim recruitment cohort only has
two options. Continuing in the full population will give summary statistics θˆ1 and
θˆ3 in the sub and full populations respectively, where these have the multivariate















(λ(1− τ)I˜)−1 ((1− τ)I˜)−1




As with the pre-interim cohort we may equivalently write this as two independent
distributions for the sub-population and the complement,
θˆ
(2)
1 ∼ N(θ1, (λ(1− τ)I˜)−1))
θˆ
(2)





1 + (1− λ)θˆ(2)2 . Alternatively the trial may continue only in the
sub-population of interest in which case the only summary statistic is θˆ
(2)
1 which
uses the rest of the available information and is distributed as,
θˆ
(2)
1 ∼ N(θ1, ((1− τ)I˜)−1).
As is the case with formulation 2 whichever option is chosen we have summary
statistics with known distributions and may conduct the analysis of the trial
as outlined in Section 3.5.2. We shall use these distributions described using I˜





4.1 Methods for comparison
When assessing the performance of trials we must understand what good
performance of a trial will look like. For Adaptive Enrichment designs we want to
compare the overall performance with competing fixed sampling designs, learning
where we may see some overall benefit from adaptation particularly when the
fixed sampling designs are doing well. The comparisons that may be made will
differ depending on the formulation of the problem being considered.
4.1.1 Running example
Throughout this chapter we shall keep returning to the same core example








for all trials essentially fixing a total sample size, we saw in Section 3.6 how we
use I˜ in place of the sample size and variance. For the designs that make use
of sub-populations we take λ = 1/2, that is the first sub-population accounts
for half of the sample. The Adaptive Enrichment designs will also have multiple
stages, by taking τ = 1/2 we assume that half of the total sample is used in each
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recruitment cohort. With these defined we may use the distributions given in
Section 3.6 for each of the possible trial designs.
Each of the trial methods require strong control of the FWER as defined in
Equation 3.1. For the designs that test multiple hypotheses we use a closed
testing procedure described in Section 3.2.2. For the intersection hypothesis
we use Simes method seen in Equation 3.4. To ensure strong control of the
FWER in the Adaptive Enrichment trial we follow the analysis method from
Section 3.5.2: we apply Simes method within each recruitment cohort finding
P
(i)
13 for i = 1, 2 under the first formulation of the problem and P
(i)
12 for i = 1, 2
under the second formulation of the problem. When a single population is selected
for the post interim recruitment cohort the intersection p-value is given by the
individual p-value for testing that sub-population. We combine the p-values
from each recruitment cohort using the weighted inverse normal combination
test, Section 3.4.1 with pre-defined weights w1 =
√
τ and w2 =
√
1− τ . We will
use this testing method throughout this chapter under both formulations of the
problem setting α = 0.025.
4.1.2 Formulation 1
Recall from section 3.1.2 that under the first formulation of the problem we
consider a single sub-population of interest within the full population of patients
eligible for the trial. This gives two null hypothesis H01 : θ1 ≤ 0 in the sub-
population of interest and H03 : θ3 ≤ 0 in the full population.
When using fixed sampling methods we may conduct the trial in one of three
ways: a fixed Enrichment trial where we recruit only from the sub-population
of interest and therefore only test H01 : θ1 ≤ 0; a fixed sampling trial testing
multiple hypotheses where we recruit in both the sub-population of interest and
the complement allowing us to test both H01 : θ1 ≤ 0 and H03 : θ3 ≤ 0; or we
could conduct a trial using only the full population and only test H03 : θ3 ≤ 0.
We will not use this final option in our comparisons as the point of Adaptive
Enrichment is to make best use of sub-populations where we place emphasis on
the case where θ1 > θ2.
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For this formulation we allow an Adaptive Enrichment with a single interim
analysis where the options are to continue with both the sub and full populations,
or to enrich the trial continuing only in the sub-population of interest. Continuing
in both populations will allow testing of both H01 : θ1 ≤ 0 and 03 : θ3 ≤ 0, while
continuing only in the sub-population only allows testing of H01 : θ1 ≤ 0.
Example
Using the core example given in Section 4.1.1 we have most of what we require
to find basic properties of all three trial designs. The Adaptive Enrichment trial
also requires a decision rule. We will come to the optimisation of this rule later
in the Chapter, for now we use a simple rule of the form
decision =
continue in both populations if θˆ
(1)
3 ≥ ψ




and set ψ = 7.5 for this example. We will return to this decision rule when we
begin optimisation of Adaptive Enrichment trials in Section 4.3.4.
We find the operating characteristics of both fixed sampling trials and the
Adaptive Enrichment design. There are three outcomes we focus on for each
trial: only H01 is rejected, denote this event byR1; both H01 and H03 are rejected,
denote this event by Rb; or only H03 is rejected, denote this event by R3. The
probabilities of these events for each type of trial can be seen in Table 4.1. The
probabilities for the fixed sampling designs may be computed directly using the
mvtnorm package in R when required, Genz et al. (2008). For the Adaptive
Enrichment design we simulated 1, 000, 000 realisations of the summary statistics
of the trials in order to estimate these probabilities with a standard deviation in




In the first section of Table 4.1 we see that the fixed Enrichment design
that samples and tests the null hypothesis only in the sub-population performs
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Fixed sampling: sub-population only
θ1 θ2 θ3 P(R1) P(R3) P(Rb) P(R1) + P(R3) + P(Rb)
10 10 10 0.900 - - 0.900
7.5 7.5 7.5 0.674 - - 0.674
5 5 5 0.362 - - 0.362
10 0 5 0.900 - - 0.900
7.5 0 3.75 0.674 - - 0.674
5 0 2.5 0.362 - - 0.362
10 -10 0 0.900 - - 0.900
Fixed sampling: both populations
θ1 θ2 θ3 P(R1) P(R3) P(Rb) P(R1) + P(R3) + P(Rb)
10 10 10 0.006 0.238 0.619 0.862
7.5 7.5 7.5 0.014 0.227 0.375 0.617
5 5 5 0.021 0.128 0.164 0.313
10 0 5 0.214 0.016 0.334 0.564
7.5 0 3.75 0.141 0.020 0.185 0.347
5 0 2.5 0.070 0.019 0.084 0.174
10 -10 0 0.495 0.000 0.025 0.520
Adaptive Enrichment
θ1 θ2 θ3 P(R1) P(R3) P(Rb) P(R1) + P(R3) + P(Rb)
10 10 10 0.164 0.153 0.516 0.833
7.5 7.5 7.5 0.177 0.128 0.275 0.580
5 5 5 0.120 0.065 0.105 0.289
10 0 5 0.501 0.008 0.192 0.701
7.5 0 3.75 0.342 0.010 0.101 0.452
5 0 2.5 0.166 0.009 0.044 0.219
10 -10 0 0.665 0.000 0.012 0.677
Table 4.1: Comparing operating charateristics under the first formulation of the
problem
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exactly as expected, the probability of rejecting the null hypothesis falls as the
true treatment effect falls and is unaffected by the treatment effect in the full
population. The second section shows a fixed sampling design where multiple
hypotheses are tested. If both treatment effects are strong the overall probability
of rejecting a null hypothesis are similar between the two fixed sampling designs,
with a good chance of rejecting both null hypotheses or just the null hypothesis
in the full population when testing multiple hypotheses. However when the
treatment effect is only present in the sub-population the overall probability of
rejecting null hypotheses is much lower for the design testing multiple hypotheses
when compared to the fixed Enrichment.
Results for the Adaptive Enrichment design, shown in the third section of
Table 4.1, fall somewhere between the two fixed sampling methods. When both
treatment effects are high the Adaptive Enrichment design allows rejection of
both hypotheses with a slightly lower probability in the full population than the
fixed design testing multiple hypotheses. When a treatment effect is only present
in the sub-population of interest we see that some of the probability of rejecting
this hypothesis under the Adaptive Enrichment design lies between the two fixed
sampling alternatives.
4.1.3 Formulation 2
The second formulation of our problem also introduced in section 3.1.2 uses
two independent sub-populations within the patient population and is not
concerned with the treatment effect in the full population. The corresponding
null hypotheses are H01 : θ1 ≤ 0 in the first sub-population and H02 : θ2 ≤ 0 in
the second sub-population.
In this formulation of the problem the fixed sampling methods that we make
comparisons with are constructed slightly differently. As before we may conduct
a fixed Enrichment trial, however this may be in either the first or second sub-
population. This means recruiting in a single sub-population and then testing
either H01 : θ1 ≤ 0 or H02 : θ2 ≤ 0 as appropriate. As in the first formulation
we may still recruit patients from both sub-populations allowing us to test both
H01 : θ1 ≤ 0 and H02 : θ2 ≤ 0.
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As with the first formulation of the problem we allow an Adaptive Enrichment
design with a single interim analysis. At this point we may continue the trial in
either sub-population 1 or sub-population 2 only allowing us to test H01 : θ1 ≤ 0
or H02 : θ2 ≤ 0 respectively, or we may continue in both sub-populations testing
both H01 : θ1 ≤ 0 and H02 : θ2 ≤ 0.
Example
Returning to our core example defined in Section 4.1.1 we learn about the
competing trial designs. We define a decision rule for the Adaptive Enrichment
trial that differs slightly from the first formulation of the problem since the options
at the interim analysis have changed. We use a rule of the form
decision =

continue in both sub-populations if θˆ
(1)
1 ≥ ψ and θˆ(1)2 ≥ ψ
continue only in sub-population 1 if θˆ
(1)
1 ≥ θˆ(1)2 and θˆ(1)2 < ψ








where we set ψ = 7.5.
The final difference in this formulation is in the possible outcomes of the trial: if
only H01 is rejected we denote this event by R1, if both H01 and H02 are rejected,
denote this event by Rb and if only H02 is rejected we denote this event by R2.
The probabilities of these events for each trial design can be seen in Table 4.2.
Table 4.2 allows us to compare the fixed sampling designs with a simple
Adaptive Enrichment design for the second formulation of the problem. We see
that when the treatment effect in a sub-population is high the fixed Enrichment
trial in this population is performing well for the individual hypothesis. However
we see the issue that the fixed Enrichment trial is not robust when the
treatment effect is in the opposite sub-population, in this respect both the fixed
sample testing multiple hypotheses and the Adaptive Enrichment design offer an
improvement. The Adaptive Enrichment design gives a higher power of rejecting
at least one null hypotheses than the fixed sample testing multiple hypotheses in
all of these examples, this is largely down to the additional probability of rejecting
the null hypothesis in the sub-population with the higher treatment effect.
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Fixed sampling: sub-population 1 only
θ1 θ2 P(R1) P(R2) P(Rb) P(R1) + P(R2) + P(Rb)
10 10 0.900 - - 0.900
5 5 0.362 - - 0.362
10 5 0.900 - - 0.900
5 0 0.362 - - 0.362
5 10 0.362 - - 0.362
0 5 0.025 - - 0.025
Fixed sampling: sub-population 2 only
θ1 θ2 P(R1) P(R2) P(Rb) P(R1) + P(R2) + P(Rb)
10 10 - 0.900 - 0.900
5 5 - 0.362 - 0.362
10 5 - 0.362 - 0.362
5 0 - 0.025 - 0.025
5 10 - 0.900 - 0.900
0 5 - 0.362 - 0.362
Fixed sampling: both populations
θ1 θ2 P(R1) P(R2) P(Rb) P(R1) + P(R2) + P(Rb)
10 10 0.192 0.192 0.397 0.781
5 5 0.108 0.108 0.043 0.260
10 5 0.412 0.051 0.131 0.594
5 0 0.133 0.010 0.005 0.148
5 10 0.051 0.412 0.131 0.594
0 5 0.010 0.133 0.005 0.148
Adaptive Enrichment
θ1 θ2 P(R1) P(R2) P(Rb) P(R1) + P(R2) + P(Rb)
10 10 0.284 0.284 0.276 0.844
5 5 0.145 0.145 0.025 0.315
10 5 0.520 0.079 0.083 0.682
5 0 0.179 0.010 0.003 0.192
5 10 0.079 0.520 0.083 0.682
0 5 0.010 0.179 0.003 0.192
Table 4.2: Comparing operating characteristics under the first formulation of the
problem
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4.2 Constructing a single measure of trial per-
formance
In the examples of section 4.1 we see that each formulation has four mutually
exclusive possible outcomes, three of which involve the rejection of at least one
null hypotheses. The final columns of Tables 4.1 and 4.2 show the probability of
rejecting any combination of null hypotheses, however the overall probability of a
positive outcome may not fully capture the relative importance of each possible
outcome.
4.2.1 Weighting outcomes
Our first aim is to construct a single measure that accounts for the fact that
each hypothesis represents a different population. Let
θ =
(θ1, θ3) under the first formulation(θ1, θ2) under the second formulation.
Taking the probability of rejecting any combination of null hypotheses as a
starting point, under the first formulation of our problem this is
Pθ(R1 ∪R3 ∪Rb) = Pθ(R1) + Pθ(R3) + Pθ(Rb).
Equivalently under the second formulation we have
Pθ(R1 ∪R2 ∪Rb) = Pθ(R1) + Pθ(R2) + Pθ(Rb).
The issue with this is that equal importance is assigned to each possible outcome
of the trial, when in fact the proportion of the population we will claim receive
some benefit from the new treatment varies depending on which hypotheses have
been rejected.
We define the weighted sum of probabilities of rejecting null hypotheses as
W(θ) = ω1Pθ(R1) + ω3Pθ(R3) + ωbPθ(Rb) (4.3)
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under the first formulation of the problem and
W(θ) = ω1Pθ(R1) + ω2Pθ(R2) + ωbPθ(Rb). (4.4)
under the second formulation of the problem.
Example
Returning to our examples from Section 4.1 we compare the different trial
designs using a weighting scheme to see how this may change our interpretation
of the results, this will also provide insight into the roles of the choice of weights.
We choose weights equal to the proportion of the population that may receive
the new treatment based on the rejection of the corresponding null hypothesis,
ω1 = λ = 1/2, ω2 = 1− λ = 1/2, ω3 = 1 and ωb = 1.
The top half of Table 4.3 shows comparisons between the competing trial
designs for these weights under the first formulation of our problem. We see that
the Adaptive Enrichment design is the second best design in most cases, with
the fixed sampling design testing multiple hypotheses being the best. However
this may reflect that the weighting scheme does not fully reflect which the most
positive outcomes are. For example when θ1 = 10 and θ3 = 5 we might want to
reward the fixed Enrichment design for choosing the sub-population who receive
a larger benefit, however our weighting strategy is not capturing this. Since the
true treatment effect is not taken into account we only reward the rejection of null
hypothesis, of equal importance is whether the new treatment actually provides
a benefit to the patients.
The bottom half of Table 4.3 shows similar comparisons for these choices of the
weights under the second formulation of our problem, the Adaptive Enrichment
trial appears to be performing better than it did under the first formulation.
We see that Adaptive Enrichment is always close to the design that maximises
W(θ). Due to the overall reduction in probabilities seen in the fixed design testing
multiple hypotheses we do not see that this design is always the best choice under
this weighting strategy, however we may still wish to reflect the importance of




θ1 θ2 θ3 FE1 MH AE
10 10 10 0.450 0.859 0.751
7.5 7.5 7.5 0.377 0.609 0.492
5 5 5 0.181 0.303 0.229
10 0 5 0.450 0.457 0.451
7.5 0 3.75 0.377 0.277 0.281
5 0 2.5 0.181 0.138 0.136
10 -10 0 0.450 0.273 0.273
Formulation 2
W(θ) under:
θ1 θ2 FE1 FE2 MH AE
10 10 0.450 0.450 0.589 0.560
7.5 7.5 0.377 0.377 0.343 0.353
5 5 0.181 0.181 0.151 0.170
10 5 0.450 0.181 0.362 0.383
7.5 2.5 0.377 0.063 0.186 0.221
5 0 0.181 0.013 0.077 0.098
Table 4.3: Comparing trial designs using a weighted sum: FE1 = Fixed
Enrichment in sub-population 1, FE2 = Fixed Enrichment in sub-population 2,
MH = Fixed sampling testing multiple hypotheses, AE = Adaptive Enrichment
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4.2.2 Gain functions
The strategy of weighting together the possible outcomes is useful as it gives us
a single measure for different combinations of θ that accounts for the differences
in the patient populations that the null hypotheses represent. However this only
depends on the rejection of the null hypotheses. We would also like to reflect the
true benefit provided to patients; to do this we will construct a utility function to
give a higher weight to outcomes where the corresponding treatment effect is also
large. An introduction to this that also gives background on Bayesian decision
making that we will use later is given by Berger (2013). In particular we focus
on defining a gain function as we consider things in terms of the gain associated
with particular outcomes of the trial. We could consider this as the gain from the
perspective of the company, or the gain for the patients receiving an improved
treatment.
We define the gain function in terms of observed outcomes, defining the gain
of each possible outcome. If Ri is true we assign a gain γi(θ) for each i = 1, 2, 3, b
that also reflects the benefit of a true treatment effect of θ. Since the outcomes
are mutually exclusive the overall gain of the trial, G(θ) say, will be given by
the function γi(θ) corresponding to the null hypotheses that are rejected. For
example under the first formulation of our problem we have
G(θ) =

γ1(θ) if H01 is rejected
γ3(θ) if H03 is rejected
γb(θ) if H01 and H03 are rejected.
We assume here that the γi(θ) depend only on the true treatment effects. In
practice the definition might be extended to include things such as the estimates
of the treatment effects from the trial.
To capture the gain more clearly we define indicators I(Ri) for i = 1, 2, 3, b for
the events Ri as
I(Ri) =
1 if Ri is true0 if Ri is false.
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The important point here is that the indicators are about the final outcome of
the trial as we do not achieve any gain until the trial is complete. We define
κ as the observations from the trial and write the gain function as G(θ, κ) to
stress that the outcome of the trial depends on the observed data. We choose κ
here since in practice this may represent any information relevant gain of the new
treatment, in addition to observation of efficacy (such as we use in our examples)
we may also incorporate safety data or even new information about the disease
for example if a new treatment becomes available this may change the gain of
particular outcomes. We now write G(θ, κ) as the sum of the indicator variables
multiplied by the corresponding gain for each possible outcome of the trial. Under
the first formulation of our problem the gain is given by
G(θ, κ) = γ1(θ)I(R1) + γ3(θ)I(R3) + γb(θ)I(Rb) (4.5)
and similarly under the second formulation of our problem we have
G(θ, κ) = γ1(θ)I(R1) + γ2(θ)I(R2) + γb(θ)I(Rb). (4.6)
Our particular choice for the gain function may not be suitable for all studies,
but it need not be rigidly adhered to. The principle of optimising the interim
decision of Adaptive Enrichment trials relies only on the definition of a gain
function not its particular form, the work that follows demonstrates appropriate
methods using one particular choice of the gain function for each formulation of
the problem. We feel it should reflect the gain of the trial, whether this is the
gain to the patient population or the gain from the company perspective. The
choice of gain will influence the optimal design, not just in terms of the interim
decision rule but also which type of trial design may suitable.
Ondra et al. (2016) recently introduced two utility functions appropriate to this
setting. One that may capture important outcomes from the perspective of the
trial sponsor and another that captures important outcomes from a public health
perspective, they then compare fixed sampling trials under these utilities. Our
proposed general forms of the gain function focus on the possible trial outcomes
and evaluating the gain of each for a particular trial, allowing the construction
of appropriate gain functions across a number of trials. In addition to the
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comparison of fixed sampling designs we extend the use of the gain function
to the optimisation of Adaptive Enrichment trials.
We assess the expected performance of a trial by investigating the expected
value of the gain function for choices of θ, Eθ(G(θ, κ), this is given by
Eθ(G(θ, κ) = Eθ(γ1(θ)I(R1) + γ3(θ)I(R3) + γb(θ)I(Rb))
= γ1(θ)Eθ(I(R1)) + γ3(θ)Eθ(I(R3)) + γb(θ)Eθ(I(Rb))
= γ1(θ)Pθ(R1) + γ3(θ)Pθ(R3) + γb(θ)Pθ(Rb)
(4.7)
under the first formulation, similarly under the second formulation
Eθ(G(θ, κ) = γ1(θ)Pθ(R1) + γ2(θ)Pθ(R2) + γb(θ)Pθ(Rb). (4.8)
This is similar to the weighted sum of probabilities we had before but the weights
now depend on the true treatment effects. We use this expected gain in the
same way we used the weighted sum to make comparisons of different designs for
particular values of θ.
Example
Returning to our core example we can see the difference between the weighted
sum and the expected gain. To make this comparison we must first define the
gain functions under each formulation of the problem.
Starting with the first formulation of the problem we choose the γi(θ) to
reflect the true treatment effect and the proportion of people treated setting:
γ1(θ) = λθ1 for the gain of rejecting the null hypothesis only in the sub-population
of interest; γ3(θ) = γb(θ) = θ3 for the gain of rejecting the null hypothesis in the
full population. These values for the γi(θ) give an overall gain function of
G(θ, κ) = λθ1I(R1) + θ3I(R3) + θ3I(Rb). (4.9)
Taking the same approach for the second formulation of the problem we set:
γ1(θ) = λθ1 for the gain of only rejecting the null hypothesis in the first sub-
population; γ2(θ) = (1−λ)θ2 for the gain of only rejecting the null hypothesis in
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the second sub-population; γb(θ) = λθ1 + (1 − λ)θ2 for the gain of rejecting the
null hypotheses in both populations since this is the average benefit received by
patients over both populations. These values for the γi(θ) give an overall gain
function of
G(θ, κ) = λθ1I(R1) + (1− λ)θ2I(R2) + (λθ1 + (1− λ)θ2)I(Rb). (4.10)
Table 4.4 compares the weighted sum, Equations 4.3 and 4.4, with weights
equal to the proportion of the population represented by each hypotheses with the
expected gain given in equations 4.9 and 4.10. Under the first formulation of the
problem we see that the gain function has separated the fixed sampling methods
showing how they are particularly good when used in the most appropriate
scenario but when this is not the case there is potentially a large loss in
performance. The fixed design testing multiple hypotheses is now clearly the
best fixed design when both the sub-population and the complement receive a
benefit from the treatment, and the fixed Enrichment design is better when only
the sub-population receives a benefit. The Adaptive Enrichment design performs
well when compared to the best fixed sampling design in each situation, so across
these few scenarios the adaptive trial appears to be providing the compromise we
expected.
Similarly under the second formulation we see an increased separation between
the fixed sampling designs. We can see that if both treatment effects are high
then we should test both hypotheses, however if the treatment effects are equal
but smaller it becomes more difficult to choose between the three fixed sampling
designs as they all have similar overall performance. If there is only a treatment
effect in one sub-population then the fixed Enrichment design in that sub-
population is clearly the best option, however if the opposite sub-population
was chosen for the fixed Enrichment trial the expected gain is very low. By
comparison the Adaptive Enrichment design regularly performs almost as well as
the best fixed design in terms of Eθ(G(θ, κ)) under all of these scenarios, so it
appears that the compromise made by the Adaptive Enrichment trial is robust
to changes in θ.
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Formulation 1
W(θ) under: Eθ(G(θ, κ)) under:
θ1 θ2 θ3 FE1 MH AE FE1 MH AE
10 10 10 0.450 0.859 0.751 4.50 8.59 7.51
7.5 7.5 7.5 0.377 0.609 0.492 2.83 4.57 3.69
5 5 5 0.181 0.303 0.229 0.91 1.51 1.15
10 0 5 0.450 0.457 0.451 4.50 2.82 3.50
7.5 0 3.75 0.377 0.277 0.281 2.83 1.30 1.70
5 0 2.5 0.181 0.138 0.136 0.91 0.43 0.55
10 -10 0 0.450 0.273 0.273 4.50 2.48 3.33
Formulation 2
W(θ) under: Eθ(G(θ, κ)) under:
θ1 θ2 FE1 FE2 MH AE FE1 FE2 MH AE
10 10 0.450 0.450 0.589 0.560 4.50 4.50 5.89 5.60
7.5 7.5 0.377 0.377 0.343 0.353 2.83 2.83 2.57 2.65
5 5 0.181 0.181 0.151 0.170 0.91 0.91 0.76 0.85
10 5 0.450 0.181 0.362 0.383 4.50 0.91 2.84 3.42
7.5 2.5 0.377 0.063 0.186 0.221 2.83 0.16 1.15 1.52
5 0 0.181 0.013 0.077 0.098 0.91 0.00 0.33 0.45
Table 4.4: Comparing the weighted sum with the expected gain: FE1 = Fixed
Enrichment in sub-population 1, FE2 = Fixed Enrichment in sub-population 2,
MH = Fixed sampling testing multiple hypotheses, AE = Adaptive Enrichment
Comparing designs across the parameter space
Our parameters are not restricted to the few cases we have so far investigated.
We can investigate how the different trial designs behave in terms of the expected
gain over the space of θ. This will help us understand where each trial design
is performing well and where they are performing poorly, in addition we may
directly compare the designs finding which is performing better over the whole
parameter space.
Formulation 1
Starting with the first formulation of the problem, we will begin by looking
at the fixed sampling methods. Figure 4-1 shows how Eθ(G(θ, κ)) changes with
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Figure 4-3: Eθ(G(θ, κ)) of the Adaptive Enrichment design under formulation 1
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Figure 4-4: Regions where Adaptive Enrichment has higher Eθ(G(θ, κ)) than
fixed designs
69
θ1 for a fixed Enrichment design in sub-population 1. Unsurprisingly this looks
fairly similar to the typical power curve, the plot only shows the varying of θ1 as
the expected gain of the fixed Enrichment design on the treatment effect in the
complement of sub-population of interest.
For the fixed sampling design testing multiple hypotheses we must consider
how Eθ(G(θ, κ)) varies with both θ1 and θ2. Figure 4-2 shows the contours of
Eθ(G(θ, κ)) for θ1 and θ2. Under the fixed Enrichment design these contours
would be vertical lines, however when testing multiple hypotheses we see that
expected gain changes steeply due to the interaction between θ1 and θ2.
For the Adaptive Enrichment design we again observe how Eθ(G(θ, κ)) varies
with both θ1 and θ2. Figure 4-3 shows how the expected gain for the Adaptive
Enrichment design varies with the values of θ1 and θ2. The decision rule used
when producing this plot is the one given by Equation 4.1 with ψ = 7.5. The
behaviour of this design is somewhere between the two fixed sampling methods,
we still see curvature in the contours due to the interaction between θ1 and θ2
however it is not as extreme as the fixed design testing multiple hypotheses and
comes closer to vertical when θ2 is small, as would be expected for the fixed
Enrichment design. This again highlights how the Adaptive Enrichment design
compromises between the two fixed sampling methods.
We also make a direct comparison of the fixed sampling and Adaptive
Enrichment trials, Figure 4-4 shows where in the parameter space the Adaptive
Enrichment design performs better than the fixed Enrichment design, the fixed
design testing multiple hypotheses or both. We see that when θ2 is low in relation
to θ1 the Adaptive Enrichment design has a lower expected gain than the fixed
Enrichment design but a higher expected gain than the fixed design testing
multiple hypotheses. Conversely we see that when θ2 is high in relation to θ1
the fixed design testing multiple hypotheses gives a higher expected gain than
Adaptive Enrichment and the fixed Enrichment gives a lower expected gain. So
as we anticipated in areas where one fixed sampling design is performing poorly
the Adaptive Enrichment design takes characteristics similar to the better fixed




















Figure 4-5: Eθ(G(θ, κ)) of the fixed sampling multiple testing design under
formulation 2
There is also an area in Figure 4-4 where the Adaptive Enrichment design gives
a lower expected gain than both of the fixed sampling alternatives we compare it
with. In this region of the plot the fixed sampling designs are providing a similar
level of performance to each other, however when the Adaptive Enrichment design
chooses to enrich the trial the total sample size in that sub-population is 3/4 of
that given by the fixed Enrichment design. The Adaptive Enrichment design
enriching some of the time in this region results in lower probabilities of rejecting
null hypotheses and causes the observed reduction in the expected gain, this is a
necessary trade off for the ability to make good decisions in more extreme regions
of the parameter space.
Formulation 2
Under the second formulation of the problem we have an additional fixed
sampling option to compare the Adaptive Enrichment trial to since we may
now choose either sub-population for the fixed Enrichment design. Whichever
sub-population is chosen for the fixed Enrichment design the trial is recruited





















Figure 4-6: Eθ(G(θ, κ)) of the Adaptive Enrichment design under formulation 2
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Figure 4-7: Comparing Eθ(G(θ, κ)) of the Adaptive Enrichment design with two
of the fixed sampling alternatives under formulation 2
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This is equivalent to the fixed Enrichment design we examined under the first
formulation, so we may refer back to the results discussed for figure 4-1 since they
will be identical regardless of our choice of sub-population.
As before when considering the fixed sampling design testing multiple hypothe-
ses Eθ(G(θ, κ)) will vary with both θ1 and θ2 since we aim to test bothH01 : θ1 ≤ 0
and H02 : θ2 ≤ 0. Examining the contours of Eθ(G(θ, κ)) in figure 4-5 we see that
the expected gain increases with both θ1 and θ2. The expected gain is now sym-
metric about the line θ1 = θ2, due to the symmetry of the two sub-populations
in this formulation of the problem.
For the Adaptive Enrichment trial we use the decision rule given by equation 4.2
with ψ = 7.5, Figure 4-6 shows the contours of Eθ(G(θ, κ)). Under this
formulation of the problem the contour given by the Adaptive Enrichment design
and the fixed sampling design testing multiple hypotheses take a similar shape,
this is because under this formulation of the problem we have Pθ(R1) and Pθ(R2)
driving a large part of the expected gain and while the Adaptive Enrichment
should improve this as we move further away from θ1 = θ2 this increases slowly
and so does not dramatically change the shape of the expected gain.
To fully understand how Adaptive Enrichment is performing across different
combinations of θ1 and θ2 we show in Figure 4-7 where the Adaptive Enrichment
design gives a higher value of Eθ(G(θ, κ)) than the fixed Enrichment trial in sub-
population 1, the fixed sampling trial testing multiple hypotheses or both. In
the top part of the plot where θ2 is high we see that the Adaptive Enrichment
design is better than both of the fixed sampling designs. When θ2 is low we
see that: Adaptive Enrichment provides an improvement over fixed Enrichment
approximately when θ1 > θ2; Adaptive Enrichment provides an improvement over
the fixed sampling design testing multiple hypotheses when θ1 is high. Like the
first formulation of the problem there is a region where the Adaptive Enrichment
design is worse than both of these fixed sampling options, again this is because
when the Adaptive Enrichment design is enriched at the interim analysis it only
recruits 3/4 of the sample size that is used in the fixed Enrichment design.
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Noting that the fixed Enrichment design in sub-population 2 is symmetric to
sub-population 1 (again about the line θ1 = θ2) in this example we see that
the region where the Adaptive Enrichment design is worse than all three fixed
sampling designs becomes very small. Furthermore we see that there are large
regions of the parameter space where the Adaptive Enrichment design is better
than two of the three fixed sampling alternatives and when both θ1 and θ2 are
high it is better than all three even in this unoptimised form.
4.3 Optimisation of adaptive enrichment trials
4.3.1 Oracle decision rule
Knowing that the expected gain is the overall measure of trial performance we
can think more carefully about the interim decision to be made in the Adaptive
Enrichment trial. Taking θ as known we can make our first version of an optimal
decision. Let κ1 be the data from the pre-interim recruitment cohort available
at the interim analysis and consider the expected gain given κ1, Eθ,κ1(G(θ, κ)).
Under the first formulation of the problem from Equation 4.8 we get
Eθ,κ1(G(θ, κ)) = γ1(θ)Pθ,κ1(R1) + γ3(θ)Pθ,κ1(R3) + γb(θ)Pθ,κ1(Rb) (4.11)
where the probabilities of rejecting null hypotheses now depend on the data that
have been observed at the interim analysis. Under the second formulation of the
problem from Equation 4.8 we get
Eθ,κ1(G(θ, κ)) = γ1(θ)Pθ,κ1(R1) + γ2(θ)Pθ,κ1(R2) + γb(θ)Pθ,κ1(Rb). (4.12)
To evaluate the expected gain at the interim analysis we must find Pθ,κ1(Ri)
for i = 1, 2, 3, b, given the observations, κ1, from the pre-interim recruitment
cohort. Given the summary statistics from the pre-interim recruitment cohort
we can find these probabilities under every possible decision. Thus we may
evaluate the expected gain for the rest of the trial for each possible decision
at the interim analysis, we choose the decision that maximises the expected gain
for the remainder of the trial, this is clearly the optimal choice.
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In general we will not know the true value of θ. In this Section we shall
suppose that we do know θ and find the corresponding optimal decision rule,
we refer to this as the Oracle decision rule. This procedure provides an upper
bound for the performance of procedures that have to rely on an estimate, or
a posterior distribution, of θ at the interim analysis. The Oracle decision rule
allows us to clearly see whether Adaptive Enrichment design will be a useful tool
for conducting trials in any particular scenario, as we know it is the best possible
version of Adaptive Enrichment.
Computation under formulation 1
In order to evaluate Eθ,κ1(G(θ, κ) we must find Pθ,κ1(R1), Pθ,κ1(R3) and
Pθ,κ1(Rb). The rejection regions for the null hypotheses based on the summary
statistics for the post-interim recruitment cohort are known given κ1. Following
the testing structure defined in section 4.1.1 we know that applying the closed
testing principle,
Pθ,κ1(R1) = Pθ,κ1(Z(c)1 > Φ−1(1− α) ∩ Z(c)3 ≤ Φ−1(1− α) ∩ Z(c)13 > Φ−1(1− α))
Pθ,κ1(R3) = Pθ,κ1(Z(c)1 ≤ Φ−1(1− α) ∩ Z(c)3 > Φ−1(1− α) ∩ Z(c)13 > Φ−1(1− α))
Pθ,κ1(Rb) = Pθ,κ1(Z(c)1 > Φ−1(1− α) ∩ Z(c)3 > Φ−1(1− α) ∩ Z(c)13 > Φ−1(1− α)).
(4.13)







13 when applying the weighted inverse normal combination test, so we may re-



















Setting the critical values for each Z
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So given the pre-interim observations κ1 if the trial continues in both sub-
populations equation 4.13 becomes
Pθ,κ1(R1) = Pθ,κ1(Z(2)1 > K1,α ∩ Z(2)3 ≤ K3,α ∩ Z(2)13 > K13,α)
Pθ,κ1(R3) = Pθ,κ1(Z(2)1 ≤ K1,α ∩ Z(2)3 > K3,α ∩ Z(2)13 > K13,α)
Pθ,κ1(Rb) = Pθ,κ1(Z(2)1 > K1,α ∩ Z(2)3 > K3,α ∩ Z(2)13 > K13,α).
(4.14)
These probabilities can be made even more precise with further consideration of






1 > K13,α/2 ∪ Z(2)3 > K13,α/2) ∪ (Z(2)1 > K13,α ∩ Z(2)3 > K13,α)





Pθ,κ1(R1) =Pθ,κ1(Z(2)1 > max(K1,α, K13,α/2) ∩ Z(2)3 ≤ min(K3,α, K13,α))
+Pθ,κ1(Z
(2)
1 > K1,α ∩K13,α/2 < Z(2)3 ≤ K3,α)
+Pθ,κ1(Z
(2)
1 > max(K1,α, K13,α) ∩K13,α < Z(2)3 ≤ K3,α)
(4.15)
Pθ,κ1(R3) =Pθ,κ1(Z(2)1 ≤ min(K1,α, K13,α) ∩ Z(2)3 > max(K3,α, K13,α/2))
+Pθ,κ1(K13,α/2 < Z
(2)
1 ≤ K1,α ∩ Z(2)3 > K3,α)
+Pθ,κ1(K13,α < Z
(2)
1 ≤ K1,α ∩K13,α < Z(2)3 > max(K3,α, K13,α))
(4.16)
Pθ,κ1(Rb) =Pθ,κ1(Z(2)1 > max(K1,α, K13,α/2) ∩K3,α < Z(2)3 ≤ K13,α/2)
+Pθ,κ1(K1,α < Z
(2)
1 ≤ K13,α/2 ∩ Z(2)3 > max(K3,α, K13,α/2))
+Pθ,κ1(Z
(2)
1 > max(K1,α, K13,α) ∩ Z(2)3 > max(K3,α, K13,α)).
(4.17)
We know that if we continue in both sub-populations Z
(2)
1 = λ(1 − τ)I˜ θˆ(2)1 and
Z
(2)
















(λ(1− τ)I˜)−1 ((1− τ)I˜)−1




and so these probabilities may be found from this multivariate normal distribu-
tion.
If we continue only in the sub-population of interest things are simpler as we
only need Pθ,κ1(R1) which following the above method may be written as
Pθ,κ1(R1) =Pθ,κ1(Z(2)1 > max(K1,α, K13,α/2)).
Where Z
(2)




1 ∼ N(θ1, ((1− τ)I˜)−1)
so we may find the probability Pθ,κ1(R1) directly.
Computation under formulation 2
We will not repeat the full derivation under the second formulation as it
is mostly the same, the only difference is that at the stage of Equation 4.15,
4.16 and 4.17 we may further split these probabilities using our assumption of
independence between the two sub-populations. Thus if we continue in both
sub-populations we have
Pθ,κ1(R1) =Pθ,κ1(Z(2)1 > max(K1,α, K12,α/2))Pθ,κ1(Z(2)2 ≤ min(K2,α, K12,α))
+Pθ,κ1(Z
(2)









Pθ,κ1(R2) =Pθ,κ1(Z(2)1 ≤ min(K1,α, K12,α))Pθ,κ1(Z(2)2 > max(K2,α, K12,α/2))
+Pθ,κ1(K12,α/2 < Z
(2)
1 ≤ K1,α)Pθ,κ1(Z(2)2 > K2,α)
+Pθ,κ1(K12,α < Z
(2)
1 ≤ K1,α)Pθ,κ1(K12,α < Z(2)2 > max(K2,α, K12,α))
(4.19)
Pθ,κ1(Rb) =Pθ,κ1(Z(2)1 > max(K1,α, K13,α/2))Pθ,κ1(K2,α < Z(2)2 ≤ K12,α/2)
+Pθ,κ1(K1,α < Z
(2)
1 ≤ K12,α/2)Pθ,κ1(Z(2)2 > max(K2,α, K12,α/2))
+Pθ,κ1(Z
(2)
1 > max(K1,α, K12,α))Pθ,κ1Z
(2)
2 > max(K2,α, K12,α)).
(4.20)
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If the trial is enriched into either sub-population we have
Pθ,κ1(R1) = Pθ,κ1(Z(2)1 > max(K1,α, K13,α/2)) (4.21)
in the first sub-population or
Pθ,κ1(R2) = Pθ,κ1(Z(2)2 > max(K2,α, K12,α/2)) (4.22)





2 which have known distributions from Section 3.6. If
the trial continues in both sub-populations we have Z
(2)
1 = λ(1 − τ)I˜ θˆ(2)1 and
Z
(2)
2 = (1− λ)(1− τ)I˜ θˆ(2)2 where the distributions of θˆ(2)1 and θˆ(2)2 are given by
θˆ
(2)
1 ∼ N(θ1, (λ(1− τ)I˜)−1))
θˆ
(2)
2 ∼ N(θ2, ((1− λ)(1− τ)I˜)−1).
If the trial enriches, continuing in only sub-population i (i = 1, 2) then Z
(2)
i =
(1− τ)I˜ θˆ(2)i , where the distribution for θˆ(2)i is given by
θˆ
(2)
i ∼ N(θi, ((1− τ)I˜)−1).
4.3.2 Plotting optimal decision boundaries for Adaptive
Enrichment trials
The optimal decision boundaries computed using the conditional expected gain
for the interim decision of the Adaptive Enrichment designs do not have a simple
form, in order to plot and use them we construct a look up table using a simple
sub-dividing algorithm created for this problem. We start by computing the
optimal decision for the four corners of the overall grid we wish to compute and
iterate the following to find as fine a grid as is required:
• add midpoints between all current grid points
• for each midpoint check the surrounding grid values, if they match assign
this value to the new point
• for the midpoints with no clear value compute the optimal decision
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Figure 4-8: Creating a table to apply the optimal decision rule
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• merge all points into a new grid.
We can easily illustrate this method in Figure 4-8 our aim is to find the decision
boundary given by the dashed line. In the first part of Figure 4-8 we find the
optimal decision in each corner of our grid. Adding the midpoints in the second
part of Figure 4-8 we compute the optimal decision at the solid symbols and
assign the decision at the two white circles. In the third part of Figure 4-8 we see
how as we iterate this process we will not need to compute the optimal decision
at all of the grid points, in the areas indicated by the white symbols we allocate
the existing decision as we continue to find finer grids.
Using this method allows us to find a table giving the optimal decision rules
while only computing the optimal decision for a fraction of the grid points. When
plotting optimal decision boundaries we create the next level of the grid and plot
the points where we would have to compute the optimal decision. To apply an
approximate version of the optimal rule we use the decision of the nearest grid
point.
Example
Returning to our ongoing example we can now determine the Oracle decision
rule for any particular choice of θ. Choosing θ1 = 10 and θ2 = 5 Figure 4-9 shows
the oracle decision under the first formulation of the problem for a small selection




3 . We immediately see how
this differs from the simple decision rule we have been using which would be a
simple horizontal line through θˆ
(1)
3 = 7.5.
Similarly under the second formulation of the problem we may find the Oracle
decision rule for any particular choice of θ1 and θ2. Figure 4-10 shows the Oracle
decision rule under the second formulation of the problem where θ1 = θ2 = 10.
As with the first formulation we see that this rule greatly differs from the simple





large we continue the trial in both sub-populations, otherwise we continue only
in one. There is a blank area where the expected gain is the same for enriching
the trial into either sub-population allowing us to choose either, this is because
80
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Figure 4-9: Oracle decision rule for θ1 = 10 and θ3 = 5 under formulation 1
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Figure 4-10: Oracle decision rule for θ1 = 10 and θ3 = 10 under formulation 2
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Figure 4-11: Oracle decision rule for θ1 = 10 and θ3 = 8 under formulation 2






2 ) so to reject either null
hypothesis globally in stage 2 the critical region is defined by P
(1)
12 and since the
treatment effects are the same the probability of rejecting each null hypothesis
is equal when enriching into either sub-population. The discontinuities in the
boundaries between continuing in both sub-populations and continuing in a single
sub-population are a consequence of using Simes method for the intersection p-
value within each stage of the trial, they appear due to the transition between
2min(P1, P2) max(P1, P2) when taking the minimum to find the intersection p-
value.
Under the second formulation of the problem, because of the fact we can enrich
into either sub-population, the form of the Oracle decision rule is quite sensitive
to the value of the true treatment effects θ. The Oracle decision rule for θ1 = 10
and θ2 = 8 is shown in Figure 4-11. This Oracle decision rule is quite different
to the first one we computed, there is a much larger region where the trial would
enrich into the first sub-population, also since we no longer have symmetry there
is a clear boundary between the first and second sub-populations.
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Formulation 1
θ1 θ3 Pθ(R1) Pθ(R3) Pθ(Rb) Eθ(G(θ, κ))
10 10 0.057 0.163 0.650 7.59
10 5 0.658 0.011 0.110 4.14
10 0 0.714 0.000 0.000 3.57
Formulation 2
θ1 θ2 Pθ(R1) Pθ(R2) Pθ(Rb) Eθ(G(θ, κ))
10 10 0.228 0.228 0.381 6.09
10 5 0.645 0.025 0.071 3.82
10 0 0.712 0.000 0.000 3.56
5 10 0.025 0.645 0.071 3.82
0 10 0.000 0.712 0.000 3.56
Table 4.5: Eθ(G(θ, κ)) of the Adaptive Enrichment design using the Oracle
decision rule
Under both formulations of the problem we can simulate trials that use these
Oracle decision rules to find the operating characteristics. Table 4.5 shows some
examples of this using the Oracle decision rule under each formulation of the
problem. Under the first formulation we see that as the treatment effect in the
full population is reduced the Adaptive Enrichment trial with the Oracle decision
rule places more emphasis on the sub-population of interest as this is where there
is the most gain of rejecting the null hypothesis. The behaviour under the second
formulation of the problem is very similar where the focus of the trial slowly moves
towards a sub-population when the true treatment effect in that sub-population
is higher. Part of the reason for this is that in both formulations of the problem
when the treatment effect in a population drops the gain reduces, to the point
that if we know the treatment effect in the full population or in the opposing
sub-population is 0, there is no gain in this result and the Adaptive Enrichment
trial will always choose to enrich the trial.
The Oracle decision rules are the best possible version of the Adaptive
Enrichment trials giving the upper bound of maximum performance. When
comparing with the fixed sampling designs we can use this to learn whether
the Adaptive Enrichment trials will ever provide a benefit over the competing




θ1 θ3 FE MH OAE
10 10 4.50 8.59 7.59
10 5 4.50 2.82 4.14
10 0 4.50 2.48 3.57
Σ 13.50 13.89 15.30
Formulation 2
Eθ(G(θ, κ)) under:
θ1 θ2 FE1 FE2 MH OAE
10 10 4.50 4.50 5.89 6.09
10 5 4.50 0.91 2.84 3.82
10 0 4.50 0.00 2.62 3.56
5 10 0.91 4.50 2.84 3.82
0 10 0.00 4.50 2.62 3.56
Σ 14.41 14.41 16.81 20.85
Table 4.6: Comparing Eθ(G(θ, κ)) for Oracle Adaptive Enrichment with fixed
sampling designs: FE1 = Fixed Enrichment in sub-population 1, FE2 =
Fixed Enrichment in sub-population 2, MH = Fixed sampling testing multiple
hypotheses, OAE = Oracle Adaptive Enrichment
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Adaptive Enrichment trial designs and the fixed sampling alternatives under each
formulation of the problem.
Under the first formulation of the problem we see that in each of the scenarios
presented the Oracle Adaptive Enrichment design is the second choice of the
three trials, however the Oracle Adaptive Enrichment trial is performing more
consistently over the three scenarios; this is the aim of Adaptive Enrichment,
providing a compromise between the two fixed sampling methods in all cases.
Taking the sum of the expected gain across this small group of possible scenarios
gives a crude measure of how we perform overall. We see that while the fixed
sampling trials are fairly similar to each other in terms of overall performance in
this small selection of scenarios, with the Adaptive Enrichment trial providing a
small overall benefit.
Making the equivalent comparisons under the second formulation of the
problem. When both treatment effects are high we see that Oracle Adaptive
Enrichment is the best choice of trial, this is a very encouraging result. In all
other scenarios Oracle Adaptive Enrichment is the second choice and as with the
first formulation of the problem this is more consistent than the fixed sampling
designs. Once again taking the sum of the expected gain across all of the scenarios
as a crude measure of the overall performance of the trial designs we see that
Oracle Adaptive Enrichment trials perform better than any of the fixed sampling
designs.
What we have seen is the best possible version of Adaptive Enrichment for each
choice of θ. The results show that Adaptive Enrichment designs may provide a
benefit in place of the fixed sampling designs in the examples we have considered.
We know that in practice the decision at the interim analysis will not be able to
be made as well and we may also wish to account for our uncertainty about the
true treatment effects in our analysis of overall performance.
4.3.3 Incorporating prior uncertainty
When designing a trial it is reasonable to assume that we will not know the
true treatment effect, we capture our uncertainty about the true treatment effect
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as a prior distribution. Our plan is to use this prior distribution to assess trial
performance and to optimise the interim decision of the Adaptive Enrichment trial
under the particular choice of prior distribution and gain function. Recall from
Chapter 3 that we have strong control of the FWER for all choices of θ and so
the choice of prior distribution and optimising the decision at the interim analysis
based on this will not have an impact on the FWER. Our use of Bayesian methods
is restricted to optimising the interim decision and evaluating the comparative
performance of different designs within a framework that ensures strong control
of the FWER at all times.
Let Θ be the set of all possible values of the θ for either formulation of our
problem, the cdf of the prior distribution is given by
pi(θ) for all θ ∈ Θ. (4.23)
Where before we considered the expected gain given one particular choice of the
true treatment effects we may now consider the expected gain given the prior
distribution Epi(θ)(G(θ, κ)) we will refer to this as the Bayes expected gain of the





We seek the trial design that maximises this, as this will be the best choice
for conducting a trial given our prior beliefs and the particular definition of the
gain function. The same approach was recently taken by Ondra et al. (2016)
for comparing the overall performance of competing trial designs in this context
using their versions of utility functions, like us their aim was to compare overall
trial designs to choose which is optimal.
As our plan is to use the prior distribution to help us learn which trial is
most suitable this prior distribution should fully reflect our current knowledge
about the true treatment effects. If we have identified sub-populations before
beginning the trial it is likely we have some knowledge of what we expect the
true treatment effects to be. This may be based on knowledge from earlier stages
of development, knowledge of the disease being treated or based upon how the
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treatment is expected to work.
For the rest of the Chapter we focus on using this framework. We shall begin
by evaluating the performance of the simple Adaptive Enrichment designs used
in previous examples using Equation 4.24. We shall then optimise our simple
rules and assess performance increase from this optimisation. Finally we shall
introduce Bayes optimal decision boundaries for the decision rule at the interim
analysis, these are not restricted to any particular form.
Example
Returning again to our ongoing example, if we choose prior distributions as
appropriate for each formulation of the problem we may evaluate the Bayes
expected gain of our simple decision rule. We find the Bayes expected gain
by Monte Carlo integration, we simulate values for θ from the prior distribution
and for each value θ we simulate the data from a single trial, κ, to evaluate
I(R1), I(R2), I(R3) and I(Rb) as appropriate, from which we find the gain of
that particular realisation. Averaging this across the values of (θ, κ) gives our
estimate of Epi(θ)(G(θ, κ)). In this example we simulate 1, 000, 000 realisations to
ensure sufficient accuracy in our estimates.
In our ongoing example under the first formulation we use the prior
θ1 ∼ N(9, 16), θ2 ∼ N(3, 4).
where θ1 and θ2 are independent. This prior suggests that we believe sub-
population 1 is likely to have a higher treatment effect but has a higher variance.















Recall from Equation 4.9 that our choice of the gain function under this
formulation of the problem is
G(θ, κ) = λθ1I(R1) + θ3I(R3) + θ3I(Rb).
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Formulation 1









Table 4.7: Comparing Epi(θ)(G(θ, κ)) for fixed sampling designs with the simple
adaptive enrichment design
The top half of Table 4.7 shows that under this choice of prior and gain function
fixed Enrichment design is the better fixed sampling design. For the Adaptive
Enrichment design our naive choice for the simple decision rule actually proves to
be quite effective in this case, the Bayes expected gain of the Adaptive Enrichment
design is very close to that of the fixed enrichment design.
Under the second formulation of our problem we define the independent priors
for θ1 and θ2 as
θ1 ∼ N(6, 9), θ2 ∼ N(6, 9)
and use the gain function from Equation 4.10
G(θ, κ) = λθ1I(R1) + (1− λ)θ2I(R2) + (λθ1 + (1− λ)θ2)I(Rb).
The bottom half of Table 4.7 compares the Bayes expected gain for each of
the fixed sampling methods and the Adaptive Enrichment trial using the simple
decision rule. Due to the symmetry the fixed Enrichment design is equivalent in
either sub-population, with the fixed sampling design testing multiple hypotheses
being the best of the fixed sampling designs. Again our naive choice of decision
rule for the Adaptive Enrichment design performs well, giving a better overall
performance than both fixed sampling methods.
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Figure 4-12: Optimising the simple decision rule under formulation 1
4.3.4 Simple decision optimisation
We can now easily optimise our simple interim decision rules. For rules of any
particular form we compare the Bayes expected gain for the rule as we change
the parameters that govern it and hence we may find the optimal values for these
parameters.
Example
Continuing the example we will now optimise our simple decision rules for the
interim analysis we have worked with up to this point in the Chapter. Recall
from Equation 4.1 that in the first formulation of the problem we use a simple
rule of the form
decision =
continue in both populations if θˆ
(1)
3 ≥ ψ





Trial design Epi(θ)(G(θ, κ))
Fixed Enrichment 3.78
Multiple hypotheses 3.74
Adaptive Enrichment simple optimal rule 3.79
Adaptive Enrichment always enrich 3.31
Adaptive Enrichment never enrich 3.62
Formulation 2




Adaptive Enrichment always enrich 1.46
Adaptive Enrichment never enrich 2.04
Table 4.8: Comparing Epi(θ)(G(θ, κ)) for fixed sampling designs with the
optimised simple Adaptive Enrichment design
evaluating the Bayes expected gain as we did before for ψ = (0, 1, ..., 10) we see
from Figure 4-12 that this decision is optimal when ψ = 5. The top half of
Table 4.8 shows how the Adaptive Enrichment design with the optimal simple
decision rule compares to the fixed sampling designs, the Adaptive Enrichment
design is now slightly better than both fixed sampling designs; in particular of
the fixed sampling designs the fixed Enrichment design performs well. However
the fixed Enrichment design may be a harder choice in practice (despite the
statistical evidence of its performance). We will find a further improvement for
the Adaptive Enrichment design when we remove the restriction of using rules of
a particular form.
Similarly we can also optimise the simple rule we have been using for the second
formulation of the problem, recall from equation 4.2 that we have been using a
rule of the form
decision =






continue only in sub-population 1 if θˆ
(1)
1 ≥ θˆ(1)2 and θˆ(1)2 < ψ



























Figure 4-13: Optimising the simple decision rule under formulation 2
As before we evaluate the Bayes expected gain for ψ = (0, 1, ..., 10) giving
Figure 4-13 from which we see that the simple decision is optimal when ψ = 5.
The bottom half of Table 4.8 shows how the Adaptive Enrichment trial with
the optimal simple decision rule compares to the fixed sampling designs. We
see that the Adaptive Enrichment design is now slightly further ahead of the
fixed sampling designs, showing an improvement of approximately 9% in the
Bayes expected gain. This shows that even with a very simple decision rule the
Adaptive Enrichment design is able to provide an improvement over these fixed
sampling methods.
We also compare these optimised simple rules with the extremes of Adaptive
Enrichment designs that always enrich the trial or never enrich the trial. From
this we can clearly see that the optimised adaptive rule is providing an interesting
adaptive rule, where the trial benefits from the compromise between the two
extremes. We can also see that if we were in a scenario where we always made
one decision the equivalent fixed sampling design would clearly be preferred but
our optimised simple rule is providing a benefit for this prior.
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4.4 Bayes optimal decision
Restricting the interim decision rule for the Adaptive Enrichment trial to rules
of a particular form will not allow for the optimal decision to be made at all
times. When constructing the Oracle decision rule, Section 4.3.1, we chose the
sub-populations at the interim analysis that maximised the Bayes expected gain
for the remainder of the trial given the interim observations. We apply the same
method here while incorporating the prior distribution, this yields the Bayes
optimal decision. Berger (2013) provides a detailed look at Bayesian decision
theory in a more general setting. Schmidli et al. (2007) and Brannath et al.
(2009) both seek to optimise the interim decision of adaptive trials using the
Bayes predictive power. These are a special cases that are computationally
simpler than the Bayes optimal rule we introduce, where the gain function is
given by the probability of rejecting a null hypothesis.
For the Bayes optimal decision rule we evaluate the Bayes conditional expected
gain given the observations ,κ1, at the interim analysis, Epi(θ),κ1(G(θ, κ)) for each
of the possible interim decisions. The Bayes conditional expected gain given the





The prior distribution as we have defined it relates only to the efficacy of the new




which is the posterior distribution given the treatment effect estimates observed
in the pre-interim recruitment cohort. Having evaluated this for each of the
possible decisions we choose the decision that maximises the Bayes expected gain
as this is clearly the optimal decision, this defines the Bayes optimal decision
rule.
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Figure 4-14: Bayes optimal decision rule under formulation 1
Example: Plotting Bayes optimal decisions
In order to evaluate the overall performance of the Bayes optimal Adaptive
Enrichment designs we first need to find the optimal decision. Our overall strategy
for computing the rule follows the overall approach described for the Oracle
decision rule, Section 4.3.2. The difference is that for given interim observations
θˆ
(1)
we evaluate the interim Bayes expected gain given by equation 4.25. For
a combination of θˆ
(1)
under each possible decision we simulate values from
the posterior, Equation 4.26, and corresponding realisations of the rest of
the trial averaging to estimate the Bayes conditional expected gain for each
possible decision. Even using our simplified grid scheme, Section 4.3.2, this is
computationally intensive and the simulation causes the boundaries to not be
plotted as smoothly as in Section 4.3.1.
Under the first formulation of the problem for our ongoing example we get the




2 are small then
we enrich the trial, but as θˆ
(1)
1 increases we see that the trial continues in the full
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Figure 4-15: Bayes optimal decision rule under formulation 2
For the second formulation of the problem the Bayes optimal rule for our




2 are high we see














2 ; this is unsurprising due to
the symmetry between the sub-populations.
Example: Performance of Bayes optimal Adaptive Enrichment
Now we evaluate the Bayes expected gain for the Bayes optimal Adaptive
Enrichment trials to assess the overall performance. Table 4.9 shows how the
Bayes optimal Adaptive Enrichment trials compare with the fixed sampling
designs for these particular examples. The Bayes expected gain of the Adaptive
Enrichment trials is estimated by simulating 1, 000, 000 observations from the
prior distributions with a corresponding realisation of the trial for each, applying
an approximation of the Bayes optimal decision for each trial.
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Formulation 1
Trial design Epi(θ)(G(θ, κ))
Fixed enrichment 3.78
Multiple hypotheses 3.74
Bayes optimal Adaptive enrichment 3.88
Formulation 2
Trial design Epi(θ)(G(θ, κ))
Fixed enrichment 1.91
Multiple hypotheses 2.12
Bayes optimal Adaptive enrichment 2.44
Table 4.9: Comparing Epi(θ)(G(θ, κ)) for fixed sampling designs with the Bayes
optimal adaptive enrichment design
Under the first formulation of the problem shown in the top half of Table 4.9
we see that the Bayes optimal Adaptive Enrichment design provides a small
benefit over the fixed Enrichment design which conducts the trial only using sub-
population 1. This advantage of the Adaptive Enrichment design may seem slim,
a large part of this is explained by the fact that whenever the trial is enriched the
sample size is 3/4 that of the fixed Enrichment design; however if for example
it is not possible to achieve an agreement between all members of a trial team
over which design to use, despite there being a statistical argument for doing so,
presenting a compromise that on average performs slightly better than either of
the fixed sampling methods in this setting is of great benefit.
Under the second formulation of the problem shown in the bottom half of
Table 4.9 we see that the Bayes optimal Adaptive Enrichment design gives a large
increase in overall performance compared to the fixed sampling designs. This is
because the design is able to make use of beneficial characteristics of three fixed
sampling designs, more regularly being able to make a useful adaptation and so




Trial design Epi(θ)(G(θ, κ))
Simple Adaptive enrichment ψ = 5 3.80
Bayes Adaptive enrichment 3.88
Formulation 2
Trial design Epi(θ)(G(θ, κ))
Simple Adaptive enrichment ψ = 5 2.29
Bayes Adaptive enrichment 2.44
Table 4.10: Comparing Epi(θ)(G(θ, κ)) for fixed sampling designs with the Bayes
optimal adaptive enrichment design
4.4.1 Comparing the Bayes optimal rule with the opti-
mised simple decision rules
The Bayes optimal decision rule is much more computationally intensive than
the optimisation of simple rules of a particular form. As such we would like to
establish the benefit of this extra effort.
Example
Returning to our ongoing example we compare the Bayes optimal decision rule
with the optimised simple rules we used previously. Table 4.10 shows that for our
particular example Bayes optimal rule provides an improvement over the simple
decision rules we proposed. However if we were to change the examples slightly
we may not be certain of the best form for the simple decision rule (the ones
we have used were selected with knowledge of the form of the Bayes optimal
rule), the Bayes optimal decision is not limited to a particular form and requires
no prior understanding of how to best make the interim decision to be applied
effectively; so implementing the Bayes optimal decision rule is robust to our prior
assumptions and the rest of the parameters governing our trials recruitment,
always giving the best possible decision rule.
96
4.5 Conclusions
In this Chapter we have developed our framework for the optimisation of the
decision at the interim analysis of Adaptive Enrichment trials. In Section 4.2.2
we defined the gain function that is the single measure by which we measure
the performance of different designs. Using this gain function we defined the
Oracle decision rule, Section 4.3.1, this allowed us to construct the best possible
version of Adaptive Enrichment designs for particular choices of θ. The examples
of Section 4.3.1 showed that for an appropriate range of scenarios Adaptive
Enrichment designs may offer an improvement over fixed sampling designs.
To capture the true beliefs about the effectiveness of the new treatment we use
prior distributions, Section 4.3.3. Using a prior distribution and a gain function
we first optimise simple decision rules, however these simple decision rules are
restricted to a particular form and so not optimal in all cases. In Section 4.4 we
construct Bayes optimal Adaptive Enrichment designs which use the best possible
decision for the combination of prior distribution and gain function. Using Bayes
optimal Adaptive Enrichment designs we find that for our particular examples
the Adaptive Enrichment designs have a higher overall performance than the
fixed sampling designs we compare them with. Under the first formulation of the
problem the fixed Enrichment design still performs quite well, but the option of
only conducting the trial in one sub-population will have less appeal in practice
in addition to the observed lower overall performance.
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Chapter 5
Delayed response and survival
endpoints
5.1 Adaptive Enrichment with delayed response
5.1.1 Recruitment
Up to this point we have assumed that the data from the patients in the pre-
interim recruitment cohort are fully available whenever we wish to conduct the
interim analysis in an Adaptive Enrichment trial, however this will rarely be the
case. We assumed that the time between administering a treatment and observing
the response was negligible, but in practice we may wait weeks or months before
the response is planned to be observed. For the fixed sampling designs there is no
change as the analysis of the trial is conducted after all data collection has been
completed, however there are some changes to the Adaptive Enrichment trials.
Suppose we recruit n patients recall that for τ ∈ [0, 1], n(1) = τn patients
are recruited before the interim analysis, the pre-interim recruitment cohort,
and n(2) = (1 − τ)n patients are recruited after the interim analysis, the post-
interim recruitment cohort. At the time of the interim analysis for τ˜ ∈ [0, τ ] only
n˜(1) = τ˜n patients have had their response to the treatment observed. For the
final analysis and hypothesis testing we have the observations for the remaining
n(1) − n˜(1) patients from the pre-interim recruitment cohort. There is no impact
on the post-interim recruitment cohort we will still be able to make a choice over
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how this is recruited, as previously, and we assume all observations from both
recruitment cohorts are available at the final analysis.
Under both formulations of the problem at the interim analysis we have
treatment effect estimates θˆ
(ι)
1 in the first sub-population and θˆ
(ι)
2 in the second
sub-population from the patients in the pre-interim recruitment cohort who we
have fully observed by the interim analysis. Under the first formulation we have
θˆ
(ι)




1 + (1−λ)θˆ(ι)2 . Using the same I˜ as previously these
estimates follow known distributions,
θˆ
(ι)




















(λτ˜ I˜)−1 (τ˜ I˜)−1
(τ˜ I˜)−1 (τ˜ I˜)−1
))
.
For the remainder of the trial we continue to collect observations from the
pre-interim recruitment cohort. We estimate the treatment effect from the
observations in the pre-interim recruitment cohort who are observed after the
interim analysis. These treatment effects are θˆ
(¬ι)
1 in the first sub-population
and θˆ
(¬ι)





1 + (1−λ)θˆ(¬ι)2 the estimate of the treatment effect in the full population for
the first formulation of the problem. The distributions are
θˆ
(¬ι)




















(λ(τ − τ˜)I˜)−1 ((τ − τ˜)I˜)−1
((τ − τ˜)I˜)−1 ((τ − τ˜)I˜)−1
))
.
For all populations, the treatment effect estimate from the first stage of the













i for i = 1, 2 or 3. (5.3)
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The estimates of the treatment effects in the post-interim recruitment cohort are
unchanged and follow the distributions given in Section 3.6.
5.1.2 Hypothesis testing
The hypothesis testing may be conducted in the same way as we defined in
Section 3.5.2. We use the estimates of the treatment effects from the pre-interim
recruitment cohort θˆ
(1)
and the post-interim recruitment cohort θˆ
(2)
to construct
these hypotheses tests. These treatment effects have the same distributions as




1 ∼ N(θ1, (λτ I˜)−1))
for the sub-population 1,
θˆ
(1)
2 ∼ N(θ2, ((1− λ)τ I˜)−1)















(λτ I˜)−1 (τ I˜)−1
(τ I˜)−1 (τ I˜)−1
))
.
The distributions of the treatment effects for the post-interim recruitment








2 ∼ N(θ2, ((1− λ)(1− τ)I˜)−1)















(λ(1− τ)I˜)−1 ((1− τ)I˜)−1




if we continue only in sub-population i = 1, 2 we have
θˆ
(2)
i ∼ N(θi, ((1− τ)I˜)−1)
As usual we require strong control of the FWER as which we defined in
Equation 3.1 to be
Pθ(Reject at least one true null hypothesis) ≤ α for all θ.
but the estimates of the treatment effects at the final analysis follow the same
distributions and so we may use the same hypothesis testing methods described
in Section 3.5.2. In our examples we use a closed testing procedure, Section 3.2.2,
finding intersection P-values within each recruitment cohort using Simes method
from Equation 3.4, then using a combination test such as the weighted inverse
normal, Section 3.4.1, to find combined p-values across the whole trial which
define which hypotheses may be rejected globally.
5.1.3 Optimisation
Optimisation of the Adaptive Enrichment design changes slightly with delayed
response. We still want to make the decision that optimises the Bayes expected






to find the expected gain of each action at the interim analysis and chose the
decision that maximised this. With a delayed response we make a small change to
our notation. Under immediate response we evaluated this given all observations
from the pre-interim recruitment cohort κ1, now we may only use the observations
we have available from the pre-interim recruitment cohort at the time of interim
analysis, κι say. We evaluate the Bayes conditional expected gain given the






We may replace pi(θ|κι) by a posterior distribution given the estimates of the





Additionally Eθκι(G(θ, κ)) now depends not only on the treatment effect
estimates from the post-interim recruitment cohort, θˆ
(2)
, but also on the
treatment effect estimate from the patients in the pre-interim recruitment cohort
who have not been observed at the interim analysis θˆ
(¬ι)
. So when simulating
the possible outcomes for the remainder of the trial to evaluate the expected







As we did in Chapter 4 we will continue to return to the same core example
as we introduce new ideas. To maintain consistency we use the same choices as






chosen such that a test based on θˆ ∼ N(θ, I−1) has power of 0.9 when θ = 10 for
testing a single null hypothesis, say H0 : θ ≤ 0 at α = 0.025; for the designs that
make use of sub-populations we set λ = 0.5, meaning that the first sub-population
accounts for half of the total sample; the Adaptive Enrichment designs will also
have multiple stages, we set τ = 0.5 giving half of the sample in each stage of
the trial. With these defined we may use the distributions given in Section 5.1
for each of the possible trial designs. We conduct the hypothesis tests using the
same methods as described in Section 3.6 setting α = 0.025.
We will make use of the same gain functions and priors in our optimisation
framework as we did in the examples of Chapter 4. For the first formulation of
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the problem we had the gain function given in Equation 4.5,
G(θ, κ) = λθ1I(R1) + θ3I(R3) + θ3I(Rb),
and the prior distributions were
θ1 ∼ N(9, 16) and θ2 ∼ N(3, 4)
where θ1 and θ2 are independent. Since λ = 1/2 we have θ3 = λθ1 + (1 − λ)θ2















Under the second formulation of the problem we define the gain function as in
equation 4.6,
G(θ, κ) = λθ1I(R1) + (1− λ)θ2I(R2) + (λθ1 + (1− λ)θ2)I(Rb).
For the second formulation of the problem we chose symmetric independent prior
distributions
θ1 ∼ N(6, 9) and θ2 ∼ N(6, 9).
Plotting the Bayes optimal decision boundaries
To plot the Bayes optimal decision rule we again use the same sub dividing
strategy as we described for the Oracle decision rule, Section 4.3.2. For each grid
point where we use simulation. We simulate 500, 000 realisations of θ, then for





Eθ,κι(G(θ, κ)) for each possible decision. The grid point is assigned the decision
that gives the highest estimate of Eθ,κι(G(θ, κ)).
Setting τ˜ = 0.3 we illustrate the Bayes optimal decision rule under the first
formulation in Figure 5-1. We see that the Bayes optimal boundary has shifted
when compared to the equivalent boundary for immediate response that we saw
in Figure 4-14, under this delayed response the estimates of treatment effects
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Figure 5-1: Bayes optimal decision boundary for a delayed response under
formulation 1
must be lower in order for the trial to be enriched; this decision rule is more
similar to fixed sampling design testing multiple hypotheses, choosing to enrich
the trial less often.
With the same value of τ˜ = 0.3 the Bayes optimal decision boundary for
the second formulation of the problem is shown in Figure 5-2. Again the
trial continues in both sub-populations for lower values of the treatment effect
estimates. Under both formulations of the problem this change in the decision
rule reflects the fact that under the prior distribution this is the favoured decision
and we have less information from the trial to base our decision on due to the
delayed response.
Overall trial performance
To estimate Eθ(G(θ, κ)) in the setting of delayed response we start by
simulating 1, 000, 000 realisations of θ and θˆ
(ι)
, then applying an approximation





to find the outcome for 1, 000, 000 realisations of the trial, averaging the gain
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Figure 5-2: Bayes optimal decision boundary for a delayed response under
formulation 2
across all realisations gives us our estimate of Eθ,κι(G(θ, κ)).
Even though we are still able to optimise the Adaptive Enrichment designs
when using a delayed response the important question is how has the delayed
response affected the properties of the Adaptive Enrichment design? Table 5.1
compares the Bayes expected gain of the Bayes optimal Adaptive Enrichment
design with the fixed sampling designs as we vary the delay in response by
changing τ˜ .
Under the first formulation of the problem we see in Table 5.1 that as we
decrease τ˜ the expected gain and the probability of enriching the trial in the Bayes
optimal Adaptive Enrichment design decrease. For all of the value of τ˜ < 0.5 that
we have simulated we see that the fixed Enrichment design gives a higher Bayes
expected gain and for τ˜ = 0.1 the expected gain of the Bayes optimal Adaptive
Enrichment trial is the lowest of all three options. This shows that the impact of
the loss of information at the interim analysis of the Adaptive Enrichment design
can severely impact on the ability to make good interim decisions about a trials
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Formulation 1
Trial type % enriched Epi(θ)(G(θ, κ))
Adaptive Enrichment:
τ˜ = 0.1 20.9% 3.66
τ˜ = 0.2 33.2% 3.69
τ˜ = 0.3 40.1% 3.73
τ˜ = 0.4 44.7% 3.77
τ˜ = 0.5 45.0% 3.88
Fixed Samples:
Fixed Enrichment - 3.78
Multiple hypotheses - 3.67
Formulation 2
Trial type % enriched Epi(θ)(G(θ, κ))
Adaptive Enrichment:
τ˜ = 0.1 22.3% 2.07
τ˜ = 0.2 46.0% 2.13
τ˜ = 0.3 59.4% 2.19
τ˜ = 0.4 67.4% 2.25
τ˜ = 0.5 70.8% 2.44
Fixed Samples:
Fixed Enrichment - 1.91
Multiple hypotheses - 2.12
Table 5.1: Comparing Epi(θ)(G(θ, κ)) for Bayes optimal Adaptive Enrichment
designs with a varying proportion of interim observations
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recruitment.
Under the second formulation of the problem we see in Table 5.1 that the Bayes
optimal Adaptive Enrichment for this particular set of examples performs well.
The Bayes optimal Adaptive Enrichment trial is only worse than one of the fixed
sampling alternatives (testing multiple hypotheses) when τ˜ = 0.1. As discussed
previously this is because the Adaptive Enrichment design is able to pick from
three decisions where it offers good performance.
5.2 Longitudinal analysis
5.2.1 Data collection
When conducting a trial it is routine to collect observations about other
variables in addition to the primary endpoint for the final analysis. Many of
these additional variables will be things such as stratification factors or safety
endpoints but it is also commonplace to collect data on endpoints similar to the
primary endpoint. Suppose, for example, that the primary endpoint is measured
after 6 months, during the trial the same measurement is taken after only a
single month, a secondary endpoint. If the interim analysis were conducted after
a year those recruited within the first 6 months would have had both the short
and long term endpoints observed, however there are more data available from
the short term observations of the patients recruited between 6 and 11 months.
Assuming we are unable to use the short term endpoint in the final analysis (the
long term endpoint may be a regulatory requirement), we may still use these
extra observations to enhance our interim decision making. This will not impact
the FWER; as discussed in Section 3.5.2 we achieve strong control of the FWER
no matter how the interim decision is made. Recall that this is achieved by using
an overall closed testing procedure that defines the possible choices at the interim
analysis before the trial begins.
Let the treatment effects we have used so far in each sub-population, θ1 and
θ2, be the long term treatment effects, measured by the primary endpoint. We
define ν1 to be the short term treatment effect in the first sub-population and
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ν2 to be the short term treatment effect in the second sub-population. Suppose
at the interim analysis we have recruited n(1) patients, let nν be the number of





At the interim analysis we have τνnν patients who have observations of both









2 for the short
term treatment effect respectively; we assume that the primary and secondary





i have correlation ρ for i = 1, 2. The other (1− τν)nν
patients who have observations for the secondary endpoint at the interim analysis





As we did in Section 3.6 we assume a common variance for the short
term endpoint for the patients observations in both sub-populations and both




With λ as the proportion of patients in sub-population 1 as usual, the marginal
distributions for the estimates of ν1 and ν2 are: for the patients with both long
term and short term observations available at the interim analysis
νˆ
(1)
1 ∼ N(ν1, (τνλIν)−1), νˆ(1)2 ∼ N(ν2, (τν(1− λ)Iν)−1)
and for the patients with only the short term observations at the interim analysis
νˆ
(2)
1 ∼ N(ν1, ((1− τν)λIν)−1), νˆ(2)2 ∼ N(ν2, ((1− τν)(1− λ)Iν)−1).
From Equation 5.1 we know that the estimates of the long term treatment effect
for the patients who have observations of the primary endpoint at the interim
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analysis have the marginal distributions
θˆ
(ι)





2 are independent. In addition we now have a correlation between









2 ) = ρ.
For the patients in the pre-interim recruitment cohort who do not contribute a
long term observation at the interim analysis we continue observing the primary
endpoint. From these patients there are(1− τν)nν who had an observation of the





while the remaining n(1) − nν patients did not giving θˆ(¬ι,2)1 and θˆ(¬ι,2)2 . Let
ζ =
τ˜(1− τν)
τν(τ − τ˜) ,
note that we have 0 ≤ ζ ≤ 1 since
τν ≥ τ˜
τ

















2 ) = ρ.







1 ∼ N(θ1, ((1− ζ)(τ − τ˜)λI)−1), θˆ(¬ι,2)2 ∼ N(θ2, ((1− ζ)(τ − τ˜)(1− λ)I)−1).
(5.5)




i + (1 − ζ)θˆ(¬ι,2)i for i = 1, 2, where θˆ(¬ι)1 and θˆ(¬ι)2
follow the distributions from Equation 5.2.
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5.2.2 Interim optimisation
At the time of the interim analysis under both formulations of the problem












1 . For either the first or
second sub-population we can enhance the interim estimate of θi for i = 1 or 2
respectively by following the method described by Hampson and Jennison (2013).
































 , X =
1 00 1
1 0




v11 v12 0v12 v22 0
0 0 v33

then equation 5.6 can be written as
Y ∼ N(Xθ,Σ),
which is a normal linear model which we may fit be maximum likelihood
θˆ = (XTΣ−1X)−1XTΣ−1Y. (5.7)






where θˆ′i is an improved estimate of θi at the interim analysis.
Noting that v12 = ρ
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For the distributions we defined in Section 5.2.1 we have: in sub-population 1
v11 = (τνλIν)−1, v22 = (ζ(τ − τ˜)λI)−1, v33 = ((1− τν)λIν)−1
and in sub-population 2
v11 = (τν(1− λ)Iν)−1, v22 = (ζ(τ − τ˜)(1− λ)I)−1, v33 = ((1− τν)(1− λ)Iν)−1
We may now use our usual method for optimisation, evaluating the expected
gain for each possible decision and choosing the decision that maximises this. To





The prior distribution pi(θ) should be replaced by a prior on both θ and ν, say
pi(θ,ν). This prior is updated based on the estimate of ν and the improved
estimate of θ, hence the posterior pi(θ|κ) is given by pi(θ,ν|θˆ′, νˆ).
As with the optimisation of delayed response from Section 5.1.3, Eθ,κι(G(θ, κ))









i + (1− ζ)θˆ(¬ι,2)i for i = 1, 2, where
θˆ
(¬ι,2)
1 ∼ N(θ1, ((1− ζ)(τ − τ˜)λI)−1), θˆ(¬ι,2)2 ∼ N(θ2, ((1− ζ)(τ − τ˜)(1− λ)I)−1).
All that is left is the conditional distributions of θˆ
(¬ι,1)





























(1− ζ)(τ − τ˜)(1− λ)I˜
)
.
Using these distributions we may simulate the remainder of observations from
the pre-interim recruitment cohort at the interim analysis.
The post-interim recruitment cohort behaves in the same way as usual, if the




1 ∼ N(θ1, (λ(1− τ)I˜)−1)), θˆ(2)2 ∼ N(θ2, ((1− λ)(1− τ)I˜)−1),
if the trial continues in only a single sub-population then the distribution for
i = 1, 2
θˆ
(2)
i ∼ N(θi, ((1− τ)I˜)−1).
Hence we know all the necessary elements to optimise the interim decision of an
adaptive enrichment trial design. While the details of the distributions for the
estimates of θ wille not change in the overall hypothesis testing structure, the
interim optimisation now uses an estimate for each θ with a reduced variance. We
saw in Section 5.1 how the increased variance on the estimate of the treatment
effect at the interim analysis reduced the overall performance of the Adaptive
Enrichment trial, by introducing the secondary endpoint as we have we are able
to compensate for this loss of information caused by the delayed response.
Example








λ = 0.5, τ = 0.5 and we will use the extreme case where τ˜ = 0.1. In Section 5.1 we
saw that when τ˜ = 0.1 there was a large reduction in the overall performance of
the Adaptive Enrichment design. As usual we use the hypothesis testing methods
described in Section 3.5.2.
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Under the first formulation of the problem we use the gain function given in
equation 4.5
G(θ, κ) = λθ1I(R1) + θ3I(R3) + θ3I(Rb),
and under the second formulation of the problem we use the gain function from
equation 4.6
G(θ, κ) = λθ1I(R1) + (1− λ)θ2I(R2) + (λθ1 + (1− λ)θ2)I(Rb).
To use comparable prior distributions, under the first formulation of the problem
the marginal distributions for θ1 and θ2 should be
θ1 ∼ N(9, 16), θ2 ∼ N(3, 4)
and under the second formulation of the problem the marginal distributions for
θ1 and θ2 should be
θ1 ∼ N(6, 9), θ2 ∼ N(6, 9).
Where θ1 and θ2 are independent.
We must also define how the short term endpoint will behave, we set τν = 0.25,
ρ = 0.8 and Iν = 0.75I˜. This choice of Iν suggests we expect less variability in
the observations of the short term endpoint. Here we have chosen τν and ρ to be
the same for both sub-populations in either formulation of the problem, this is a
very simplified assumption and something that may vary in practice. If we were
to define different values of τν and ρ for each sub-population we could still apply
the same optimisation framework.
Formulation 1
Using the same correlation in the prior distribution as we do for the data we













Interim analysis % enriched Epi(θ)(G(θ, κ))
Long term endpoint only 20.9% 3.66
Enhanced optimisation 41.9% 3.75
Immediate response 45.0% 3.88
Table 5.2: Comparing Epi(θ)(G(θ, κ)) of Bayes optimal Adaptive Enrichment













which gives the same marginal distribution for the long term endpoints as we
used previously. This is to say that we believe the treatment effect in the short
term endpoint is consistent between the two sub-populations and we have the
same amount of certainty about this in both sub-populations.
Table 5.2 shows how the Bayes optimal Adaptive Enrichment design performs
when using the enhanced optimisation from the short term endpoint under the
first formulation of the problem. We see that the enhanced optimisation has
approximately doubled the probability of enriching the trial when compared to
making the decision using only the long term endpoint, this brings this probability
closer to that seen when assuming an immediate response. The expected gain of
the enhanced Adaptive Enrichment design shows an increase over using only the
long term endpoint, as with the probability of enriching the trial the expected
gain has moved closer to the expected gain achieved by the trial using immediate
response.
Formulation 2













Interim analysis % enriched Epi(θ)(G(θ, κ))
Long term endpoint only 22.3% 2.07
Enhanced optimisation 56.6% 2.18
Immediate response 70.8% 2.44
Table 5.3: Comparing Epi(θ)(G(θ, κ)) of Bayes optimal Adaptive Enrichment













which as in the first formulation of the problem yields the marginal distributions
for the long term endpoints as required. This particular prior suggests we expect
the short term endpoint to show a stronger treatment effect than the long term
endpoint, we have also assumed a lower prior variance suggesting we believe we
know more about the short term endpoint prior to starting the trial.
In Table 5.3 we compare the enhanced optimisation with the optimisation
based only on the long term endpoint to see how these methods compare with
the immediate response version of the problem. We see a similar increase in
the probability of enriching the trial as we did with the first formulation of the
problem when using the enhanced optimisation compared to just using the long
term endpoint, however this probability has not moved as close to the design
assuming immediate response as we saw in the first formulation of the problem.
There is a similar story for the expected gain of the designs, the enhanced
Adaptive Enrichment design for delayed response has not recovered all of the
expected gain that is achieved when using an immediate response.
Under both formulations of the problem we have seen that enhancing the
optimisation procedure using the short term endpoint can provide a benefit.
We see that the probability of enriching the trial for the enhanced optimisation
procedure is closer to that given by a design assuming immediate response, from
this change we see an improvement in the expected gain.
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5.2.3 Adding to the joint model
In addition to the correlation structure we used in Section 5.2.1 the treatment
effects for the short term endpoint and the long term endpoint may be directly
related. We might assume that the treatment effect in the short term endpoint
is simply some multiple of the treatment effect in the long term endpoint, for
example
νi = ξθi for i = 1, 2.
If ξ < 1 then the treatment effect on the short term endpoint is smaller than
what we ultimately expect to observe in the long term endpoint, if ξ > 1 the
treatment effect is magnified for the short term endpoint. The prior distribution
may now be updated using the observations of secondary endpoint directly at
the interim analysis gives the posterior pi(θ|ν), further reducing the uncertainty
about the true treatment effect at the interim analysis.
5.2.4 Example
Returning to our example we experiment with an extreme case, we set τν =
τ˜ = 0 such that we have no observations of the primary endpoint at the interim
analysis. We also set ρ = 0 meaning that the decision at the interim analysis is
based solely on the posterior distribution given the estimate of the short term
treatment effect. This choice of ρ is computationally simpler, we now simulate
1, 000, 000 values of νˆ1 and νˆ2, estimate the Bayes optimal decision and simulate
a single realisation of the trial for each combination of νˆ1 and νˆ2. Finding the
average gain of this simulation gives an estimate for the Bayes expected gain of
the trial under this decision rule.
Using ξ = 2 and only the information from the short term endpoint at
the interim analysis we apply the Bayes optimal decision rule under the first
formulation of the problem. The probability of enriching for the Adaptive
Enrichment trial is 26.1% and the expected gain is 3.69. Table 5.4 compares this
with the alternatives, firstly we compare with the Adaptive Enrichment designs
that always make the same decision from which we see that making an adaptation
based only on the short term endpoint has provided a small improvement over
the decision to never enrich that would have been made using only the prior
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Decision rule Epi(θ)(G(θ, κ))
Adaptive Enrichment always enrich 3.31
Adaptive Enrichment never enrich 3.62
Secondary endpoint only 3.69
Immediate response 3.88
Fixed sampling designs Epi(θ)(G(θ, κ))
Multiple hypotheses 3.67
Fixed Enrichment 3.78
Table 5.4: Comparing Epi(θ)(G(θ, κ)) Adaptive Enrichment designs with no
information on the final endpoint under formulation 1
distribution. Comparing the Adaptive Enrichment trials with the fixed sampling
alternatives we see that the Adaptive Enrichment trial has provided a very
small improvement over the fixed sampling design testing multiple hypotheses.
The fixed Enrichment design gives a higher expected gain than this Adaptive
Enrichment design, but if we were to increase ξ or Iν we would increase the
overall performance of the trial.
Repeating this for the second formulation of the problem we see that the Bayes
optimal Adaptive Enrichment trial using only the short term endpoint at the
interim analysis is 43.2% giving an expected gain for the trial of 2.12. Comparing
this with the alternative designs in table 5.5 we again see that an adaptive rule
based only on a short term endpoint has provided a small improvement over the
adaptive decision that would have been made using only the prior distribution.
Comparing to the fixed sampling designs for this example the testing of multiple
hypotheses was preferred and the Adaptive Enrichment design has matched the
expected gain of this design.
The Adaptive Enrichment designs we have seen in this example do not provide
any overall improvement over the fixed sampling alternatives, however that is not
necessarily our aim if we are willing to make the decision based only on a short
term endpoint. If we are unable to achieve an agreement on which fixed sampling
design to use, despite the statistical argument for doing so, we have seen that
starting recruitment for the trial and making the decision later based on some
short term endpoint that is related to the final endpoint will not necessarily cause
117
Decision rule Epi(θ)(G(θ, κ))
Adaptive enrichment always enrich 1.46
Adaptive enrichment never enrich 2.04
Secondary endpoint only 2.12
Immediate response 2.44
Fixed sampling designs Epi(θ)(G(θ, κ))
Multiple hypotheses 2.12
Fixed enrichment 1.91
Table 5.5: Comparing Epi(θ)(G(θ, κ)) adaptive enrichment designs with no
information on the final endpoint under formulation 2
a loss of performance for the trial.
5.3 Survival endpoints
5.3.1 A single survival endpoint
Up until this point all of our trial designs we have assumed that the observations
from individuals are normally distributed, this has allowed us to simulate
summary statistics that are also normally distributed. In the setting of clinical
trials it is common to observe time to event or survival endpoints. We define a
survival endpoint as the time after treatment until some event, this event could
be death or some other form of disease progression, this is called the survival
time. Collett (2015) gives a summary of appropriate techniques for the analysis
of survival data.
Defining the log-rank score statistic
We take the approach of Turnbull and Jennison (2000), using the log-rank test
for hypothesis testing in the setting of survival endpoints. Suppose for simplicity
that we are using a single population for the trial, as we did in Chapter 2
we recruit n patients in total, n1 of these patients are randomised to the new
treatment and the remaining n2 are randomised to the control. From these
patients we observe the survival times which follow the hazard functions hA(t)
for the new treatment and hB(t) for the control, from these we seek to test the
null hypothesis H0 : h1(t) = h2(t) for all t > 0. The log-rank test is particularly
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useful in the setting of proportional hazards,
h1(t) = ξh2(t), (5.9)
for some constant ξ.
The definition of the log-rank score statistic for K analyses, from Turnbull
and Jennison (2000) Section 3.7 is as follows. Let dk denote the number of
uncensored events at analysis k. We denote the survival times of the patients by
t1,k < t2,k < ... < tdk,k where each ti,k is measured as the time between study
entry and failure. Let riA,k and riB,k be the numbers known to have survived for
each treatment at the corresponding survival time ti,k and
δiB,k =
1 if the failure at time k was on treatment B0 if the failure at time k was on treatment A.









For λ close to one and θ = log(ξ) close to zero we use the approximation
Sk ∼ N(θIk(θ), Ik(θ)) (5.11)
for sufficiently large information Ik(θ) where Ik(θ) ≈ dk/4. Conditional on the
observed information sequence the joint distribution of S1, ...., Sk approximates
the standard form of joint distribution for score statistics given by Turnbull and
Jennison (2000). Using the sequence S1, ...., Sk allows use to use the independent
increments property, S1, S2 − S1 independent, Whitehead (1997).
Adaptive Enrichment with survival endpoints
Returning to the Adaptive Enrichment design we may now consider how this
might be implemented using a survival endpoint. We shall define the distribution
of the log-rank score statistics in terms of I˜ as we do for normally distributed
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responses in Section 3.6. However in this setting splitting I˜ is not as simple
as simply splitting the number of patients between the sub-populations, we
must make a number of assumptions about the data collection: we assume a
proportional hazards model within each sub-population as in Equation 5.9; we
assume that in each sub-population at each stage of the trial we may find the
associated log-rank score statistic as in Equation 5.10 and that these log-rank
score statistics each follow a distribution of the form given in Equation 5.11; and
we assume that the recruitment and number of patients at risk and events in each
sub-population are such that we observe the distributions of the log-rank score
statistics that we shall define shortly. In practice this final assumption is highly
unlikely as the number and times of each event that contribute to Ik(θi) are
random variables. At the end of the trial the exact distributions for the log-rank
score statistics will be known and so this does not impact on the strong control
of the FWER; the place where this does have an impact is in the optimisation of
the interim decision, as this must be based on expected numbers of events.
Under these assumptions we may define the distributions of the log-rank score
statistics for an Adaptive Enrichment design. Firstly the pre-interim recruitment
cohort give log-rank score statistics over 2 analyses. At the interim analysis we
observe log-rank score statistics from the events in the pre-interim recruitment
cohort Sˆ
(ι)
1 in the first sub-population and Sˆ
(ι)
2 in the second sub-population where
Sˆ
(ι)
1 ∼ N(λτ˜ I˜θ1, λτ˜ I˜), Sˆ(ι)2 ∼ N((1− λ)τ˜ I˜θ2, (1− λ)τ˜ I˜).
For the rest of the trial we continue to follow up the pre-interim recruitment
cohort, this gives the log-rank score statistics Sˆ
(¬ι)
1 in the first sub-population
and Sˆ
(¬ι)
2 in the second sub-population, where
Sˆ
(¬ι)
1 ∼ N(λτ˜ I˜θ1, λτ˜ I˜), Sˆ(¬ι)2 ∼ N((1− λ)τ˜ I˜θ2, (1− λ)τ˜ I˜).
By independent increments of the score statistic at the end of the trial the log-















Under the first formulation of the problem we also find the log-rank score statistic






2 . These log-rank score statistics for the
pre-interim recruitment cohort follow the distributions,
Sˆ
(1)
1 ∼ N(λτ I˜θ1, λτ I˜) (5.12)
Sˆ
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The distributions of the log-rank score statistics for the post-interim recruit-
ment cohort depend on which decision has been made, if we continue in both
sub-populations in the sub-population 1 we have
Sˆ
(2)
1 ∼ N(λ(1− τ)I˜θ1, λ(1− τ)I˜),
in sub-population 2 we have
Sˆ
(2)
2 ∼ N((1− λ)(1− τ)I˜θ2, (1− λ)(1− τ)I˜)
and under the first formulation of the problem the log-rank score statistic in the





















λ(1− τ)I˜ (1− τ)I˜
(1− τ)I˜ (1− τ)I˜
))
.
The hypothesis testing may be conducted at the end of the trial in the same way
as we described in Section 3.5.2, using the weighted inverse normal combination
test to combine the P-value from the pre-interim and post-interim recruitment
cohorts. By definition all follow up on patients recruited before the interim
analysis contributes only to test statistics for the pre-interim recruitment cohort,
as stated by Jenkins et al. (2011) this ensures independence between the test
statistics of the pre-interim and post-interim recruitment cohorts as required for
the combination tests.
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Parallels to delayed response
We can clearly see a parallel with the delayed response from Section 5.1.
The log-rank score statistics used to analyse the trial with a survival endpoint
correspond exactly with estimates of the treatment effect since for vji = var(S
(j)
i )











Using the same optimisation structure as Section 5.1 for Adaptive Enrichment
trials using the log-rank score statistic for the survival endpoint will yield the
same performance as achieved with delayed responses if all other parameters are
the same, since the distributions are equivalent.
5.3.2 Using progression free survival to improve decision
making at the interim analysis
In Section 5.2 we made use of a secondary endpoint to enhance the interim
decision rule of the Adaptive Enrichment design in the setting of longitudinal
data collection. We consider now how a similar approach could be taken in
the context of survival data. For example suppose we collect times for both
overall survival and progression free survival, where overall survival is the primary
endpoint for the trial. Events for overall survival may occur slowly for overall
survival compared to progression free survival, so at the interim analysis we may
have more information on progression free survival.
If we construct the Adaptive Enrichment design using log-rank test based on
overall survival we may construct the trial as described in Section 5.3.1; we
remarked in Section 5.3.1 how this was equivalent to the delayed response seen
in Section 5.1. In the same way we could extend the approach from Section 5.2
to this setting. Using the framework for enhancing the decision at the interim
analysis of Adaptive Enrichment trials would maintain strong control of the
FWER as the hypothesis testing structure would still only depend on overall
survival.
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To use the optimisation framework from Section 5.2 we would require a joint
model for the log-rank score statistics of overall survival and progression free
survival. In Section 5.2 we assumed that the distributions were bi-variate normal
between the primary and secondary endpoint, if this is a reasonable assumption
for overall survival and progression free survival we may proceed in exactly the
same way. In Section 5.2.3 we extended the joint model further assuming the
treatment effects were directly related, this is equivalent to assuming the log
hazard ratios are directly related for overall and progression free survival; in this
setting we might consider a relationship between the hazard ratios, perhaps we




Sensitivity of optimal designs to
the model assumptions
6.1 Changing the prior distribution
Across all of our examples we have throughout Chapters 4 and 5 we have used
the same prior distribution for each formulation of the problem. We have seen
that Adaptive Enrichment designs can be an effective tool under these particular
choices of the prior distribution. The framework for making the Bayes optimal
decision introduced in Section 4.4 allows us to find the optimal decision under any
choice of prior or gain function; with this in mind we investigate how Adaptive
Enrichment designs perform under different choices for the prior distribution.
6.1.1 Returning to immediate response
In this Chapter we return to our assumption of an immediate response for all
summary statistics while we investigate other aspects of the trial. The summary
statistics follow the distributions given in Section 3.6 defined using I˜, where I˜
takes a fixed value across all trials. Under the first formulation of the problem
we test the null hypotheses H01 : θ1 ≤ 0 and H03 : θ3 ≤ 0, and under the
second formulation of the problem we test the null hypotheses H01 : θ1 ≤ 0 and
H02 : θ2 ≤ 0. For the designs that use multiple populations λ is the proportion
of the sample in the first sub-population and for Adaptive Enrichment designs τ
is the proportion of the sample recruited in the pre-interim recruitment cohort.
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In this Chapter we use the same fixed set of parameters defining the
distributions of the observations we used throughout Chapters 4 and 5. These






we set α = 0.025 and use λ = 0.5 and τ = 0.5 to govern the split of the sample
between sub-populations and recruitment cohorts. As usual we will ensure strong
control of the FWER as given in Equation 3.1 by using the hypothesis testing
method described in Section 3.5.2
6.1.2 Alternative prior distributions
When changing the prior distributions one extreme case that still allows
for comparison with our previous examples is to switch our choice of prior
distribution for the first and second formulations of our problem.
Example: formulation 1
Under the first formulation of the problem we use the gain function given in
equation 4.5,
G(θ, κ) = λθ1I(R1) + θ3I(R3) + θ3I(Rb)
and the new prior distribution
θ1 ∼ N(6, 9), θ2 ∼ N(6, 9) (6.1)
where θ1 and θ2 are independent. Since λ = 1/2 we have θ3 = λθ1 + (1 − λ)θ2















Table 6.1 shows the expected gain of the Bayes optimal Adaptive Enrichment
trial for this example, comparing this with the expected gain from the comparable
fixed sampling designs. We see that the fixed sampling design testing the null
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Trial design Epi(θ)(G(θ, κ))
Bayes optimal Adaptive Enrichment 3.33
Fixed Enrichment trial 1.91
Fixed sample multiple hypotheses 3.17
Table 6.1: Values of Epi(θ)(G(θ, κ)) with prior distribution from Equation 6.1 for
formulation 1
hypotheses H01 and H03 is clearly the best fixed sampling design, the Adaptive
Enrichment trial still offers an overall improvement in the Bayes expected gain
of the trial. In fact this improvement is larger than the improvement we have
previously observed from Adaptive Enrichment in the first formulation of the
problem.
Example: formulation 2
Under the second formulation of the problem we us the gain function given in
equation 4.6,
G(θ, κ) = λθ1I(R1) + (1− λ)θ2I(R2) + (λθ1 + (1− λ)θ2)I(Rb)
and the new prior distribution
θ1 ∼ N(9, 16), θ2 ∼ N(3, 4) (6.2)
where θ1 and θ2 are independent.
Table 6.2 shows the expected gain of the Bayes optimal Adaptive Enrichment
trial for this example, comparing this with the expected gain from the comparable
fixed sampling designs. We see that the fixed Enrichment trial in the first sub-
population is clearly the best choice. Although it is not the best overall the
Adaptive Enrichment design provides an improvement over the fixed Enrichment
design in the second sub-population and the fixed sample testing multiple
hypotheses.
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Trial design Epi(θ)(G(θ, κ))
Bayes optimal Adaptive Enrichment 3.33
Fixed Enrichment trial sub-pop 1 3.77
Fixed Enrichment trial sub-pop 2 0.46
Fixed sample multiple hypotheses 2.82
Table 6.2: Values of Epi(θ)(G(θ, κ)) with prior distribution from Equation 6.2 for
formulation 2
6.1.3 Uniform prior distributions
Another alternative would be to change the shape of the prior distribution
altogether, a simple example of this would be to use a Uniform distribution
instead of a Normal distribution.
Example: formulation 1
Recall that under this formulation of the problem we have typically used prior
distributions given by
θ1 ∼ N(9, 16), θ2 ∼ N(3, 4)
where θ1 and θ2 are independent. Defining uniform priors in a similar area of the
parameter space we use
θ1 ∼ Unif(4, 12), θ2 ∼ Unif(0, 8) (6.3)
where again θ1 and θ2 are independent.
Under the uniform distribution the probability of enriching in the Bayes
optimal Adaptive Enrichment trial is 35.7%, which is slightly different to our
usual choices for normally distributed priors. Table 6.3 shows the expected gain
of the Bayes optimal Adaptive Enrichment trial for this example, comparing
this with the expected gain from the fixed sampling designs. We see that of
the fixed sampling designs sampling in both sub-populations and testing both
null hypotheses is now clearly the better choice. The Adaptive Enrichment trial
provides a small improvement overall; the benefit here is smaller than we have
previously seen for this formulation of the problem because the extreme values of
θ, where Adaptive Enrichment is not as good as the fixed sampling alternatives,
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Trial design Epi(θ)(G(θ, κ))
Bayes optimal Adaptive Enrichment 3.30
Fixed Enrichment trial 3.01
Fixed sample multiple hypotheses 3.27
Table 6.3: Values of Epi(θ)(G(θ, κ)) for uniform priors from Equation 6.3 under
formulation 1
are more likely under the uniform prior.
Example: formulation 2
Recall that under the second formulation of the problem we have typically used
prior distributions given by
θ1 ∼ N(6, 9), θ2 ∼ N(6, 9).
where θ1 and θ2 are independent. Defining uniform priors in a similar area of the
parameter space we use
θ1 ∼ Unif(2, 10), θ2 ∼ Unif(2, 10).
where again θ1 and θ2 are independent.
Under the uniform distribution the probability of enriching in the Bayes
optimal Adaptive Enrichment trial is 64.5% which again is slightly different to
what we have seen previously. Table 6.3 shows the expected gain of the Bayes
optimal Adaptive Enrichment trial for this example, comparing this with the
expected gain from the fixed sampling designs. We see that the fixed sampling
trials are very similar in terms of their overall performance. The Adaptive
Enrichment design again provides an improvement over the fixed sampling
alternatives in this second formulation of the problem.
6.1.4 Comparing an alternative prior distribution
When considering the overall performance of the trial the same prior distribu-
tions for optimising the decision at the interim analysis and assessing the overall
performance of the trials. In practice the prior distribution used for optimising
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Trial design Epi(θ)(G(θ, κ))
Bayes optimal Adaptive Enrichment 2.09
Fixed Enrichment trial 1.78
Fixed sample multiple hypotheses 1.83
Table 6.4: Comparing Epi(θ)(G(θ, κ)) for competing trial designs for formulation
2
the Adaptive Enrichment will be a summary of the prior beliefs of the investiga-
tors; however there may not be full agreement on this prior.
Suppose we have one prior distribution that summarises the entire beliefs of
the trial team, pia(θ) say, we use this prior to optimise the Adaptive Enrichment
trial and find the overall performance in the usual way. Perhaps we have one
member of the development team who wishes to assess the design under their
own prior beliefs, pib(θ) say.
Example: formulation 1
Under the first formulation of the problem we define the prior distribution
summarising the overall beliefs pia(θ) to be
θ1 ∼ N(9, 16), θ2 ∼ N(3, 4).
















We define the alternative prior distribution pib(θ) to be
θ1 ∼ N(6, 9), θ2 ∼ N(6, 9),
where θ1 and θ2 are independent. Since λ = 1/2 we have θ3 = λθ1 + (1− λ)θ2 we
















Trial design Epib(θ)(G(θ, κ))
Adaptive Enrichment optimal for pia(θ) 2.82
Fixed Sample testing multiple hypotheses 3.17
Fixed Enrichment 1.91
Adaptive Enrichment optimal for pib(θ) 3.33
Table 6.5: Comparing Epi(θ)(G(θ, κ)) for different prior distributions under
formulation 1
Trial design Epib(θ)(G(θ, κ))
Adaptive Enrichment optimal for pia(θ) 2.05
Fixed Sample testing multiple hypotheses 2.12
Fixed Enrichment in sub-population 1 1.91
Fixed Enrichment in sub-population 2 1.91
Adaptive Enrichment optimal for pib(θ) 2.44
Table 6.6: Comparing Epi(θ)(G(θ, κ)) for different prior distributions under
formulation 2
In Table 6.5 we see a comparison of the expected gain under pib(θ). We see
that when the interim decision of the Adaptive Enrichment design is optimised
for pia(θ) then Epib(θ)(G(θ, κ)) is lower than the best fixed sampling alternative;
if we were to optimise for pib(θ) then the Adaptive Enrichment design is the best
choice of trial.
Example: formulation 2
We make the equivalent analysis in formulation 2 using the same choices for
pia(θ) and pib(θ). We see in Table 6.6 that we see the same outcomes as we did
for formulation 1. When the interim decision of the Adaptive Enrichment design
is optimised for pia(θ) then Epib(θ)(G(θ, κ)) is lower than the best fixed sampling
alternative; if we were to optimise for pib(θ) then the Adaptive Enrichment design
is the best choice of trial.
The examples in this section demonstrate the importance of the choice of prior
distribution when evaluating the performance of Adaptive Enrichment designs.
We have shown that when optimising the interim decision of Adaptive Enrichment
designs the choice of prior will impact on the overall performance of the design;
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this also shows that using a simple rule without knowledge of the Bayes optimal
decision boundary may be a very bad choice. Under the first formulation of
the problem in our examples the Adaptive Enrichment design is always the
best choice of design, however the results for the second formulation of the
problem demonstrate that under some prior distributions the fixed sampling
alternatives offer a better overall performance than Adaptive Enrichment designs;
the consequence of this is that in practice we know that the Adaptive Enrichment
design will not always be the best choice, the overall performance should be
considered before choosing to use an Adaptive Enrichment design over the fixed
sampling alternatives.
6.2 Changing the parameters of the design
In addition to assuming the same prior distribution throughout Chapters 4
and 5 we have also assumed a fixed pattern of recruitment. We took the
proportion of the sample in the first sub-population to be half of the overall
sample, setting λ = 1/2. Similarly we set τ = 1/2 conducting the interim analysis
after half of the total sample had been collected. The final parameter governing








We now experiment with different choices for the values of these parameters.
6.2.1 Sub-population proportion
The choice of the proportion of the population in the first sub-population
(given by λ) will vary depending on the criteria for being a member of the
sub-population. Typically the sub-population may be selected by a predictive
biomarker indicating that a patient may respond in a particular way to the new
treatment, and so we may not be able to select the proportion of patients that
will be recruited in this sub-population. The methods presented in Chapters 4
and 5 do not rely on a specific choice of λ; we may conduct the trial and optimise
the decision at the interim analysis for all λ ∈ (0, 1).
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Example
Taking all other parameters as we have in our previous examples under the
first formulation of the problem we use the familiar prior distribution
θ1 ∼ N(9, 16), θ2 ∼ N(3, 4),
where θ1 and θ2 are independent; the joint distribution of θ1 and θ3 will vary with
λ since θ3 = λθ1 + (1 − λ)θ2. The gain function for the first formulation of the
problem given in equation 4.5 is
G(θ, κ) = λθ1I(R1) + θ3I(R3) + θ3I(Rb).
For the second formulation of the problem we define the prior distributions to be
θ1 ∼ N(6, 9), θ2 ∼ N(6, 9).
where θ1 and θ2 are independent and use the gain function given in equation 4.6,
G(θ, κ) = λθ1I(R1) + (1− λ)θ2I(R2) + (λθ1 + (1− λ)θ2)I(Rb).
Varying the value of λ we apply the optimised decision rule and find the Bayes
expected gain of the Adaptive Enrichment trial and compare this with the Bayes
expected gain of each of the fixed sampling alternatives in Table 6.7. We see that
under the first formulation of the problem the Adaptive Enrichment trial gives a
small performance increase over both fixed sampling designs over many choices
of λ. We note that as λ increases we also see that the fixed Enrichment trial
improves when compared with the fixed sample testing multiple hypotheses.
Under the second formulation of the problem we evaluate values of λ up to 0.5
since we have symmetry between the sub-populations. We see that for low values
of λ (and hence a high proportion of the sample in the second sub-population)
the fixed Enrichment trial in the second sub-population is the best choice of
trial; both fixed Enrichment designs will give the same probability of rejecting
the null hypothesis by symmetry, the difference is because of the appearance of
λ in the gain function. For λ = 0.4 and 0.5 the Adaptive Enrichment trial gives
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Formulation 1
λ = 0.1 λ = 0.3 λ = 0.5 λ = 0.7 λ = 0.9
Adaptive Enrichment 1.06 2.39 3.88 5.25 6.85
Fixed Enrichment 0.75 2.27 3.77 5.28 6.79
Multiple hypotheses 1.03 2.24 3.74 5.25 6.70
Formulation 2
λ = 0.1 λ = 0.2 λ = 0.3 λ = 0.4 λ = 0.5
Adaptive Enrichment 2.93 2.73 2.56 2.46 2.44
Fixed Enrichment sub-pop 1 0.38 0.76 1.14 1.52 1.91
Fixed Enrichment sub-pop 2 3.42 3.04 2.66 2.28 1.91
Multiple hypotheses 2.89 2.54 2.31 2.17 2.12
Table 6.7: Comparing Epi(θ)(G(θ, κ)) varying values of λ
the highest Bayes expected gain. Comparing the Bayes expected gain of the
fixed sampling design testing multiple hypotheses to the Bayes optimal Adaptive
Enrichment design we see that the advantage of the Adaptive Enrichment trial
increases as λ gets closer to 0.5.
6.2.2 Timing of the interim analysis
The timing of the interim analysis dictates both how much of the sample
has been recruited and hence how much information we have when making the
decision at the interim analysis, and how much of the sample we can alter the
recruitment for. We have used τ = 1/2 previously, but this is not the only option.
In practice we might alter the timing of the interim analysis to improve the overall
performance of the trial. Whenever the interim analysis is to be conducted, we
are able to optimise the decision using the Bayes optimal decision introduced in
Section 4.4 since the distributions of the remaining observations are known.
Example
Returning to our example we now set λ = 1/2 and allow τ to vary. Table 6.8
shows how the Bayes optimal Adaptive Enrichment trial performs for each
formulation of the problem. We see that under the both formulations of the
problem there would be an advantage to conducting the interim analysis earlier
in the trial. This may seem strange since the decision will be made with more












Table 6.8: Comparing Epi(θ)(G(θ, κ)) varying values of τ
interim decision. Using this knowledge we could optimise the timing of the interim
analysis for any particular Adaptive Enrichment trial, evaluating the expected
gain of the Bayes optimal Adaptive Enrichment trials for different values of τ to
find the value of τ that maximises the Bayes expected gain.
6.2.3 Total sample size of the trial
We fixed I˜ for each trial to ensure that the Adaptive Enrichment design







was to give power of 1−β = 0.9 testing H0 : θ ≤ 0 at α = 0.025 when θˆ ∼ N(θ, I˜).
However this nominal power level is based on the sample size we are able to
achieve and this may well be chosen to also balance the cost of the trial. Given
that the sample size will not always achieve this value of I˜ we might wish to
know how Adaptive Enrichment will perform as I˜ varies.
Example




Φ−1(1− β) + Φ−1(0.975)
10
)2
where we vary the nominal power 1− β.
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Formulation 1
1− β 0.70 0.80 0.90 0.95
Adaptive Enrichment 2.87 3.32 3.88 4.26
Fixed Enrichment 3.15 3.46 3.77 3.95
Multiple hypotheses 2.65 3.13 3.74 4.17
Formulation 2
1− β 0.70 0.80 0.90 0.95
Adaptive Enrichment 1.65 1.98 2.44 2.75
Fixed Enrichment 1.30 1.62 1.91 2.10
Multiple hypotheses 1.39 1.64 2.12 2.53
Table 6.9: Comparing Epi(θ)(G(θ, κ)) varying values of 1− β
Table 6.9 shows how the Bayes expected gain of the Bayes optimal Adaptive
Enrichment trial compares with the alternative fixed sampling designs as the
nominal power 1− β varies for each formulation of the problem. Under the first
formulation of the problem we see that as 1 − β increases the Bayes expected
gain of the Bayes optimal Adaptive Enrichment increases in comparison to the
fixed Enrichment trial, the adaptive design has a lower performance than the
fixed Enrichment design for lower values of 1 − β and is higher for 1 − β = 0.9.
Conversely comparing the Bayes expected gain of the adaptive design with the
fixed design testing multiple hypotheses we see that while the performance of the
fixed design is always lower, the advantage of the Adaptive Enrichment design
decreases as 1− β increases.
Under the second formulation of the problem we see that the Bayes optimal
Adaptive Enrichment trial maintains a similar overall advantage in the Bayes
expected gain to the fixed sampling designs. For all values of 1 − β the fixed
trial testing multiple hypotheses is preferred to the fixed Enrichment trial, as
1 − β increases the advantage of testing multiple hypotheses increases. If we
think about the typical shape of a power curve this is due to the fact that the




Variations to the Adaptive
Enrichment design
7.1 Hypothesis testing methodology
The methods we have used to conduct the hypothesis tests across all examples
in Chapters 4, 5 and 6 are only one possible example of conducting hypothesis
test suitable for the trials we have considered. We showed in Section 3.2.3 that
all hypothesis testing procedures that ensure strong control of the FWER can be
written as closed testing procedures, within this we have used Simes method to
test the intersection hypothesis. However, this is not the only method we could
have chosen. Similarly the weighted inverse normal was not the only possible
choice of combination test we could have made. We could use an alternative
method for the overall hypothesis testing procedure we use in the Adaptive
Enrichment trial.
Once again in this Chapter we will use the same standard setup where using







setting α = 0.025, λ = 0.5 and τ = 0.5. For both formulations of the problem we
must set the method for hypothesis testing.
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Under the first formulation of the problem we use the gain function from
equation 4.5
G(θ, κ) = λθ1I(R1) + θ3I(R3) + θ3I(Rb),
and the prior distributions
θ1 ∼ N(9, 16), θ2 ∼ N(3, 4).
where θ1 and θ2 are independent. Since λ = 1/2 we have θ3 = λθ1 + (1 − λ)θ2















Under the second formulation of the problem we use the gain function from
equation 4.6
G(θ, κ) = λθ1I(R1) + (1− λ)θ2I(R2) + (λθ1 + (1− λ)θ2)I(Rb).
For the second formulation of the problem we chose the symmetric prior
θ1 ∼ N(6, 9), θ2 ∼ N(6, 9).
where θ1 and θ2 are independant
7.1.1 Improved Simes method for the intersection hypoth-
esis
Under the first formulation of the problem where we test the null hypotheses
as H01 : θ1 ≤ 0 and H03 : θ3 ≤ 0 we know that there is a correlation between
the estimates of the treatment effect between the sub-population of interest
and the full population, since patients in the sub-population are also in the
full population. Given λ and under the assumption of independence between
the sub-population and the complement we know this correlation is ρ =
√
λ.
This correlation will cause Simes method to become conservative for testing the
intersection hypothesis.
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λ ρ FWER % of nominal α
0.25 0.50 0.024 96.0
0.50 0.71 0.023 91.0
0.75 0.87 0.021 84.8
0.90 0.95 0.020 81.9
Table 7.1: Conservatism of Simes method for the intersection hypothesis given
positive correlation between variables
This knowledge can be used to improve Simes method, recall from equation 3.4
that the intersection p-value is given by P12 = min(2min(P1, P2),max(P1, P2)).
Since max(P1, P2) will reject the intersection hypothesis when the individual
tests also reject the individual null hypotheses at level α, in order to maintain
consonance we will replace 2min(P1, P2) in the formula by ψρmin(P1, P2). We
choose ψρ to spend the full α for a given ρ. Thus the improved Simes method for
the intersection p-value is given by,
P12 = min(ψρmin(P1, P2),max(P1, P2)). (7.1)
Example
We can find exactly how conservative Simes method is in terms of the FWER,
Table 7.1 shows how this conservatism increases with λ in the fixed sampling
design testing multiple hypotheses. For the fixed sampling design comparing
multiple hypotheses we compare the effectiveness of the improved Simes method
from equation 7.1 where for our choice of λ = 0.5 we find ψρ = 1.77 for
ρ =
√
0.5, with the original version of Simes method from Equation 3.4 in
Table 7.2. We see that the improved version of Simes method gives a small
increase in the probability of rejecting the null hypotheses in all cases, increasing
the corresponding expected gain.
Using the improved Simes method given by equation 7.1 we find the Bayes
expected gain of the Bayes optimal Adaptive Enrichment design and compare
this with the expected gain of the fixed sampling alternatives in table 7.3. This
shows that the improved version of Simes method gives a higher Bayes expected
gain for both the Adaptive Enrichment trial and the fixed sampling trial testing
multiple hypotheses. The improvement in the Adaptive Enrichment design is
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Original Simes
θ1 θ3 Pθ(R1) Pθ(R3) Pθ(Rb) Eθ(G(θ, κ))
10 10 0.01 0.24 0.61 8.59
10 5 0.21 0.02 0.33 2.82
10 0 0.49 0.00 0.02 2.48
0 0 0.01 0.01 0.01 0.00
Improved Simes
θ1 θ3 Pθ(R1) Pθ(R2) Pθ(Rb) Eθ(G(θ, κ))
10 10 0.01 0.25 0.62 8.67
10 5 0.23 0.02 0.33 2.90
10 0 0.51 0.00 0.02 2.57
0 0 0.01 0.01 0.01 0.00
Table 7.2: Comparing Simes and Improved Simes under formulation 1: R1 is the
event that we only reject H01, R3 is the event that we only reject H03 and Rb is
the event that we reject both H01 and H03
higher than the improvement in the fixed sampling trial, and we now see that
the advantage of the Adaptive Enrichment design is higher than we had using
the original version of Simes method. This shows that the improved version
of Simes method can provide an improvement for any clinical trial under the
first formulation of the problem and is particularly beneficial for the Adaptive
Enrichment design.
7.1.2 Dunnet type rule for the intersection hypothesis
A second method that would allow us to make use of the correlation between the
sub-population and the full population uses the principle introduced by Dunnett
(1955). This method makes use of the correlation introduced when using a
common control arm for multiple treatments, while we do not have a common
control we do know the joint distribution of the summary statistics. Under the
first formulation of the problem we are testing the null hypotheses H01 : θ1 ≤ 0
and H03 : θ3 ≤ 0, when conducting a fixed sampling trial to test these hypotheses
















Trial design Epi(θ)(G(θ, κ))
Adaptive Enrichment 3.88
Fixed Enrichment 3.78
Fixed sample multiple hypotheses 3.74
Improved Simes
Trial design Epi(θ)(G(θ, κ))
Adaptive Enrichment 3.94
Fixed sample multiple hypotheses 3.80
Table 7.3: Comparing Epi(θ)(G(θ, κ)) using Improved Simes method for the
intersection hypothesis under formulation 1
and we reject H01 ∩H03 when max(Z1, Z3) > r where r is such that
P(max(Z1, Z3) > r) ≤ α
We may find the corresponding p-value under the Dunnett type method, for
observations z1 and z3 we define
d = max(z1, z3)
the p-value for the intersection hypothesis is given by
p13 = P(Z1 ≥ d ∪ Z3 ≥ d). (7.2)
Defining the test in this way ensures that the testing procedure is consonant as
defined in Section 3.2.4.
Example
As we did with the improved Simes method we start by comparing the
Dunnett method from eqaution 7.2 with the original version of Simes method
from equation 3.4 for the fixed sampling design comparing multiple hypotheses,
Table 7.4 shows this comparison, we see that the Dunnett type method performs
very similarly to the improved Simes method, showing a small improvement over
Simes method when θ1 = 10 and θ3 = 0.
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Original Simes
θ1 θ3 Pθ(R1) Pθ(R3) Pθ(Rb) Eθ(G(θ, κ))
10 10 0.01 0.24 0.61 8.59
10 5 0.21 0.02 0.33 2.82
10 0 0.49 0.00 0.02 2.48
0 0 0.01 0.01 0.01 0.00
Improved Simes
θ1 θ3 Pθ(R1) Pθ(R2) Pθ(Rb) Eθ(G(θ, κ))
10 10 0.01 0.25 0.62 8.67
10 5 0.23 0.02 0.33 2.90
10 0 0.51 0.00 0.02 2.57
0 0 0.01 0.01 0.01 0.00
Dunnett
θ1 θ3 Pθ(R1) Pθ(R2) Pθ(Rb) Eθ(G(θ, κ))
10 10 0.01 0.25 0.62 8.67
10 5 0.23 0.02 0.33 2.89
10 0 0.52 0.00 0.02 2.60
0 0 0.01 0.01 0.01 0.00
Table 7.4: Comparing intersection hypothesis tests under formulation 1: R1 is
the event that we only reject H01, R3 is the event that we only reject H03 and
Rb is the event that we reject both H01 and H03.
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Original Simes
Trial design Epi(θ)(G(θ, κ))
Adaptive Enrichment 3.88
Fixed Enrichment 3.79
Fixed sample multiple hypotheses 3.67
Improved Simes
Trial design Epi(θ)(G(θ, κ))
Adaptive Enrichment 3.94
Fixed sample multiple hypotheses 3.80
Dunnett
Trial design Epi(θ)(G(θ, κ))
Adaptive Enrichment 3.96
Fixed sample multiple hypotheses 3.77
Table 7.5: Comparing Epi(θ)(G(θ, κ)) using improved tests for the intersection
hypothesis
Using the Dunnett type method we find the Bayes expected gain of the Bayes
optimal Adaptive Enrichment design and compare this with the expected gain of
the fixed sampling alternatives in Table 7.5 we see that using the Dunnett type
method gives an overall improvement over the original version of Simes method
for both the fixed sampling and Adaptive designs. When compared with the
improved version of Simes method we see that for the fixed sampling design the
improved version of Simes method gives a higher Bayes expected gain, however
for the adaptive design we see that the Dunnett type method is marginally
better. There is no clearly preferred method between the improved Simes and
Dunnett type methods, but in both cases we see that we can improve on the basic
hypothesis testing structure we used throughout Chapters 4, 5 and 6.
7.1.3 χ2 combination test
The weighted inverse normal described in Section 3.4.1 is known to be the
optimal choice of combination test when the weights are chosen in proportion to
the sample size within each stage of the trial. A commonly used alternative is
the χ2 combination test introduced by Fisher (1925). Suppose we have p-values
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P (1) and P (2) from the first and second stages of the trial then under the null
hypothesis
−2log(P (1)P (2)) ∼ χ24.
Suppose we have a random variable R following the same distribution so R ∼ χ24,
the combined p-value for testing the null hypothesis at the end of the trial is
given by
p(c) = P(R ≥ −2log(p(1), p(2)) (7.3)
where p(1) and p(2) are the p-values observed in each stage of the trial.
Example
Consider a trial testing only H03 : θ3 ≤ 0 where we conduct an interim analysis
that always continues in the full population, but suppose we do not know the
proportion of the sample τ that has been used at the interim analysis. From the
pre-interim recruitment cohort we observe
θˆ
(1)
3 ∼ N(10, (τ I˜)−1)
and from the post-interim recruitment cohort we observe
θˆ
(2)
3 ∼ N(10, ((1− τ)I˜)−1).
Choosing weights w1 = w2 = 0.5 we compare the weighted inverse normal
combination test with inverse χ2 combination test from equation 7.3 as τ varies in
Figure 7-1. We see that as τ varies the probability of rejecting the null hypothesis
with the χ2 combination test varies less, the probability of rejecting the null
hypothesis under the weighted inverse normal is higher for choices of τ close to
the weights but decreases the further from optimal the weights become. We have
typically used τ = 0.5 meaning that the sample is either split with half of the
sample in the first and second recruitment cohorts, or a quarter in the first cohort
and three quarters of the sample in the second cohort. We see that in both of
these cases that the weighted inverse normal combination test is more powerful,
thus if the proportion of the sample in each stage of the trial is well understood
the weighted inverse normal will be the better choice (it would even be possible
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Figure 7-1: Comparing the power of combination tests
to optimise the weights to account for the adaptation).
Using the χ2 combination test we may still find the Bayes optimal Adaptive
Enrichment design, Table 7.6 compares the Bayes expected gain of the Bayes
optimal Adaptive Enrichment designs using the weighted inverse normal and χ2
combination tests for each formulation of our problem. Under both formulations
of the problem we see that unsurprisingly the Bayes expected gain of the Bayes
optimal Adaptive Enrichment trials is much lower when using the χ2 combination
test.
7.1.4 Changing the ordering of testing methods
The final element of the hypothesis testing that we kept consistent throughout
all examples of Adaptive Enrichment trials in Chapters 2, 4 and 5 is the ordering
of the overall testing procedure. We have found an intersection p-value within
each stage of the trial and then used a combination test to find overall P-values
for the individual and intersection hypothesis. This has the advantage that when
the trial is enriched at the interim analysis we may set the intersection P-value
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Formulation 1
Combination test Epi(θ)(G(θ, κ))
Weighted inverse normal 3.88
Inverse χ2 3.25
Formulation 2
Combination test Epi(θ)(G(θ, κ))
Weighted inverse normal 2.44
Inverse χ2 2.26
Table 7.6: Comparing Epi(θ)(G(θ, κ)) using different combination tests under each
formulation of the problem
to be that of the remaining individual hypothesis. An alternative that still gives
strong control of the FWER is to use a combination test to find the combined
P-values of the individual hypotheses and then apply a closed testing procedure
on these combined P-values.
Example
Under the first formulation of the problem, if we apply the alternative overall





If the trial continues in both the sub-population and the full population then the




3 . Otherwise if the trial
continues only in the sub-population this only gives P
(2)
1 and we set P
(2)
3 = 1. We













3 ; to which we apply Simes method to find the p-value
for the intersection hypothesis P
(c)
13 and apply the closed testing procedure.
Similarly under the second formulation of the problem we may apply the





2 . If the trial continues in both the sub-population and the full population




2 . Otherwise if
the trial continues only in the first sub-population this only gives P
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1 and we set
P
(2)





1 = 1. Applying the weighted inverse normal combination test we find









Intersection p-value Epi(θ)(G(θ, κ))
Within each stage 3.88
After combination test 3.90
Improved Simes method within each stage 3.94
Formulation 2
Intersection p-value Epi(θ)(G(θ, κ))
Within each stage 2.44
After combination test 2.38
Table 7.7: Comparing Epi(θ)(G(θ, κ)) using different combination tests under each







2 ; to which we apply Simes method to find the p-value
for the intersection hypothesis P
(c)
12 and apply the closed testing procedure.
For each formulation of the problem Table 7.7 compares the Bayes expected
gain of the Bayes optimal Adaptive Enrichment trials when finding the intersec-
tion p-values within each stage or at the end. We see that changing the testing
order of the Adaptive Enrichment design provides an improvement in the Bayes
expected gain for formulation 1 but reduces the Bayes expected gain in formula-
tion 2, again showing that there is no clearly better testing method. This shows
that the hypothesis testing method should be carefully selected for any particular
trial in order to make the best choice.
It is worth noting that under the first formulation of the problem the small
improvement offered by changing the testing order is not as large as using the
improved version of Simes method within each stage; the improved version of
Simes method cannot be used at the end of the trial as the correlation is not
known until the interim decision has been made.
7.2 Early stopping for futility
Stopping trials early for futility is a common tool available in clinical trials,
there is a dual benefit to this it both saves resources for the trial sponsor when
the treatment does not look promising and patients are protected from adverse
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side effects of treatments that will not help them. To an extent, by selecting an
appropriate sub-population for the post-interim recruitment cohort the Adaptive
Enrichment trial achieves early stopping for a proportion of the population. We
may extend this to allow early stopping of both populations for futility.
Previously we made general definitions of gain functions for the first and second
formulations of the problem in equations 4.5 and 4.6, under the first formulation
this is
G(θ, κ) = γ1(θ)I(R1) + γ3(θ)I(R3) + γb(θ)I(Rb)
and similarly under the second formulation of our problem we use
G(θ, κ) = γ1(θ)I(R1) + γ2(θ)I(R2) + γb(θ)I(Rb).
Under both formulations of the problem the event Rb is only possible when
continuing in both sub-populations, with the event R3 also only being possible
when continuing in both sub-populations for the first formulation of the problem,
by choosing to enrich the trial into either population the corresponding outcome
R1 or R2 becomes more likely. Each of the possible decisions has a clear
motivation from the choice of the gain function, when introducing other possible
decisions it should be clear in the gain function where the benefit of these possible
decisions comes from.
We must add the possibility of early stopping to the gain function in order to
motivate this decision at the interim analysis. Define S as the event that the trial
is stopped at the interim analysis, the gain of stopping at the interim analysis is
given by γS(θ). We define the overall gain function to be
G(θ, κ) = γ1(θ)I(R1) + γ2(θ)I(R3) + γb(θ)I(Rb) + γS(θ)I(S). (7.4)
under the first formulation of the problem and
G(θ, κ) = γ1(θ)I(R1) + γ2(θ)I(R2) + γb(θ)I(Rb) + γS(θ)I(S) (7.5)
under the second formulation of the problem.
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Example
Returning to our example we set γS(θ) = 1.5, and our specific choice for
the gain function for the first formulation of the problem given in Equation 7.4
becomes
G(θ, κ) = λθ1I(R1) + (λθ1 + (1− λ)θ2)I(R3) + (λθ1 + (1− λ)θ2)I(Rb) + 1.5I(S),
similarly under the second formulation of the problem Equation 7.5 becomes
G(θ, κ) = λθ1I(R1) + (1− λ)θ2I(R2) + (λθ1 + (1− λ)θ2)I(Rb) + 1.5I(S),
Under these choices of gain function the Bayes optimal decision boundaries
remain the same when choosing whether to enrich the trials or not. The trial
is stopped early for futility when the estimated treatment effect in both sub-
populations is low, this means that there is a minimum value for the Bayes
expected gain for the remainder of the trial at the interim analysis. This is similar
to stopping the trial early for futility when the observed treatment effect at the
interim analysis is below some threshold, but achieved through the gain function
that has been central to our optimisation structure. We choose γS(θ) = 1.5 in
this case to illustrate the impact of early stopping in our decision framework, in
practice more thought would be required for this value; it may represent the cost
of sampling, or perhaps an opportunity cost where the resources used for a trial
may be allocated elsewhere if it is stopped early for futility.
Table 7.8 shows the Bayes expected gain of the Bayes optimal Adaptive
Enrichment design that allows early stopping for futility with the fixed sampling
designs. Under both formulations of the problem we see that stopping early
for futility has increased the Bayes expected gain of the Adaptive Enrichment
trial. For both formulations of the problem the increase in performance from the
early stopping is similar to the increase we see from the Bayes optimal Adaptive
Enrichment trial when compared to the fixed sampling design testing multiple
hypotheses. We could of course apply this method of early stopping to the fixed
sampling designs, introducing an interim analysis purely for this purpose.
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Formulation 1
Trial design Epi(θ)(G(θ, κ)) P(Stopping early)
Adaptive Enrichment early stopping 4.06 0.21
Adaptive Enrichment 3.88 -
Fixed Enrichment 3.77 -
Fixed samlpe multiple hypotheses 3.74 -
Formulation 2
Trial design Epi(θ)(G(θ, κ)) P(Stopping early)
Adaptive Enrichment early stopping 2.75 0.35
Adaptive Enrichment 2.44 -
Fixed Enrichment 1.91 -
Fixed sample multiple hypotheses 2.12 -




Conclusions and some possible
extensions
8.1 Conclusions
The first part of our work in Chapter 2 was to set up the hypothesis testing
structure we use for Adaptive Enrichment designs. This hypothesis testing
structure ensures strong control of the familywise error rate for each of the
possible decisions at the interim analysis regardless of the method used to make
the decision; we used this hypothesis testing structure throughout our examples.
In Chapter 7 we discuss some small changes that could be made to this hypothesis
testing structure and see that this may improve the overall performance of some
of our methods slightly. In particular these changes are useful when we wish to
test null hypothesis in a sub-population and the full population.
We have introduced the use of a Bayes decision framework to optimise the
interim decision of Adaptive Enrichment trials. This framework is very flexible
allowing us to find the Bayes optimal decision at the interim analysis for
any choice of the design parameters, where the Bayes optimal decision rule
is the best possible decision rule for the set of parameters. In Chapter 7 we
demonstrated this flexibility further by adding an additional decision at the
interim analysis, allowing for early stopping for futility. Having developed
the necessary framework in Chapter 4 we construct Bayes optimal Adaptive
Enrichment designs, the example showed that the Bayes optimal adaptive designs
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can offer an improvement over fixed sampling alternatives.
In Chapter 4 we also compared the performance of the Bayes optimal decision
rule and optimised rules of a simpler form. While the optimised simple rules
did give the Adaptive Enrichment designs a higher overall performance than the
fixed sampling alternatives the Bayes optimal decision rules were clearly better.
The simple decision rules that we used were chosen to be close to the Bayes
optimal decision boundary while being simple to implement, in practice if a simple
decision rule is chosen poorly even when optimised it will not give a good overall
performance for the Adaptive Enrichment design; there is a further example of
this in Chapter 6 where we compare the performance of interim decision rules
optimised for different prior distributions.
While developing our optimisation structure we used an immediate response in
our examples, meaning that all data are available when an analysis is conducted.
This is not a requirement of our optimisation structure. In Chapter 5 we began
by using a delayed response, unsurprisingly this reduced the overall performance
of the trial as decisions must be made on less data but are not able to change
the remaining recruitment of the trial any more than an immediate response. We
showed that the loss in overall performance can be recovered by the introduction
of a secondary endpoint; we assumed a correlation structure between the primary
and secondary endpoint and used this to improve the estimate of treatment effect
for the primary endpoint at the interim analysis.
In Chapter 6 we examine how Adaptive Enrichment designs perform across a
range of possible scenarios. Using our optimisation framework we see that the
Adaptive Enrichment designs provide an improvement in the overall performance
when compared to these fixed sampling alternatives in many cases; however
Adaptive Enrichment designs are not always the best choice. Using our
optimisation framework we suggest comparing the potential performance of an
Adaptive Enrichment design with the fixed sampling alternatives for a given
situation to find which the most suitable choice suitable choice is. It is possible
to use the simplified computation of the Oracle decision rule, Chapter 4, to give
an impression of whether an Adaptive Enrichment design may be useful for a
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particular scenario.
Overall using the Bayesian decision framework for the optimisation of the
interim decision of Adaptive Enrichment designs has proved to be a powerful tool.
We have shown that although we must be sure that an Adaptive Enrichment
trial is the correct choice, when it is we can provide the best version of an
Adaptive Enrichment design in all settings. When used appropriately these Bayes
optimal Adaptive Enrichment designs can provide a large improvement in overall
performance when compared to fixed sampling alternatives.
8.2 Extensions
8.2.1 Parameters governing recruitment
We have assumed that λ the proportion of the sample in the first sub-
population is equal to the proportion that this represents the sub-population
in the overall patient population, we could instead consider oversampling a sub-
population particularly one that is rare in the patient population. We have also
assumed that λ must be consistent between stages of the trial but we could even
consider allowing this to be changed for the post-interim recruitment cohort.
Our optimisation framework from Chapter 4 would still allow us to optimise
these trials and find their overall performance.
We have assumed that there are only two sub-populations under both
formulations of the problem, however it may be possible to identify more sub-
populations where the treatment is expected to behave differently. Under the
second formulation we assumed that our sub-populations are independent, this
assumption may not hold. If for example if each sub-population is identified
by the presence of a sub-population specific biomarker some patients may be
biomarker positive for multiple sub-populations, this will introduce a correlation
between the summary statistics of the patient populations.
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8.2.2 Sample size
Throughout our examples we have assumed a fixed overall sample size for the
Adaptive Enrichment designs, that is the same as we used for the fixed sampling
designs. The Bayes expected gain showed that we could achieve a higher overall
performance using an Adaptive Enrichment trial in our examples, if the cost of
sampling was particularly high we might aim to reduce the sample size using the
Adaptive Enrichment trial such that we achieve the same Bayes expected gain as
the fixed sampling designs.
Conversely when we looked at early stopping for futility we could consider this
as a cost of sampling. With a cost of sampling defined we could consider adapting
the sample size at the interim analysis in addition to selecting a sub-population.
If after the interim analysis we ran the rest of the trial as a group sequential
trial Turnbull and Jennison (2000) this would give the lowest expected sample
size for the remainder of the trial, this would give the lowest cost of sampling in
terms of the Bayes expected gain for the trial at the time of the interim analysis.
8.2.3 Niche population
In our null hypotheses we have investigated whether the new treatment was
equivalent to or better than the control treatment in either sub-population or
the full population depending on the formulation of the problem. In practice
when conducting the trial to allow for investigation of the sub-population we
may be looking for an effect in a niche population, we might look for a higher
improvement over the control treatment, for example we might investigate the
null hypothesis Hniche : θ1 ≤ b where b is some higher treatment effect.
Without the formal definition of a niche hypothesis under the first formulation
of the problem we may reject the null hypotheses in both the sub-population and
the full population. In this instance it may not be clear that the result in the full
population is not driven by a very high treatment in the sub-population where we
claimed we believed the new treatment may work better. In this scenario we may
require further proof that the treatment effect is not only from the sub-population.
We may for example seek to show that the treatment effect in the complement of
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the sub-population is above some threshold, or perhaps incorporate the treatment
effects more carefully in the gain function.
8.2.4 Similar and simplified decisions
In the final example of Section 4.4 we saw that optimising a simple decision rule
was able to give an overall Bayes expected gain close to that of the Bayes optimal
decision rule. The Bayes optimal decision boundaries that we have computed
show exactly where the alternative interim decisions are equivalent in terms of the
Bayes expected gain for the remainder of the trial, the simple rules were chosen
to be similar to the Bayes optimal decision rules which is why their optimal
behaviour is close. We could consider similar decisions at the interim analysis,
where the expected gain of two or more decisions is close we could make either
decision and still be close to optimal. We could investigate how large a region
may be defined as a similar decision without a large impact on the overall Bayes
expected gain of the trial. From this we may inform simplified decision rules for
the trial, where the simplified rule is contained entirely within the similar region.
8.2.5 Overall treatment effect estimates
When discussing the possible outcomes of the trials we have only considered
which null hypotheses have been rejected. In addition to details about hypothesis
tests we will also wish to make inferences about the treatment effects after
conducting the trial. Constructing the estimates and confidence intervals
corresponding to the results of the Adaptive Enrichment trial are not trivial, as
using the pooled data will not necessarily correspond with the results of the overall
hypothesis testing procedures we have used. These treatment effect estimates
could be used to enhance the information passed to the gain function, giving a
clearer idea of what gain is achieved through any particular outcome.
8.2.6 Multiple interim analyses
A final area that our optimisation framework could easily be extended to is the
idea of conducting multiple interim analyses. In both of the formulations of the
problem we have presented there is only one adaptation to be made, and we may
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only make this adaptation at the interim analysis. We have seen that changing
the timing of the interim analysis can be of benefit for the Adaptive Enrichment
trials.
We could offer more opportunities to make this adaptation, for example we
might conduct two interim analyses where we may enrich the trial at the second
analysis if we have not already done so at the first. If we have not already made
the adaptation by the time of the second interim analysis the optimisation at
this point is exactly as we saw previously, we evaluate the Bayes expected gain
for the rest of the trial for each possible decision and choose the decision that
maximises this. At the first interim analysis there is an additional level to the
computation, for the decision that continues the trial in both sub-populations at
the interim analysis the expected gain also depends on the optimal decision that
may be made at the second interim analysis.
This could be extended to allow for any number of interim analyses up to a
maximum of conducting an interim analysis after every patient, although this
would not be practical. Extending to more interim analyses would mean our
optimisation at any particular analysis would have to account for all future
decisions which would also need to be optimised, and so the computation time
would be expected to increase dramatically with each additional analysis.
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Appendix A
A summary of techniques for
practical use
A.1 Recruitment of trials
In Section 3.1.2 we introduce the two formulations of the problem that we
have worked with throughout. Under the first formulation of the problem we
have a single sub-population of interest within a full population. We define θ1 as
the treatment effect in the sub-population and θ2 as the treatment effect in the
complement, the proportion of the sample in the sub-population is given by λ and
hence the treatment effect in the full population is given by θ3 = λθ1 + (1−λ)θ2.
We aim to test the null hypotheses H01 : θ1 ≤ 0 in the sub-population and
H03 : θ3 ≤ 0 in the full population.
Under the second formulation of the problem we have a two separate sub-
populations. We define θ1 as the treatment effect in the first sub-population and
θ2 as the treatment effect in the second, the proportion of the sample in the first
sub-population is given by λ as previously. In this formulation of the problem
we ignore the full population aiming to test the null hypotheses H01 : θ1 ≤ 0 in
sub-population 1 and H03 : θ3 ≤ 0 in sub-population 2.
In Chapter 3 we made the assumption that the variance would be the same for
both the new treatment and the control treatment, σ2 say, and that our sample
size, n say, would be split equally between the new treatment and the control.
156
Suppose we conduct a trial to test the null hypothesis H0 : θ0 ≤ 0, then we














across all of the trials we then write the distributions of the summary statistics
in terms of I˜.
Fixed sampling trials recruitment
Under both formulations of the problem we may conduct a fixed Enrichment
trial in the first sub-population to test the null hypothesis H01 : θ1 ≤ 0 as
introduced in Section 3.3.6. Similarly under the second formulation of the
problem we may conduct a fixed Enrichment trial in the first sub-population
to test the null hypothesis H02 : θ2 ≤ 0. In both cases the summary statistic θˆi
for i = 1, 2 follows the distribution given in Section 3.6
θˆi ∼ N(θi, I˜−1).
The other fixed sampling alternative we consider is sampling from both
sub-populations and testing both null hypotheses, this was first discussed in
Section 3.3. Under both formulations of the problem we find summary statistics
in each of the sub-populations, θˆ1 and θˆ2 say, which follow the distributions given
in Section 3.6
θˆ1 ∼ N(θ1, (λI(θ))−1))
and
θˆ2 ∼ N(θ2, ((1− λ)I(θ))−1).
Under the first formulation of the problem the estimate of the treatment effect
in the full population, θˆ3 is given by θˆ3 = λθˆ1 + (1 − λ)θˆ2 and follows the joint
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The recruitment of the Adaptive Enrichment trials is split between the pre
and post-interim recruitment cohorts as explained in Section 3.5.1. In addition
to λ being the proportion of the sample in the first sub-population we define τ
as the proportion of the sample from the pre-interim recruitment cohort. Under
the second formulation of the problem the pre-interim recruitment cohort has












2 ∼ N(θ2, ((1− λ)τ I˜)−1).
The post-interim recruitment cohort may then follow one of three options: If
the trial continues in both sub-populations then the estimates of the treatment




2 say, are distributed
as given in Section 3.6
θˆ
(2)




2 ∼ N(θ2, ((1− λ)(1− τ)I˜)−1);
if the trial continues in only a single sub-population for i = 1, 2 depending on
which population is picked the corresponding estimate of the treatment effect is
distributed as in Section 3.6,
θˆ
(2)
i ∼ N(θi, ((1− τ)I˜)−1) for i = 1, 2
Under the first formulation of the problem also find estimates of the treatment
effect in the full population where possible. In the pre-interim recruitment cohort
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If the trial continues in both sub-populations then the estimate of the treatment
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A.2.1 FamilyWise Error Rate
For all trials we have considered throughout this work we have required
strong control of the FamilyWise Error Rate (FWER). This was introduced in
Section 3.2.1, where strong control is defined in Equation 3.1 as
Pθ(Reject at least one true null hypothesis) ≤ α for all θ.
A.2.2 Closed testing procedure
We have used closed testing procedures to ensure strong control of the FWER,
we introduce these in Section 3.2.2. Suppose we have two null hypotheses
H01 : θ1 ≤ 0 and H02 : θ2 ≤ 0. In order to reject H01 globally at level α the
individual tests of H01 and H01 ∩H02 must both be rejected. Similarly in order
to reject H02 globally at level α the individual tests of H02 and H01 ∩H02 must
both be rejected.
In Section 3.2.3 we noted that any testing procedure that gives strong control
of the FWER may be written as a closed testing procedure. Given that we require
strong control of the FWER for our trial designs this means that choosing to use
a closed testing procedure does not restrict the usefulness of our results as this
simply covers all testing procedures.
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Simes
The closed testing procedure requires a test of the intersection hypotheses, the
first method we use for this is Simes method. We introduced this in Section 3.3.3.
Suppose we have two null hypotheses H01 : θ1 ≤ 0 and H02 : θ2 ≤ 0 with
corresponding p-values P1 and P2, the intersection p-value P12 say, is given by
Equation 3.4 which is
P12 = min(2min(P1, P2),max(P1, P2)).
We used Simes method in our comparisons of Adaptive Enrichment and fixed
sampling alternatives throughout Chapters 4, 5 and 6.
Improved Simes and Dunnett
Under the first formulation of our problem where we consider a sub-population
within a full population testing the null hypotheses H01 : θ1 ≤ 0 and H03 :
θ3 ≤ 0. Under this formulation of the problem there is a correlation between
the treatment effect in the sub-population and the treatment effect in the full
population and hence also the corresponding Z-values, say Z1 is the Z-value in















This correlation structure makes Simes method conservative, in Section 7.1 we
saw how we could remove this conservatism. Suppose P1 and P3 are the p-values
corresponding to H01 and H03 then the intersection P-value P13 is given by
P13 = min(ψρmin(P1, P3),max(P1, P3)),
where ψρ is chosen such that Simes method spends the full α. We saw in the
example of Section 7.1.1 that the improved Simes method slightly increased the
overall performance of both the Adaptive Enrichment trial and the fixed sampling
trial testing multiple hypotheses.
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An alternative to the improved version of Simes method is our version of the
Dunnett type method seen in Section 7.1.2. Let
d = max(z1, z3)
the P-value for the intersection hypothesis is given by Equation 7.2 which is
p13 = P(Z1 ≥ d ∪ Z3 ≥ d).
As with the improved Simes method this uses the full α available for the
hypothesis test. The example of Section 7.1.2 shows that the Dunnett type
method improves the overall performance of both the Adaptive Enrichment trial
and the fixed sampling trial testing multiple hypotheses. The improved Simes
method gave a larger improvement to the fixed sampling trial and the Dunnett
method gave a larger improvement for the adaptive trial in this case. Given that
there is no universally preferred option we recommend choosing the hypothesis
testing methods to suit any particular trial.
A.2.3 Combination tests
In Section 3.4 we introduced the concept of a combination test for the Adaptive
Enrichment trial. Combination tests are necessary since the Adaptive Enrichment
trial is split into two stages, where the choice of what will be observed in the
second stage depends on the first stage observations. For any analysis we split
the data according to when the patient was recruited, obtaining an estimate of
the treatment effect for the pre-interim and post-interim recruitment cohorts.
That is for a treatment effect, θ say, we find θˆ(1) from the pre-interim recruitment
cohort and θˆ(2) from the post-interim recruitment cohort where θˆ(1) and θˆ(2) will
be conditionally independent for the Adaptive Enrichment trials.
Weighted inverse normal
The first form of combination test that we have used is the weighted inverse
normal that we introduced in Section 3.4.1. Suppose Z(1) and Z(2) are the Z-
values corresponding to θˆ(1) and θˆ(2). We find the combined Z-value, Z(c) say, for
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i = 1. When these weights are
proportional to the sample size in each recruitment cohort this test achieves the
highest power.
χ2 combination test
An alternative the weighted inverse Normal combination test is the χ2
combination test . Suppose P (1) and P (2) are the P-values corresponding to
the Z-values Z(1) and Z(2), then
−2log(P (1)P (2)) ∼ χ24.
The combined p-value for testing the null hypothesis at the end of the trial is
given by Equation 7.3
p(c) = P(−2log(P (1)P (2)) ≥ −2log(p(1), p(2))
This combination test is not as powerful as the weighted inverse Normal when
the weights are correct, we are able to choose reasonable weights for Adaptive
Enrichment designs so the χ2 combination test does not seem to be particularly
useful.
A.2.4 Overall testing procedure
In Section 3.5.2 we discussed the options for the overall testing procedure of
Adaptive Enrichment trials. The first option that we use in most of our examples
is to find the P-value for the intersection hypothesis within each stage of the trial
and then use a combination test to find the overall p-values. For example under
the second formulation of the problem in the pre-interim recruitment cohort we
find P
(1)
1 in the first sub-population and P
(1)
2 in the second sub-population in the
usual way and then find the intersection p-value P
(1)
12 using Simes method.
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In the post-interim recruitment cohort if the trial has continued in both sub-






12 in the same way. If











12 are found using a
combination test.
The second option is to find the combined p-values for the individual hypotheses











2 we find P
(c)
12
using Simes method. Whichever method is used we reject H01 globally at level α
if P
(c)
1 ≤ α and P (c)12 ≤ α. Similarly we reject H02 globally at level α if P (c)2 ≤ α
and P
(c)
12 ≤ α as given by the closed testing procedure.
Both overall testing procedures ensure strong control of the FWER and in
our example we do not see a large difference in the overall performance of the
Adaptive Enrichment trial whichever is used. It is worth noting that under
the first formulation of the problem there is a larger benefit in using either the
improved Simes method of Dunnett type method for the intersection hypothesis
within each stage of the trial (they cannot be applied at the end as the correlation
is not pre-defined).
A.3 Defining the gain function
The key component from our decision framework is to define a single measure of
trial performance, we do this by the introduction of gain functions in Section 4.2.2.
If we define R1 as rejecting the null hypothesis in the first sub-population, R2
as rejecting the null hypothesis in the second sub-population, R3 as rejecting the
null hypothesis in the full population andRb as rejecting the both null hypothesis
under a particular formulation of the problem. Under the first formulation of the
problem we define the general form of the gain function in Equation 4.5
G(θ, κ) = γ1(θ)I(R1) + γ3(θ)I(R3) + γb(θ)I(Rb).
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Under the second formulations of the problem we define the general form of the
gain function in Equation 4.6
G(θ, κ) = γ1(θ)I(R1) + γ2(θ)I(R2) + γb(θ)I(Rb).
The key under both formulations of the problem is that the gain depends on
the eventual outcomes of the trial, with the gain of an outcome being given by
γi(θ) for i = 1, 2, 3, b. We have allowed the gain of an outcome to depend on the
true treatment effects, in practice we could also incorporate the estimates of the
treatment effects or other endpoints such as the safety of the new treatment.
A.4 Optimisation of adaptive enrichment
A.4.1 Assessing overall trial performance
In addition to our gain function in Section 4.3.3 we allow for the use of prior
distributions to account for our uncertainty about the true treatment effects, say
the pdf of this prior distribution is given by pi(θ). The Bayes expected gain






Evaluating the Bayes expected gain of different trials for choices of the prior
distribution and the gain function will show their comparable overall performance,
where the trial that maximises the Bayes expected gain is the best choice.
A.4.2 Optimising simple decision rules
In Section 4.3.4 we saw how we might use this measure of overall performance
to optimise decision rules of any particular form. Finding the values of the
parameters of the simple decision rules that maximise the Bayes expected gain.
Under the first formulation of the problem we optimised a simple decision rule of
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the form given in Equation 4.1
decision =
continue in both populations if θˆ
(1)
3 ≥ ψ
continue only in the sub-population if θˆ
(1)
3 < ψ.
The optimised version of this simple decision rule gave the Adaptive Enrichment
trial a similar overall performance to the fixed Enrichment trial. Under the second









continue only in sub-population 1 if θˆ
(1)
1 ≥ θˆ(1)2 and θˆ(1)2 < ψ







The optimised form of this simple decision rule gave an Adaptive Enrichment
trial that provided an improvement over all fixed sampling methods that we
made comparisons with.
The simple rules that we optimised were chosen knowing the form of the Bayes
optimal decision boundary and so are able to perform reasonably well. However
applying a simple rule without this knowledge could severely hamper the overall
performance of the design; in Section 6.1.4 we see that decision rules of the wrong
form meant the Adaptive Enrichment design was no longer the best choice of
design in examples where with the right optimisation it provided a clear benefit.
A.4.3 Bayes optimal decisions
Optimising decision rules of any particular form at best limits the overall
performance of the trial, in Section 4.4 we introduce the Bayes optimal decision at
the interim analysis. Defining κ1 to be the data available at the time of the interim
analysis the Bayes expected gain for the remainder of the trial, Epi(θ),κ1(G(θ, κ))






where the choice of sub-populations at the interim analysis that maximises this
is the Bayes optimal decision.
We have shown that these Bayes optimal Adaptive Enrichment trials offer an
improvement over the fixed sampling alternatives, in Chapter 6 we saw a variety of
examples where this was the case. Under the first formulation of the problem we
saw that the Bayes optimal Adaptive Enrichment design offered an improvement
over the fixed sampling designs in a variety of settings. The advantage of the
adaptive design is not typically large, however providing a compromise between
fixed sampling designs and not reducing the overall performance of the trial will
be beneficial in practice when agreement cannot be achieved over which of the
fixed sampling designs should be used.
Under the second formulation of the problem the Bayes optimal Adaptive
Enrichment trials do not offer such consistency in out performing the fixed
sampling alternatives. If the treatment effects in both sub-populations are similar
then the adaptive design offers a larger benefit than it does under the first
formulation of the problem, as they mimic the good features of three comparable
fixed sampling trials.
However in Section 6.1.2 we tried a prior distribution where the true treatment
effect is high in one sub-population, the fixed Enrichment trial in this sub-
population was clearly the best choice of trial. As a more general note this
shows us that Adaptive Enrichment designs are not always the best choice and
we should check whether they are suitable for a particular scenario before using
them in practice.
A.4.4 Early stopping for futility
In Section 7.2 we discussed how the gain function will motivate the possible
choices at the interim analysis, improving the chances of a possible outcome
allowing us a better chance of receiving the corresponding gain. With this in
mind we may include any number of possible decisions at the interim analysis
so long as they are motivated by the gain function. In Section 7.2 we allow the
inclusion of stopping the trial early for futility, defining S as the event that the
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trial is stopped early we write the gain function under the first formulation of the
problem is defined by Equation 7.4
G(θ, κ) = γ1(θ)I(R1) + γ2(θ)I(R3) + γb(θ)I(Rb) + γS(θ)I(S).
Under the second formulation of the problem the gain function giving early
stopping is given by Equation 7.5
G(θ, κ) = γ1(θ)I(R1) + γ2(θ)I(R2) + γb(θ)I(Rb) + γS(θ)I(S).
Under both formulations of the problem this early stopping improved the overall
performance of the Adaptive Enrichment trials as should be expected.
A.5 When is Adaptive Enrichment useful
A.5.1 Oracle Adaptive Enrichment
Before we constructed the Bayes optimal decision at the interim analysis we
consider the Oracle decision rule in Section 4.3.1. This has the same structure as
the Bayes optimal decision but we assume we know the true treatment effects, θ
say. We evaluate the expected gain for the remainder of the trial given θ, this is
given by Equation 4.11
Eθ,κ1(G(θ, κ)) = γ1(θ)Pθ,κ1(R1) + γ3(θ)Pθ,κ1(R3) + γb(θ)Pθ,κ1(Rb)
under the first formulation of the problem and Equation 4.12
Eθ,κ1(G(θ, κ)) = γ1(θ)Pθ,κ1(R1) + γ2(θ)Pθ,κ1(R2) + γb(θ)Pθ,κ1(Rb).
under the second formulation of the problem. As with the Bayes optimal
decision rule we choose the sub-population that maximises this. This is less
computationally intensive than the Bayes optimal decision rule, and may help us
to learn in what cases the Adaptive Enrichment trial will provide a benefit when
compared with the fixed sampling alternatives since it gives an upper bound on
the possible performance of the Adaptive Enrichment design.
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A.6 Additional data types
A.6.1 Delayed response and survival endpoints
Most of our examples have assumed that observations from patients are
immediately available, or at least they are available quickly enough that we may
use all of the observations from the pre-interim recruitment cohort at the time of
the interim analysis. In practice this will not be the case and we are unlikely
to wish to halt recruitment while we wait to be able to conduct an interim
analysis. In Chapter 5 we remove this assumption of immediate response to
see how Adaptive Enrichment performs.
We start in Section 5.1 by assuming a delay between recruiting a patient and
observing their response, in fact the analysis of overall performance that we make
in the case of delayed response is parallel with assuming that we have a survival
endpoint; we show this to be the case in Section 5.3 using log-rank score statistics
to summarise the trial. We may still find the Bayes optimal decision at the interim





now depends on the remaining observations from the pre-interim recruitment
cohort in addition to the observations from the post-interim recruitment cohort.
We see that as the proportion of the pre-interim recruitment cohort we
have observations from decreases the Bayes expected gain of the Bayes optimal
Adaptive Enrichment trials decreases too. This reduction showed a linear trend in
our examples, this would allow us to determine a minimum acceptable proportion
of observations in order for the trial to provide a benefit. We could also combine




When introducing delayed responses in Section 5.1 we stated that one of the
reasons for this might be a delay between giving the new treatment and observing
the final response, however responses could be collected in a longitudinal fashion
with only the final observations contributing to the final analysis. In Section 5.2
we show how using longitudinal observations such as this may be used to
enhance the decision at the interim analysis. We compare these optimal decisions
with Adaptive Enrichment trials using only the final observations, this shows
the improvement from the enhanced decisions. In our examples we recovered
approximately half of the performance lost when assuming a delayed response for
the observations.
The optimisation methods of Section 5.2 would also apply to survival end-
points under a suitable joint model. We discuss how this may be done in using
progression free survival to enhance the interim decision of an Adaptive Enrich-
ment trial where the final analysis is to be conducted based on overall survival
in Section 5.3.2, although we do not have a full example of ow to simulate the
designs in this case.
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